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Abstract
Signals derived from adipose tissue, such as interleukin-6 (IL-6), might 
explain the link between obesity and type 2 diabetes and cardiovascular 
disease. Significant amounts of IL-6 are released by adipose tissues. 
However, whether adipocytes within the tissue are responsible for the 
release, how this release is regulated and what the paracrine/autocrine 
effects of this adipokine might be are not known.
Rodent obesity, as with human obesity, is associated with elevated 
plasma IL-6 concentrations. In both lean and obese animals, the 
epididymal fat depot released more IL-6 than did the subcutaneous, but 
was only significantly different in the obese [lean; 2.8 (2.5-5.9) pg/ml vs. 
obese; 8.6 (4.6-24.5) pg/ml, median (interquartile range), p=0.0001]. 
Furthermore, whereas subcutaneous adipose tissue from both lean and 
obese animals released comparable levels of IL-6, epididymal IL-6 
production increased significantly in obesity.A large proportion (up to 
50%) of adipose tissue IL-6 secretion, from both depots, was constitutive. 
However, following stimulation, the largest change in the rate of 
production of IL-6 was observed in the epididymal tissue of obese 
animals. Although both the basal and stimulated release was found to be 
through a Golgi-dependant process, this release was transcriptionally 
regulated and, unlike leptin, IL-6 was not stored within the adipocytes 
prior to release.
The chronic exposure of differentiating preadipocytes to IL-6 enhanced 
lipid accumulation within the adipocytes. This lead to increased leptin 
secretion from the IL-6-treated cells, without an increase in ob 
expression. IL-6 did not affect the recruitment of preadipocytes to 
adipogenesis, nor did it increase the expression of the adipogenic 
modulators PPARy or C/EBPa. However, in differentiated adipocytes, IL-6 
treatment enhanced basal and insulin-stimulated glucose uptake and 
caused a reduction in adrenergically stimulated lipolysis.
In conclusion, chronic hyper-secretion of IL-6 from adipocytes causes 
increased lipid deposition and adipocyte hypertrophy, indirectly inducing 
insulin resistance.
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Obesity
Obesity is one of the most important health issues in the developed 
world, and its spread is extending further into the developing world. The 
current World Health Organisation definition of obesity is a body mass 
index (BMI) greater than 30 kg/m2. A 2001 report by the National Audit 
Office in England estimated that 65% of English adults were overweight 
(a BMI greater than 25), with 19% of the population obese. In 1980 this 
figure was approximately 7% [1J. In the USA, an estimated 61.3 million 
people are obese: 27% of the population [2]. As a result, obesity 
commands the second highest cost in healthcare in these countries, after 
smoking-related diseases [3]. Numerous pathologies are associated with 
obesity [4], the most prominent being type 2 diabetes, insulin resistance 
and cardiovascular disease.
The majority of researchers have attributed the rise in obesity, 
particularly among children, to a combination of increased intake of 
inappropriate (high-fat, high-carbohydrate) food and a sedentary lifestyle 
[5]. Other influences are involved, particularly genetic susceptibility [6], 
which might affect weight gain, pathogenesis of disease and treatment. 
Notably, whether through genetic predisposition or lifestyle, certain ethnic 
groups appear to have a greater propensity towards obesity. Among the 
most studied are the native American Pima Indians [7], who have a 
higher proportion of insulin resistance and type-2 diabetes than 
Caucasian populations. Other ethnic groups appear to have a greater 
prevalence or propensity for obesity and its associated pathologies 
compared with Caucasians in similar communities [8-10]. Additionally, 
other theories have been advanced to explain the rise in obesity, 
including an adenovirus originally observed in chickens [11] and pollution 
[12].
Physiologically, obesity is characterised by an excess of adipose 
tissue. All adipose is not created equal, however, and can broadly be 
divided into two: subcutaneous adipose tissue, which is located between 
the muscle and skin, and can be found all over the body [13]; and visceral
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(or omental) adipose tissue, which lies primarily in the body cavity, 
surrounding the internal organs. The depots differ for various biochemical 
functions, including adipogenesis [14, 15], lipolysis [16], glucose uptake 
[17], the release and/or expression of adipokines or other adipocyte 
factors [18, 19] and their response to stimuli [20]. Furthermore, the 
deposition of visceral fat (rather than subcutaneous) appears to be a 
greater risk factor for insulin resistance, type-2 diabetes and 
cardiovascular disease [21, 22].
Therefore, the study of adipose tissue and the understanding of 
the mechanisms involved in adipose tissue function will help to prevent 
and treat obesity and the diseases with which it is associated.
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Adipose Tissue
Adipose tissue is composed of a variety of ceil types, including 
adipocytes, preadipocytes, blood vessels, neurons and immune cells. Of 
note, especially concerning the adipocyte release of inflammatory 
cytokines, is the increased infiltration of macrophages into the adipose 
tissue in the obese state [23] and the reported conversion of adipocytes 
to macrophages [24], The precise constitution of adipose tissue varies 
with depot and obesity, but it has been estimated that up to ~60% of cells 
in the tissue could be macrophages [23].
This section will introduce the anatomy and physiology of the 
adipocyte and adipose tissue, as well as its relevance to the organism 
and disease. A number of the most prominent adipokines will be 
reviewed, excluding interleukin-6 (IL-6), which is described in the 
subsequent section.
The adipocyte
The adipocyte from white adipose tissue has many roles (although 
humans, apart from neonates, do not have traditional brown adipose 
tissue as other mammals do, there is a degree of plasticity within human 
adipose tissue [25]. It should be assumed that all data reviewed and 
presented here are based upon white adipose tissue). It is, of course, a 
storage depot hoarding excess energy as triglyceride within lipid vacuoles 
in the cell, enabling energy release in times of insufficient energy input. 
As such, it also has a role in glucose metabolism and insulin sensitivity. 
Furthermore, as part of the adipose tissue it has other roles, namely 
insulation and protection for the internal organs. More recently, however, 
the importance of the adipocyte as an endocrine signalling cell has been 
recognised.
Adipocytes are formed from stem cells of the fibroblast lineage in 
response to various stimuli [26]. An adipocyte is clearly distinguishable 
from a preadipocyte by its rounded shape (whereas the preadipocyte 
tends to be spindle-shaped) and lipid vacuole. Numerous adipocyte-
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specific genes, including the ob gene (the product of which is leptin) and 
adipsin are expressed [27], and other genes that are required for 
adipocyte function, such as the glucose transporter GLUT4 [28] or 
lipoprotein lipase (LPL) [29], are upregulated during differentiation. Once 
formed, the adipocyte is able to carry out its role in storage and signalling.
It is becoming apparent that obesity affects the normal function of 
the adipocyte. Hypertrophy, rather than hyperplasia, appears to be the 
main mechanism involved in non-morbid obesity [30, 31] (certain forms of 
obesity do appear to involve hyperplasia in addition to hypertrophy [32, 
33]). This is significant, because hypertrophic adipocytes appear to have 
altered functions compared with cells containing less lipid. Leptin 
expression, for example, is greater in large adipocytes [34, 35].
Humans, animals and cell lines -  how adipose tissue is studied
As with most biological systems, the physiology, anatomy and function of 
adipose tissue can be studied using one of three general methods: 
humans, animals (typically rodents) or cell lines. Although not necessarily 
specific to adipocyte research, the benefits and problems of each will be 
briefly discussed.
Study on humans is, of course, the gold standard. There are 
numerous types of study that can be carried out on volunteers, the least 
invasive of which tend to be the associative studies. These usually 
involve the correlation of various indices of obesity (BMI, percentage 
body fat as measured by bio-impedance, dual-energy x-ray 
absorptiometry (DEXA) or callipers, or waist-to-hip ratio) with particular 
molecules (often adipokines) in the circulation. More invasive procedures 
involve the cannulation of veins that drain specific adipose tissue depots. 
By comparing the concentrations of adipokines or other products in the 
plasma or serum from these locations with those in arterial samples 
(representing the circulating levels) an index of what is released or 
cleared by the adipose tissue can be created [36, 37]. Moreover, 
molecules of interest can be injected into humans and the effects on body 
fat and adipose tissue can be investigated using the methods above.
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Furthermore, microdialysis techniques have been adapted for in vivo 
analysis and enable the continuous sampling of molecules and 
metabolites from the intracellular space surrounding subcutaneous 
adipose tissue [38], Finally, adipose tissue from various depots can be 
excised and investigated in vitro. This enables expression or release 
studies of different tissues, the study of specific molecular processes in 
the adipocyte that would be difficult in vivo and the investigation of 
adipose tissue without the fear of toxicity or further injury to the subject. In 
addition to direct measurements from explanted tissue, human adipose 
tissue can be maintained in primary cultures for longer-term studies or 
exogenous-compound treatments that would be impractical in vivo. There 
are problems with humans as a study material: subjects must be 
volunteers, ethical considerations are far more stringent and social, 
genetic and background conditions are heterogeneous.
Animals (rats and mice are the most frequently used for research 
into obesity) are often an effective substitute for humans. They are cheap, 
pose less of an ethical problem and enable a wider scope for intervention. 
Furthermore, they are genetically homogeneous, and can be fed and 
exercised in regimented and controlled environments for the duration of 
their lives. Numerous strains of mouse and rat have contributed to our 
knowledge of obesity. As well as investigating the effect of specific diets, 
and how they cause obesity, transgenic animals lacking various genes 
have helped to identify products such as leptin and its receptor system. A 
non-exhaustive list of animals used includes obv_ and dbv_ mice, both of 
which suffer early-onset obesity (and its related pathologies) and were 
found to lack leptin and its receptor, respectively. Additionally, gene 
knockouts of tumour necrosis factor (TNF)-a and IL-6 have also been 
used, as well as knockouts for other intracellular adipocyte factors. These 
are in addition to the methods described for use in human studies, 
enabling animal models to be used as versatile materials for obesity 
research. Problems do exist, not least because humans and mice are 
very different. Apart from the obvious anatomical disparity, there are 
considerable molecular differences. This is well illustrated by the
15
discovery of resistin in murine obesity, a molecule believed to link obesity 
to insulin resistance [39] (see ‘Other adipokines’), but for which a precise 
human homologue has yet to be identified.
The third method available to researchers is the use of cell lines. In 
addition to adipose tissue obtained from human volunteers or animals, 
from which the adipocytes can be isolated and grown, are preadipocyte 
cell lines. Most frequently used are the cell lines 3T3-L1 and 3T3-F442A. 
These, in addition to ob1771 cells, are fibroblasts that are committed to 
the adipocyte lineage. There are also uncommitted stem cells with the 
ability to differentiate into adipocytes, such as 3T3-NIH, 7F2 or CRL- 
12557 cells. Cell lines have the advantage of requiring no ethical 
approval and a population of identical cells that can be treated with 
defined media. 3T3-L1 cells, in particular, have provided considerable 
information on the molecular mechanisms of adipocyte function. 
Developed during the 1970s [40, 41], much of the work on adipocyte 
differentiation has been carried out using this cell line. However, the 
strengths of cell lines are also one of their weaknesses. Although using 
defined media is helpful in investigating specific processes, there is no 
guarantee that similar mechanisms exist in vivo or truly represent the 
physiological state, which cannot be recreated in these systems.
Therefore, it is worthwhile considering the source of information 
when investigating research on adipose tissue and obesity. Undeniably, 
however, the three forms of study have contributed massively to our 
understanding of the adipocyte and adipose tissue.
Adipogenesis
Adipogenesis is the terminal differentiation of a preadipocyte or stem cell 
into an adipocyte. For adipogenesis to occur, a number of requirements 
must be met, including growth arrest and the expression and activation of 
the transcription factors -  proteins that can bind to promoter regions of 
DNA to enhance or reduce gene expression -  that control adipogenesis. 
Most data concerning adipocyte differentiation have come from the cell 
line 3T3-L1, and latterly from knockout animals lacking various
16
transcription factors. This has resulted in detailed information pertaining 
to adipogenesis in vitro, but relatively little information as to the 
requirements in vivo. This section will describe the mechanism of 
adipogenesis, the methods used to achieve it in vitro and how they relate 
to the in vivo system.
Three major families of transcription factors are involved in the 
differentiation of adipocytes: CCAAT/enhancer binding proteins (C/EBPs), 
peroxisome proliferator activated receptors (PPARs) and adipocyte 
determination and differentiation-dependent factor 1/sterol regulatory 
element binding protein 1 (ADD1/SREBP1). Of the three families, 
ADD1/SREBP1 appears to have the least influence on adipogenesis. The 
ectopic expression of ADD1/SREBP1 is insufficient to initiate 
differentiation, although it does enhance the process under the correct 
conditions [42]. Instead, it seems probable that ADD1/SREBP1 controls 
the expression of some adipocyte genes, including LPL and fatty acid 
synthase (FAS) [42, 43], and is possibly involved in the synthesis of 
PPARy ligands [44].
The central molecular basis of adipogenesis can be ascribed to 
four transcription factors, which are expressed within hours of exposure 
to adipogenic stimuli. These are C/EBPp, C/EBP5, C/EBPa and PPARy 
(specifically PPARy2). Broadly, C/EBPp and C/EBP5 are rapidly 
transcribed and, together, result in the expression of C/EBPa and PPARy, 
which are the most important transcription factors that are involved in 
adipocyte differentiation (Figure 1.1). C/EBPa and PPARy maintain the 
expression of each other, and upregulate the transcription of most of the 
genes that are required for adipogenesis and the function of the mature 
adipocyte. The expression of C/EBPp and C/EBP8 wane once PPARy 
and C/EBPa have been induced [45, 46].
Members of the C/EBP family of transcription factors are bZIP 
proteins, containing a basic leucine zipper domain at the C-terminal for 
binding to DNA [47]. Following the adipogenic signal, the immediate and 
transient expression of C/EBPp and C/EBP5 occurs [48]. Of the two,
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Adipogenic signal
C/EBPp
and
C/EBP8
PPARy C/EBPa
i
Adipogenesis
Increased transcription
Figure 1.1 -  Transcription factors involved in adipogenesis.
Adipogenic signals are initially mediated through the transcription factors 
C/EBPp and C/EBP6. These two factors increase the expression of the 
two major adipogenic transcription factors, PPARy and C/EBPa, which 
are self-perpetuating and initiate the transcription of all the genes that are 
required for adipogenesis to occur.
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C/EBP(3 has the more fundamental role; the ectopic expression of 
C/EBPp alone is sufficient to initiate adipogenesis in the absence of any 
external stimuli [49], whereas C/EBP5 expression is insufficient to 
achieve this.
The transience of expression of C/EBPp and C/EBP5 is because 
their sole purpose appears to be to initiate the transcription of the central 
controller of adipocyte differentiation, PPARy [50, 51]. The third member 
of the C/EBP family that occurs in adipocytes, C/EBPa, is expressed 
concurrently with PPARy. C/EBPa is a powerful inducer of adipogenesis, 
and ectopic expression is sufficient to induce differentiation in the 
absence of external factors [52]. C/EBPa controls the expression of a 
number of vital genes within the adipocyte; in addition to PPARy, C/EBPa 
upregulates the transcription of adipsin, leptin, p3-adrenoceptors, insulin 
receptor (IR) and insulin receptor substrate-1 (IRS-1) [53-55].
Undoubtedly the most important factor that is required for 
adipogenesis is PPARy2, the adipocyte-specific isoform of PPARy [56]. 
Although PPARyl is also expressed in adipocytes, the two isoforms differ 
at the amino-terminus, with PPARy2 containing an extended 30-amino 
acid sequence [57]. PPARy2 is approximately five times more effective at 
stimulating transcription in adipocytes than is PPARyl [58], and PPARy2 
(but not PPARyl) expression alone can restore adipogenesis in PPARy- 
deficient adipose tissue [59]. PPARy exerts its effects through 
heterodimerisation with RXR, the retinoid-X receptor. Within the promoter 
region for PPARy lies a C/EBP-binding consensus sequence, thus 
explaining the upregulation of PPARy by the C/EBPs [50, 60]. However, 
PPARy is such a potent stimulator of adipocyte differentiation that 
adipogenesis will occur even in the absence of any member of the C/EBP 
family [59, 61]. This is also true for other cell types, such as human 
liposarcoma [62] (the expression of both PPARy and C/EBPa also results 
in adipocyte-like differentiation in other cell types [63]). Furthermore, 
PPARy can restore considerable adipocyte function to C/EBPa-knockout
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cells [54]. C/EBPa is inadequate for restoring adipogenesis in PPARy- 
deficient cells [64], and PPARy-deficient animals are frequently nonviable 
during gestation, with survivors having little adipose tissue [65]. As the 
central molecule in adipogenesis, therefore, the action of PPARy is likely 
to result in the expression of almost all adipocyte genes that are not 
specifically controlled by C/EBPa or ADD1/SREBP1. It is also required for 
the continued expression of C/EBPa (and vice-versa) [66]. Antagonism 
between PPARy and C/EBPa also exists for the expression of ob, in 
which the former inhibits expression and the latter increases it [53]. 
Whether this is a common phenomenon has yet to be established.
Promoters of adipogenesis
In vitro differentiation of adipocytes uses a number of different methods 
but all follow the same general principles: growth arrest must occur, 
PPARy and C/EBPa must be induced and the anti-adipogenic effect of 
any other factors must be minimised. Although numerous compounds are 
available to induce differentiation, only one is central to all methods: 
insulin. Insulin, however, has no direct effect on adipogenesis. It does 
potentiate the effect of other factors [67], increasing the number of cells 
within the population that differentiate, as well as increasing lipid 
accumulation in the differentiated adipocytes [68]. Differentiation without 
lipid accumulation can occur [69] but this is rarely desirable. Insulin-like 
growth factor-1 (IGF-1) is also required, but in vitro this is a component of 
calf serum, and thus supplemented in the media [70, 71]. The thyroid 
hormone triiodothyronine (T3) enhances insulin sensitivity and glucose 
uptake, and has been used in the differentiation of adipocytes [72].
Therefore, in addition to insulin, other mediators must be used. 
Glucocorticoids, such as dexamethasone, are potent effectors of 
adipocyte differentiation, with myriad pro-adipogenic effects. 
Dexamethasone causes a rapid rise in the expression of C/EBP5 [73, 74], 
possibly by the activation of the glucocorticoid receptor, which is a 
member of the PPAR superfamily. It also: downregulates the growth-
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arrest-associated gene 2 (GAS2), enabling post-mitotic growth arrest 
[75]; reduces (3-adrenoceptor density on the cell surface, reducing 
lipolysis [76]; increases intracellular cyclic AMP (cAMP) [77]; and 
downregulates pref-1 (preadipocyte factor-1), a gene product that is 
responsible for maintaining the cell in the preadipocyte state [78]. 
Additionally, in association with insulin, it increases the expression of 
GLUT4, enabling the enhancement of glucose uptake and lipid deposition 
[79]. Another powerful inducer of adipogenesis is cAMP, the levels of 
which are increased in differentiating adipocytes by the use of the non­
specific phosphodiesterase inhibitor isobutylmethylxanthine (IBMX). 
Raising cAMP levels within the cell has numerous effects, but those 
relevant to adipogenesis include the inhibition of hormone sensitive lipase 
(HSL) activity [77], the suppression of TNFa expression [80], increasing 
intracellular levels of C/EBPp [81], and decreasing levels of the C/EBPa 
promoter repressor Sp1 [82]. IBMX is usually used in conjunction with 
dexamethasone and insulin.
Direct ligands for PPARy are also excellent adipogenic factors. 
Natural ligands include a number of members of the prostaglandin (PG) 
family, which are produced by mature adipocytes [83]. PGF2a is a potent 
stimulator of differentiation [84], although possibly through a non-PPARy- 
related mechanism. However, 15-deoxy-A12,14-PGJ2 can directly bind to 
and activate PPARy, and might be an endogenous ligand for 
adipogenesis in vivo [26, 85]. Prostaglandins are rarely used in vitro, and 
are substituted for either indomethacin or members of the 
thiazolidinedione (TZD) family of compounds. Indomethacin, a non­
steroidal anti-inflammatory drug (NSAID), binds to and activates PPARy, 
resulting in differentiation [86, 87]. Other NSAIDs can induce adipocyte 
differentiation, notably ibuprofen, but are markedly less potent than 
indomethacin, implying that the mechanism is through the activation of 
PPARy rather than through changes in cyclooxygenase activity [88]. 
Finally, TZDs are extremely effective modulators of PPARy activity and 
adipogenesis [89], which has been suggested as the source of action for
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their anti-diabetic properties. TZDs are potent enough to induce 
adipogenesis in cell lines that are not normally involved in the formation 
of adipocytes, such as stromal bone-marrow cells [90]. Indomethacin and 
TZDs are used to differentiate adipocytes in vitro, the former with insulin, 
and the latter in combination with dexamethasone, IBMX and insulin.
In spite of what is known about the modulators of adipocyte 
differentiation in vitro, relatively little is understood about endogenous 
activators in vivo. Prostaglandins are a possibility, as are T3, insulin and 
insulin-like growth factor-1 (IGF-1). Other molecules that have been 
investigated, such as growth hormone, have successfully differentiated 
cell lines but inhibited adipogenesis in primary culture, making them 
unlikely in vivo effectors [91].
Inhibitors of adipogenesis
A number of endogenous inhibitors of adipocyte differentiation have been 
identified. Probably the best characterised inhibitor is TNFa, which not 
only prevents differentiation but reverses the commitment of cells that are 
already undergoing adipogenesis and induces apoptosis in mature 
adipocytes [92, 93]. Other cytokines and growth factors can also inhibit 
adipogenesis, in particular IL-1 p and a variety of growth factors [94], This 
inhibition appears to be by the activation of various MAPK (mitogen- 
activated protein kinases) intermediaries, which appear to bind to, 
phosphorylate and inactivate PPARy2 [95].
One preadipocyte factor that is absent in mature adipocytes 
appears to be responsible for maintaining the cell in the undifferentiated 
state. Pref-1 is a transmembrane protein containing epidermal growth 
factor (EGF)-like repeats [96]. Its mechanism of action has not been 
described, but it appears only to function when released as a secreted 
factor, created by alternative splicing or proteolytic cleavage [97]. It, 
therefore, appears to be a novel autocrine/paracrine repressor of 
adipocyte differentiation. Pref-1 is not a good marker for preadipocytes, 
however, because although it inhibits adipogenesis, its presence is 
neither required for the preadipocyte state nor its absence a signal for
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differentiation [98], and its expression is not restored by the addition of 
TNFa [99]. It is most likely to be a factor that prevents differentiation if 
present, and is completely absent in the mature adipocyte.
Adipose tissue as an endocrine organ
With the realisation that adipose tissue was secreting a considerable 
number of factors into the circulation, the tissue needed to be reclassified 
from an energy-storage cell to a multi-functional organ. The identification 
of the product of the ob gene, leptin, as an adipocyte-derived secretory 
signalling factor was the first step in this understanding [100, 101]. 
Subsequently, the production and release of TNFa and IL-6 were 
described [102, 103], and, more recently, resistin and adiponectin were 
discovered [39, 104, 105]. It is now widely accepted that adipose tissue is 
an endocrine organ [106, 107]. Of these candidates, only leptin and 
adiponectin are truly adipocyte derived; TNFa, IL-6 and resistin are (or a 
proportion is) released by the non-adipocyte fraction of the adipose 
tissue, of which infiltrated macrophages constitute a significant part [23] 
(although the functions of macrophage-like adipocytes have not been 
established [24]). Here, four of the major adipokines that are related to 
obesity (leptin, TNFa, resistin and adiponectin) will be discussed, in 
addition to IL-6.
Leptin
The search for leptin began with the development of a genetically obese 
mouse during the 1960s [108]. These obv~ mice suffer from early-onset 
obesity as a result of severe hyperphagy [109], and had increased fat 
deposition compared with pair-fed wild-type counterparts [110]. The 
animals exhibit the pathologies that are associated with obesity, such as 
insulin resistance and hyperinsulinaemia [111]. The gene that is 
responsible for the obesity, the ob gene, was cloned in 1994 [100], and 
the product it encodes was isolated soon afterwards [101]. With the ability 
to reduce weight and feeding in obv“ mice it was hailed as a satiety factor
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that might cure obesity [112]. Although this was overoptimistic [113], the 
product of the ob gene, leptin, has revolutionised the study of adipose 
tissue biology.
Leptin was the first true endocrine molecule that was discovered to 
be produced largely by adipocytes. It is a 167 amino acid 16-kDa protein 
that is secreted from mature adipocytes but is absent from preadipocytes. 
Circulating concentrations or expression levels are increased in the 
obese and with age [114] and correlate with BMI [115], percentage body 
fat [116], total body lipid content [35] and adipocyte lipid volume [34]. The 
ob gene contains a binding site for the promoter C/EBPa, which appears 
to cause its transcription during adipogenesis [117]. Investigations using 
TZDs have shown that this C/EBPa effect is antagonised by PPARy, with 
a dramatic reduction in leptin levels following PPARy activation [53]. 
Expression levels of leptin vary considerably between adipose tissue 
depots, with subcutaneous adipose tissue release and mRNA levels 
considerably greater than those of visceral tissue [118]. Furthermore, the 
response to regulators of leptin expression or release, such as insulin, 
dexamethasone and TGF-p, was differentially modulated between these 
tissues [119-121]. Leptin signals through a system of leptin receptors, 
which are similar to gp130. A mutation in the leptin receptor is the 
fundamental defect of the diabetic dbv_ mouse, which is obese and 
insulin resistant [122]. Leptin receptors are expressed in numerous 
peripheral tissues throughout the body, as well as in the brain and the 
central nervous system [123].
The biological effects of leptin are numerous, and some of its 
actions appear to be contradictory, especially in the case of 
autocrine/paracrine responses. Animal studies indicate a tendency to 
inhibit insulin action and lipogenesis and to stimulate lipolysis [124] 
(although possibly only in visceral depots [125]), and these effects have 
also been observed in human adipocytes [126]. Leptin has also been 
implicated in adipocyte apoptosis and the control of cell numbers [127]. 
Correlations between leptin and whole body insulin resistance have been 
observed, as well as the inhibition of insulin action on adipocytes [128,
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129]. However, other studies have found no link between leptin and 
insulin resistance [130] or have identified leptin as an anti-diabetic agent 
[131]. Furthermore, lipodystrophic subjects, with little adipose tissue and 
low levels of leptin, suffer from severe insulin resistance that is reversed 
by the administration of leptin [132]. Part of this confusion might be a 
result of leptin resistance, with the response of leptin in the obese being 
muted because of this [133]. This resistance might also be one of the 
reasons why leptin was less successful as a satiety factor than was 
hoped. Leptin, under normal circumstances, is a potent satiety factor. The 
expression of ob is markedly reduced in fasting animals, and increases 
upon feeding [134, 135], and circulating leptin is able to cross the blood- 
brain barrier and act centrally to reduce feeding [136]. Administering 
leptin to humans has not been particularly successful in combating 
obesity [113], except in the case of individuals with congenital leptin 
deficiency [137]. One further significant metabolic effect of leptin is the 
apparent inhibition of insulin release from pancreatic (3-cells [138]. The 
role of leptin in feeding, obesity and impaired insulin action is complex, 
made more difficult by the effects of insulin resistance, and despite the 
research effort thus far, no clear overall mechanism has been delineated.
In addition to these effects, leptin has many other actions: it is a 
permissive factor for the onset of puberty, in which it has been suggested 
that leptin acts as a signal of sufficient fat stores, enabling the process to 
begin [139]; it is a growth factor promoting haematopoiesis [140] and 
angiogenesis [141]; it causes the proliferation of pancreatic (3-cells [142], 
embryonic cells [143] and pituitary cells [144]; it is involved in wound 
healing [145]; and it is a differentiation factor for osteoblasts [146].
Leptin, therefore, is a true adipocyte-derived hormone, and 
certainly the first reported to have central as well as peripheral effects. 
Whether it has autocrine/paracrine effects, and what they are, is more 
contentious. The expression of ob has recently been detected in other 
tissues, including keratinocytes, endothelial cells, pituitary cells and the 
stomach [145, 147, 148]. How this relates to adipocyte-derived leptin is 
unknown.
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TNFct
As its name suggests, TNFa was originally described as a factor that 
induces necrosis in tumours, and is released from macrophages in 
response to endotoxin stimulation [149]. A second molecule was later 
described, which was termed cachectin and was also macrophage 
derived, which dramatically reduced the activity of lipoprotein lipase (LPL) 
in adipocytes [150], as well as reducing the expression of a number of 
adipocytes genes, including adipsin [151]. Cachectin was subsequently 
identified as TNFa [152], TNFa is also involved in the acute phase 
response, and can induce IL-6 secretion [153]. More recently, its 
expression has been shown in adipocytes, where it might have an 
autocrine/paracrine role in metabolism [102].
TNFa is a 26-kDa transmembrane protein, which can be cleaved to 
create a soluble 17-kDa form of the protein, although both forms of the 
molecule are biologically active [154]. The actions of TNFa are 
dependent upon two receptors, TNFR1 and TNFR2 [155]. Both receptors 
can bind to TNFa and result in signal transduction, and it is possible that 
the varying actions of the cytokine are modulated by each receptor [156]. 
TNFR1, for example, has been implicated in cytotoxic and apoptotic 
signalling [157], whereas TNFR2 has been described as a ligand-passing 
receptor [158]. Despite this, both receptors have the ability to initiate 
phosphorylation cascades and activate multiple pathways [159].
The metabolic effects of TNFa have been well studied, especially 
concerning insulin resistance and diabetes [160]. Curiously, however, 
despite the fact that TNFa is expressed and produced by adipose tissue, 
and that this production is significantly increased in obese individuals, it 
does not appear to be released by adipose tissue or increased in the 
circulation [103, 161]. Nevertheless, TNFa remains a potent modulator of 
adipocyte function. As described by the actions of cachectin, it is a potent 
inhibitor of the actions and production of the lipogenic enzyme LPL, and 
causes an increase in lipolysis, contributing to hyperlipidaemia [162]. 
Furthermore, TNFa induces apoptosis in adipocytes [93, 163], particularly
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from visceral adipose tissue [164], in addition to its ability to inhibit the 
differentiation of adipocytes through PPARy [165], It also increases the 
release of leptin from adipocytes without affecting transcription [166]. 
Finally, TNFa directly affects insulin signalling at numerous points within 
the pathway, therefore inhibiting its action. It suppresses the 
phosphorylation of the IR and its substrates to inhibit the activation of the 
signalling cascade [167], as well as reducing the expression of the 
insulin-dependent glucose transporter GLUT4 [168], which ultimately 
results in whole-body hyperglycaemia [169],
Of particular interest, in terms of both the treatment of disease and 
for research purposes, is the fact that all of these functions of TNFa are 
antagonised and reversed by the TZDs. The addition of TZDs in vitro, or 
the administration of the compounds in vivo, improves insulin sensitivity 
by increasing both the expression and phosphorylation of GLUT4 [170], 
enabling the differentiation of adipocytes [171] and inhibiting TNFa- 
mediated lipolysis [172]. The expression of TNFa in adipocytes does not 
appear to be directly affected by TZDs [173], but an improvement in 
metabolic status and weight loss following TZD treatment might reduce 
TNFa levels. It has been suggested that TNFa in adipose tissue is 
designed to prevent weight gain by limiting the availability and function of 
adipose tissue, but that this results in insulin resistance and the 
deposition of lipid with other tissues, such as muscle and liver [174].
Other adipokines
During the past three years, tremendous interest in two novel adipokines 
has been aroused. These two molecules, resistin and adiponectin, are 
adipose-specific cytokines that have been implicated in the development 
of insulin resistance. With only a few years’ research, the information on 
both of the adipokines is limited and their relevance is as yet 
undetermined, but the possibilities (especially of adiponectin) are 
intriguing.
27
Resistin (which was briefly also known as Fizz3) was first identified 
in 2001, and levels of it were found to be increased in obesity. When 
levels of resistin were reduced by TZDs or anti-resistin antibodies, the 
accompanying insulin resistance was abolished [39]. It was also reported 
to inhibit adipocyte differentiation [175] and, working as a dimer [176], 
appeared to be the adipose-derived molecule that linked obesity and 
insulin resistance [177]. Just as quickly, however, contradictory reports 
were presented. Resistin expression was inhibited by both insulin and 
TNFa, which indicates that a role in insulin resistance is unlikely [178, 
179]. Furthermore, resistin does not appear to be increased in all models 
of obesity [180]. The situation is complicated further by the fact that these 
findings were demonstrated in murine systems, and this has not 
translated well into humans. There are a number of significant differences 
between human and murine resistin, such that some have questioned 
whether, ‘another as yet unidentified gene is the true human homolog of 
the murine Retn gene’ [181]. Resistin expression in human adipocytes is 
minimal, with adipose tissue release accounted for by non-adipocyte 
cells, including preadipocytes [105]. Neither does it appear to correlate to 
indices of obesity, at least in cross-sectional studies [105], although 
correlations have been reported in longitudinal studies [182]. Resistin is 
expressed in other human tissues, however, notably macrophages and 
the placenta [183]. In macrophages, resistin expression is induced by 
cytokines, including IL-6, TNFa and IL-1p [184], Whether this 
upregulation also occurs in adipose tissue is unknown.
Adiponectin, also known as ACRP30 (adipocyte complement- 
related protein of 30 kDa), was initially described in adipocytes, based 
upon its homology to the complement factor C1q [185]. It shares 
evolutionary homology with TNFa [186] and its release from adipocytes is 
enhanced by insulin [187]. Since 2001, promising data have been 
published concerning the effects of adiponectin on insulin sensitivity. In 
both hepatic tissue and muscle, incubation with adiponectin improves 
insulin action [188]. In vivo experiments have provided some particularly 
interesting results, because, unlike the majority of other adipokines,
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adiponectin has a positive effect on insulin sensitivity. Not only does 
administering adiponectin to obese or diabetic organisms improve insulin 
action [189] but a lack of the adipokine results in insulin resistance [190]. 
Circulating levels of adiponectin are reduced in obese individuals, with 
plasma concentrations having a negative correlation with various indices 
of obesity and insulin resistance [191, 192], a situation that does not 
appear to be shared by any other major adipokines that correlate with 
obesity. The release of adiponectin is greater from visceral adipose tissue 
depots, and it appears that release from this depot correlates more 
conclusively with obesity [20]. There does not appear to be acute control 
of the expression or release of adiponectin [193], but the adipokine does 
appear to be under the control of the transcription factor PPARy; 
treatment with TZDs increases adiponectin levels [194], and 
polymorphisms in the PPARy gene affect circulating levels of the 
adipokine [195]. Whether the obesity-related reduction in adiponectin 
release is related to PPARy effects remains to be determined.
Adiponectin appears to be an excellent target for links between 
obesity and its related metabolic diseases. The role of resistin is more 
controversial, but (as with adiponectin) too little is known to draw 
meaningful conclusions from either adipokine.
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Interleukin-6
A brief history
The molecule that is now referred to as IL-6 was originally identified in 
1987, under a number of different guises, by a number of research 
groups. It was initially reported in 1980 from the cloning of its mRNA as 
interferon-p2 (IFN-p2), owing to similarities in anti-viral activity with IFN-p, 
[196]. It was subsequently isolated and sequenced by a number of 
separate research groups (and known as 26K factor, on account of its 
size), noting that it had interferon-like activity but no apparent structural 
homology [197].
A growth factor for hybridomas and plastocytomas in mice was 
isolated from helper T cells and macrophages [198]. A similar human 
molecule was also discovered, and its sequencing revealed a homology 
not to the mouse protein, but to IFN-p2/26K [199]. In separate 
experiments, a third molecule, B-cell stimulatory factor 2 (BSFp-2), was 
isolated based on the ability of a T-cell product to stimulate the release of 
immunoglobulin from B cells [200]. The cloning of this revealed it to be an 
interleukin, and to be identical to IFN-p2/26K. Notably, this is not an 
exhaustive list of the names for IL-6, most of which were derived from its 
actions on a variety of cell types, but an indication of the methods that 
lead to the sequencing and positive identification. Once the sequence 
was published, other factors, such as hepatocyte-stimulating factor, T-cell 
replacing factor and thrombopoietin, were found to be identical to IL-6 
[201, 202].
The structure of both the gene and the protein of IL-6 are now well 
characterised. At the DNA level, there is 65% homology between the 
mouse and human gene [203], and both genes have four introns and five 
exons. The proteins share 42% homology, although much of the 
divergence occurs at the amino terminus, which does not appear to 
contain vital functional information [204]. Human IL-6 is a 21-28-kDa
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protein, depending upon post-translational modification by both N- and O- 
linked glycosylation and serine phosphorylation [205]. Initially produced 
as a 212-residue protein, a 28 amino acid hydrophobic region is cleaved 
to release the mature protein. The solution structure of the protein was 
completed in 1997, indicating that IL-6 has five a-helices, four of which 
form a four-helix bundle (in common with other cytokines, such as 
leukaemia inhibitory factor, LIF, and ciliary neurotrophic factor, CNTF), 
which are separated by loops of various lengths [206]. The murine form of 
the protein is 22-29 kDa, but is not N-glycosylated, and consists of a 211 
amino acid translated peptide from which 24 residues are cleaved [207]. 
In spite of the differences in post-translational modification, human IL-6 is 
active in murine systems, and non-glycosylated forms of the protein are 
functionally active.
The IL-6 receptor system
IL-6 is a member of a superfamily of cytokines, the class 1 cytokine 
receptor family, based upon a common receptor system. Other members 
of the family include LIF, oncostatin-M (OSM), CNTF, cardiotrophin-1 
(CT-1) and interleukin-11 (IL-11), and a degree of functional redundancy 
is exhibited between the members [208]. All members of the family signal 
through the transmembrane receptor gp130, which contains cytoplasmic 
signal transduction domains similar to those of other cytokine receptors 
[209]. Although gp130 does not bind to the cytokines directly, it interacts 
with specific cytokine receptors that do not contain innate signalling 
capacity. A schematic of the receptor binding complexes formed is shown 
in Figure 1.2. The product of the ob gene, leptin, also signals through a 
similar system. Instead of binding to gp130, however, the leptin receptor 
(OB-R) is homologous to gp130 and contains its own signal transducing 
properties [210].
The IL-6 receptor (IL-6R) binds to IL-6 as a heterotrimer with two gp130 
molecules, and is a 468 amino acid, 80-kDa peptide [211]. It has no 
intrinsic signalling domains, lacks tyrosine phosphorylation sites and is 
functional when the cytoplasmic region of the receptor is deleted,
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Figure 1.2 -  Class 1 cytokine receptor binding to gp130.
Ligand and receptor binding to gp130 for signal transduction. Figure 
adapted from Heinrich et al. [217],
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indicating that the purpose of the receptor is to bind to IL-6 and associate 
with gp130 [212]. In addition to its signal transducing function, gp130 also 
appears to create high-affinity IL-6 binding sites in conjunction with IL-6R, 
despite gp130 not directly binding to IL-6. The IL-6R exists in two forms, a 
membrane-bound receptor and a circulating soluble form (slL-6R); the 
latter is formed by the proteolytic cleavage of the membrane receptor 
[213, 214]. Significantly, the binding of SIL-6R to IL-6 potentiates the 
activity of IL-6, enabling it to bind and activate gp130 without the 
involvement of the membrane-bound receptor.
None of the other members of the class I cytokine receptor family 
members binds to IL-6R, although a similar mechanism is used for each. 
LIF, CT-1, CNTF and OSM all bind to the LIF receptor (LIFR) and 
subsequently form a heterodimer with gp130, with the exception of CNTF, 
which also binds to its own receptor and forms a heterotrimer. OSM can 
also bind to a dedicated receptor, OSM-R, and subsequently bind to 
gp130 as a heterodimer. IL-11 is similar to IL-6, in that it binds to its own 
receptor (IL-11 R) along with two molecules of gp130 (Figure 1.2) [215]. 
As does IL-6R, the leptin receptor exists in both soluble and membrane 
bound forms, termed short and long [216]. The short form is not only able 
to bind leptin in the circulation but also contains signal transducing 
capacity [217]. The soluble form of OB-R is formed by different 
mechanisms, depending upon the organism; soluble mouse OB-R is the 
product of a splice variant following gene transcription, whereas in 
humans, the formation mirrors that of slL-6R, with proteolytic cleavage of 
the membrane receptor [218].
JAK/STAT and intracellular signalling
The activation of gp130 signal transduction by IL-6 binding results in an 
intracellular signalling cascade and the activation of nuclear transcription 
factors. Two major pathways are activated, the JAK/STAT (Janus kinase/ 
signal transducer and activator of transcription) pathway and the MAPK 
pathway. The ultimate targets for these cascades are the transcription 
factors STAT3 (STAT1 is also a minor IL-6 target) and nuclear factor
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(NF)-IL-6, from the JAK/STAT and MAPK pathways, respectively. A 
representation of these two pathways is shown in Figure 1.3.
The JAK/STAT pathway involves the phosphorylation and 
activation of the JAK family of tyrosine kinases, followed by tyrosine 
phosphorylation of STAT3 and STAT1. JAKs are associated with the 
gp130 receptors at the cytoplasmic membrane region, prior to IL-6-IL-6R 
binding. IL-6 and its family members affect three Janus kinases: JAK1, 
JAK2 and Tyk2 [219]. Following the binding of IL-6-IL-6R to gp130, the 
receptor associated JAKs are brought into close association and become 
activated by tyrosine phosphorylation [219]. Activated JAKs 
phosphorylate tyrosine residues on the cytoplasmic region of gp130, 
providing a docking location for STATs. Once associated with gp130, the 
STAT is tyrosine phosphorylated by the proximal JAK [220]. Activated 
(phosphorylated) STATs dissociate from gp130 and dimerise, and 
transport to the nucleus (via diffusion), enabling DNA binding and the 
regulation of transcription [221].
The three JAKs that respond to IL-6 (and other members of the 
IL-6 family of cytokines), JAK1, JAK2 and Tyk2, are not equally potent. 
JAK1 appears to be the dominant molecule. Neither JAK2 nor Tyk2 could 
substitute for normal JAK1 functions in cells lacking this kinase [222]. 
Likewise, STAT3 is the major transcription factor involved in IL-6 
signalling, acting as a STAT3 homodimer [223]. Whereas JAK1-deficient 
cells are unable to process IL-6 signalling, a deficiency in STAT3 alters 
the response, resulting in STAT1 homodimers and eliciting a response 
more akin to that of interferon-y (IFN-y) [221]. Under more normal 
conditions, STAT1 homodimers can be (but infrequently are) formed, as 
can STAT3-STAT1 heterodimers.
The alternative method for IL-6 signal transduction is via the MAPK 
pathway. The precise mediators of this cascade have not been identified, 
but the initial interaction between activated gp130 is with SHP2 (SH2- 
domain-containing tyrosine phosphatase). Phosphorylated (and therefore 
active) SHP2 can bind to and activate the Grb/SOS (growth factor 
receptor bound protein/son of sevenless) complex, subsequently binding
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Figure 1.3 -  IL-6 signalling through gp130.
The activation of gp130 by the binding of IL-6 to IL-6R results in the 
phosphorylation of gp130-associated JAKs. The subsequent tyrosine 
phosphorylation of gp130 enables the binding of intracellular 
messengers. The left-hand portion shows a simplification of the activation 
and dimerisation of STAT3, which diffuses to the nucleus and modulates 
transcription. The right-hand side shows the activation of the MAPK 
pathway; the activation of SHP2 and a signalling cascade involving the 
phosphorylation of a number of kinases. MAPK translocates to the 
nucleus and activates the transcription factor NF-IL-6 (C/EBPp).
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to Ras. This activates the MAPK pathway, involving the consecutive 
phosphorylation and activation of Raf, MEK and MAPK prior to the 
activation of the transcription factor NF-IL6 [224]. Intriguingly, NF-IL6 is 
also known as the transcription factor C/EBPp, a member of the 
transcription family that is crucial for the differentiation of adipocytes 
[225], In addition to activating the MAPK pathway, a complex involving 
SHP2 might also activate, or assist in activating, STATs. Notably, the 
small GTPase Rac-1, a member of the Raf family of signal transducing 
components, is involved in IL-6-induced STAT3 activation [226].
How these two pathways interact is still under investigation, 
leaving a number of questions unanswered. How does IL-6 elicit its 
multifarious responses using only two (major) transcription factors? How 
do the same factors elicit different responses in numerous cell types, 
following the same initial signal? And, with the (partial) redundancy that 
occurs among the cytokines, how are the specific signals from individual 
cytokines separated? Furthermore, it is not just IL-6 and the cytokines 
that signal via these intracellular messengers. MAPK signals can be 
initiated by stress signals, hormones, growth factors and other cytokines 
[227]. Mutational analyses of tyrosine residues in gp130 have indicated 
that JAKs, STATs and SHP2 bind to different moieties on the receptor 
[215, 228], but how the differential activation of each occurs is unclear. 
Other epitopes on gp130 differentially respond to the binding of the 
various members of the IL-6 family of cytokines [229], and intracellular 
adaptor proteins have been implicated in responses to specific cytokines 
[230]. Furthermore, IL-6 can induce contradictory signals in the same cell 
at the same time [231], indicating that the final response might depend 
upon other factors within the cell at the time of stimulation. Intracellular 
signalling is still poorly understood; although the major pathways have 
been elucidated, very little is known about specific control mechanisms or 
redundancy and promiscuity among the signal transducing elements.
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Cellular sources and the release of IL-6
As indicated by its multiple discovery, IL-6 is released from a wide variety 
of cells [202, 232], including monocytes and macrophages, T cells, mast 
cells, fibroblasts, tumour cells, endothelial cells, epithelial cells, 
keratinocytes, skeletal muscle [232] and, of course, adipose tissue [103]. 
The regulation of IL-6 release differs among the cell types, even following 
the same stimulus. Lipopolysaccharide (LPS) induces IL-6 release from 
various cells, including macrophages and human umbilical vein 
endothelial cells (HUVEC) [198, 233], as do viral infections and other 
cytokines, such as TNFa and IL-1p [234]. IL-1p induces IL-6 release from 
adipocytes [235], and circulating levels of IL-6 are chronically raised in 
obesity, with significantly more release from omental adipose tissue 
depots [236],
The gene encoding IL-6, which is located on chromosome 7p21 
[237], contains a number of transcriptional regulators, including a c-fos 
serum response element [203], a second messenger multiple response 
element (MRE) region and TATA box [238], an interleukin response 
element (ILRE) [239] and a C/EBP site [240]. These enable acute and 
specific control through a number of mediators. Nuclear factors that are 
known to activate the IL-6 gene include NF-IL-6 (C/EBPp) and NF-kB, 
and repression has been shown by glucocorticoids. Polymorphisms in the 
(human) IL-6 gene that affect expression have also been observed, most 
markedly the -174 G/C polymorphism [241] which might be related to 
differences in insulin signalling.
The control of IL-6 release is, therefore, carefully regulated and 
dependent on a wide range of inhibitors and promoters in a number of 
cell types. Normal circulating IL-6 levels in humans are less than 3 pg/ml. 
Infection or injury can drastically, but acutely, increase these levels, up to 
levels greater than 200 pg/ml. Similar acute elevations are seen after 
exercise. Plasma levels tend to return to baseline rapidly (< 24 h) once 
the stimulus is removed. However, chronic elevation of IL-6 also occurs, 
notably in ageing [242], obesity [243], diabetes [244] and coronary heart
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disease (CHD) [245]. Concentrations in these conditions rarely rise above 
10 pg/ml, but levels remain elevated, and might be involved in pathogenic 
responses [246].
The acute phase response and other effects
Just as several modulators control IL-6 release, the protein itself has 
multifarious effects, again on a whole host of cell and tissue types. 
Obviously, many of these functions are those that led to the isolation and 
cloning of IL-6 itself: hybridoma and plasmacytoma growth, T-cell 
activation and B-cell differentiation, as well as an abundance of less well- 
studied roles. Possibly the best-documented role, however, is that of the 
acute phase response.
The acute phase response is the defence mechanism that is 
triggered following infection or injury in the organism. The pathway 
involves the local release of inflammatory mediators, including IL-6, as 
well as IL-ip, TNFa and interferons, followed by systemic reactions 
resulting in fever, lymphocyte proliferation and the release of acute phase 
proteins from the liver. Partial redundancy occurs among the cytokines in 
their ability to initiate the response, and the addition of one of the 
cytokines will (at least partially) cause the reaction to proceed [247]. 
However, although TNFa and IL-1p elicit most of the normal response, 
only IL-6 is capable of stimulating the release of all of the acute phase 
proteins [248]. Studies on human hepatocytes or cultured hepatic cells 
revealed the range of proteins that are upregulated by IL-6, including C- 
reactive protein (CRP), fibrinogen, serum amyloid A and haptoglobin 
[249]. As implied by its name, the reaction is acute; IL-6 is rapidly 
released, within 30 minutes of LPS injection, peaking at 2 h [250]. IL-6 
clearance is also rapid, with a biphasic clearance consisting of an initial 
half-life of three minutes and a longer secondary half-life of 55 minutes 
[251].
IL-6 can also act as a growth and differentiation factor for a 
number of cell types. It is a potent activator of growth for both B-cell 
hybridomas and murine plasmacytomas [202], in which it can replace
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feeder cells. IL-6 is required for terminal B-cell differentiation, without 
affecting resting B-cell status or B-cell growth [202]. T-cell activation by 
IL-6 occurs in synergy with IL-1(3, resulting in thymic and peripheral T-cell 
proliferation and cytolytic T-cell responses [252].
This demonstrates the numerous actions of IL-6 as an acute 
activator of various facets of the immune system. The responses that are 
elicited are beneficial in fighting infection or repairing injury but would be 
deleterious to health if prolonged. Latterly, metabolic and endocrine 
effects of IL-6 have been described (of which some, but not all, are 
related to the acute phase response). The chronic elevation of plasma 
IL-6 in obesity, diabetes and cardiovascular disease has pathogenic 
consequences, which might, in part, be due to the inappropriate activation 
of the acute phase response, albeit at reduced levels. The metabolic and 
endocrine effects of IL-6, and the differences in chronic exposure, are 
discussed below.
Most of our knowledge of IL-6 comes from investigation into its 
immunological functions. Nevertheless, recent studies have indicated the 
importance of cytokines such as IL-6 in metabolic activity, not least the 
fact that IL-6 is released in significant concentrations by adipose tissue, 
especially in the obese [103]. Prior to this discovery, other ‘inflammatory’ 
cytokines, such as TNFa, had been reported in adipocytes, and 
implicated in pathologies of obesity [102]. The question still remains as to 
whether IL-6 has similar properties.
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IL-6 and adipose tissue
In spite of the volume of literature that is available concerning the role of 
IL-6 and the immune response, relatively little is known about the role and 
regulation of the cytokine in adipose tissue, even compared with the other 
adipokines. It is released by adipose tissue [103, 253], and circulating 
levels correlate with all measurements of obesity and insulin resistance 
[254]. Its circulating levels are reduced with weight loss and reduction in 
fat mass [255], and its release, in obese subjects at least, is significantly 
greater from visceral adipose tissue [236]. Several factors have been 
reported to affect adipocyte release of IL-6: it is upregulated by 13- 
adrenoceptor stimulation [256], catecholamines and insulin [257], IL-ip 
[235], exercise [258], TNFa and growth hormone, as well as IL-6 itself 
[259, 260]; and it is unaffected by food intake [261] or glucocorticoids 
[262] (although dexamethasone has been reported to reduce IL-6 
expression [257]). This indicates that adipose-tissue-derived IL-6 is an 
autocrine/paracrine modulator, or acts on peripheral organs as a true 
endocrine signal. However, much of the research concerning the IL-6 
effect on adipocytes is contradictory.
Notwithstanding the correlations with insulin resistance, IL-6 has 
been reported to increase basal and insulin stimulated glucose uptake in 
cultured adipocytes [263], or to have no effect [264]. Recently, however, it 
has been suggested that IL-6 reduces the expression of the insulin 
signalling components IRS-1 and GLUT4, as well as PPARy [265, 266]. 
Similarly, there is little agreement concerning the effects of lipolysis. In 
breast adipocytes, IL-6 increased basal and stimulated lipolysis [267], 
and exercise-induced-IL-6 might also enhance the release of fatty acids 
from adipocytes [258]. Whole-body lipolysis increases with the infusion of 
IL-6 [268] and LPL activity is reduced [269]. However, other research has 
suggested that IL-6 has no effect on lipolysis in adipocytes [270]. The fact 
that IL-6 resulted in lipolysis from adipocytes surrounding lymph nodes 
but not gonadal adipocytes indicates that depot-specific differences in
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response to IL-6 might occur [271], IL-6 might also affect the expression 
or release of other adipokines. It has been reported to reduce the 
expression of leptin [272] and adiponectin [273] but to increase resistin 
levels [184].
Intriguingly, whole-body IL-6 knockouts are prone to late-onset 
obesity, which can be reversed by the administration of IL-6 [274], and 
intracerebroventricular IL-6 reduces food intake and body weight [275]. 
This suggests that IL-6, similar to leptin, has a central role in the 
development of obesity. Whether this translates into humans has yet to 
be established, although low levels of IL-6 in cerebrospinal fluid are 
inversely correlated with obesity [276]. The origin of cerebrospinal IL-6 is 
unknown, as is the ability of circulating IL-6 to be transported from the 
circulation.
Research into IL-6 and adipose tissue to date makes it very 
difficult to assess its importance. Although many statements have been 
made regarding its effects, disparity in the methods used ensures that 
different reports cannot be judged against each other adequately.
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Aims of the study
Although the immunological effects of IL-6 have been well characterised, 
little is known of the importance of adipose-tissue-derived IL-6. Seemingly 
opposite effects have been recorded. This study, therefore, intends to 
investigate both the release and autocrine/paracrine effects of IL-6 in 
relation to adipose tissue.
First, the mechanism of IL-6 release from adipose tissue will be 
established. This will include investigations into the release of IL-6 from 
adipose tissue obtained from both lean and obese animals, to establish 
whether there is a fundamental difference in the tissue itself in the obese 
state. Furthermore, the variation in IL-6 release between visceral and 
subcutaneous depots will be examined.
The second part of this study will investigate the consequences of 
incubating IL-6 with cultured adipocytes, mimicking the 
autocrine/paracrine effects. Three major functions of adipocytes and 
adipose tissue will be examined: adipogenesis, glucose uptake and 
lipolysis. In addition, the effect of acute versus chronic incubation of IL-6 
will be assessed.
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Chapter 2 -  Materials and Methods
Materials
Unless otherwise stated, laboratory chemicals and reagents were 
purchased from Sigma, Poole, UK.
Cell culture and laboratory plastics were purchased either from 
Corning Costar, Schiphol-Rijk, The Netherlands; Nalge-Nunc (via Fisher 
scientific, Leicester, UK); or Sarstedt, Leicester, UK. Dulbecco’s modified 
Eagle medium (DMEM), penicillin/streptomycin and trypsin were obtained 
from Gibco (Invitrogen), Paisley, UK. Bovine calf serum (BCS) and 
cosmic calf serum (CCS) were from Perbio, Tattenhall, UK. ‘Cell-gro’ 
serum-free media (containing albumin) was supplied by Mediatech, VA, 
USA. p-adrenoceptor agonists were from Sigma, except CL316243, 
which was a gift from Gokhan Hotamisligil, Harvard University, USA. 
Differentiation agents were also supplied by Sigma, with the exception of 
BRL 49653 (rosiglitazone), which was a kind gift from GlaxoSmithKline, 
Harlow, UK. 3H-deoxyglucose was purchased from NEN, MA, USA, and 
was measured using a Wallac (Turku, Finland) 1209 RackBeta liquid 
scintillation counter. Recombinant mouse and human IL-6 and mouse 
IL-1p were purchased from R&D Systems, Abingdon, UK.
Murine IL-6 and leptin ELISA kits were supplied by R&D Systems. 
Reagents for glycerol assay were from Sigma. Colourimetric assays were 
read on an Opsys MR (Dynex Technologies, Virginia, USA) plate reader, 
or a Uvikon 922 spectrophotometer (Kontron Instruments, Watford, UK).
Products for RNA isolation were all obtained from Sigma. Materials 
for cDNA synthesis were from Promega, Southampton, UK, except for 
nuclease-free water, which was supplied by Ambion, Huntingdon, UK. 
End-point reverse-transcription (rt)-PCR analysis products were also 
supplied by Promega. SYBR-Green reagents for real-time rt-PCR 
analysis were purchased from Applied Biosystems, Warrington, UK. All 
oligonucleotides were synthesised by Oswel, Southampton, UK. End­
point rt-PCR was carried out on a Hybaid Omn-E thermal cycler (Thermo 
Hybaid, Ashford, UK): real-time rt-PCR on an ABI-PRISM 7000 (Applied
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Biosystems). Agarose gel equipment was purchased from Bio-Rad, 
Hemel Hempstead, UK.
Probes for northern blot analysis were a generous gift from 
Gokhan Hotamisligil. Isolation material for these probes was purchased 
from Qiagen, Crawley, UK. Transfer paper was purchased from ICN, CA, 
USA or Amersham Pharmacia, Chalfont St. Giles, UK. Restriction 
enzymes were supplied by Promega. A Hoefer UVC 500 cross-linking 
machine was used, and blots were developed using a Kodak X-OMAT 
1000 processor (Hemel Hempstead, UK).
Equipment for western blotting and reagents for protein estimation 
were purchased from Bio-Rad. Protease inhibitors (‘Complete Mini’ 
cocktail) were from Roche Diagnostics, Basel, Switzerland. ECL reagents 
were obtained from Amersham Pharmacia. Antibodies were purchased 
from Chemicon (Hampshire, UK) or Santa Cruz (CA, USA).
Animals were purchased from Harlan Sera-Lab, Loughborough, 
UK. The murine preadipocyte cell line 3T3-L1 was obtained from ATCC 
(VA, USA), and the 3T3-F442A cells were a gift from Gokhan 
Hotamisligil.
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Methods
Preadipocyte cell culture
3T3-L1 and 3T3-F442A preadipocytes were grown on 75 cm2 tissue 
culture flasks in 10 ml of DMEM containing 10% BCS and 1% 
penicillin/streptomycin, in a controlled environment at 37°C and 10% CO2. 
Upon attaining near-confluence (approximately 85%), cells were 
trypsinised and passaged or seeded for differentiation. These cell lines 
were chosen for a number of reasons: 3T3-L1 cells are readily available 
from commercial sources; both cell lines are well established murine cell 
lines for adipocyte research [40], with numerous published methodologies 
[277, 278]; and the ability to differentiate these cells and use them for 
measurements was already established in our laboratory (unpublished 
data).
Cells for differentiation and experimentation were seeded onto 6- 
well tissue-culture plates at a density of 6 x 104 cells/well, and incubated 
at 37°C and 10% C 02 in 1 ml DMEM/BCS. After 24 h, the media was 
changed to a new mixture of DMEM containing 10% CCS and 1% 
penicillin/streptomycin. Preadipocytes were grown to confluence at 37°C 
and 10% C 02, whereupon they were transferred to a differentiation- 
induction medium.
Adipocyte differentiation
Upon attaining confluence, preadipocytes were treated for 72 h with a 
differentiation induction media designed to cause growth arrest, entry into 
the adipogenic cell cycle and lipid deposition [41, 279]. Unless otherwise 
stated, the induction media consisted of DMEM containing 10% CCS 
supplemented with the glucocorticoid dexamethasone (0.1 pM), the 
phosphodiesterase inhibitor IBMX (0.5 mM), insulin (5 j-ig/ml) and the 
thiazolidinedione BRL 49653 (rosiglitazone, 1 pM). These inducers (with 
or without thiazolidinediones) are the most frequently cited for the
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differentiation of 3T3-L1 and 3T3-F442A adipocytes [280]. Although the 
precise concentrations of the compounds vary, they remain relatively 
similar (for example, dexamethasone concentrations are generally cited 
in the range 0.1-0.6pM: IBMX is invariably used at 0.5 mM) [98, 166, 
281], Moreover, this technique was established within the laboratory 
(unpublished data). After 72 h incubation at 37°C and 10% CO2, 
dexamethasone, IBMX and BRL 49653 were withdrawn and the cells fed 
with fresh DMEM/CCS containing 1 pM insulin every 48 h until > 90% of 
cells were lipid containing adipocytes (assessed by light microscopy).
Other adipogenic factors or methods were also used to assess 
adipogenesis (Chapter 4). The first alternative method substituted 1 mM 
IBMX for dexamethasone, BRL 49653 and 0.5 mM IBMX 
(dexamethasone was removed to investigate whether its numerous 
actions were essential for differentiation. One idea, which was not 
followed up owing to time limitations, was to investigate a more 
physiological method for differentiating adipocytes: the removal of 
dexamethasone was intended to be a starting point for this); the second 
substituted 125 pM indomethacin for dexamethasone, IBMX and BRL 
49653. These cells were otherwise treated identically to the general 
method described above, with the 72 h incubation in the adipogenic 
mixture followed by feeding with DMEM/CCS supplemented with insulin 
every 48 h until fully differentiated. As with the dexamethasone, IBMX 
and insulin treatment, this is a well-established protocol [282]. A third 
alternative method involved feeding with DMEM/CCS supplemented with 
2 nM T3 and 17 nM insulin, in the absence of all other adipogenic factors, 
for both the initial 72 h and at every subsequent 48 h feeding [283, 284]. 
The precise methodologies are further described in Chapter 4, and their 
background is explored in Chapter 1.
Light and confocal microscopy
Cell confluence and differentiation were assessed by eye using light 
microscopy. To obtain a quantitative measure of differentiation (as 
defined by lipid accumulation), samples of cells were treated with the
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fluorescent neutral-lipid-staining dye BODIPY 493/503 [285]. Adipocytes 
at selected time points during differentiation were displaced and seeded 
onto sterile coverslips. Cells were incubated for 15 minutes in a 40 pM 
solution of BODIPY 493/503 in HEPES buffer, pH 7.4. Cells were viewed 
on a Zeiss confocal microscope, with the dye excited at 493 nm and 
fluorescence measured at 503 nm. Images were viewed using LSM 
Image 5 Processor.
The BODIPY 493/503 images were then binarised above a 
threshold, so that all pixels containing signal (lipid droplets) were set to 
unity and all background to zero. A projection of a z-stack was used to 
include the full cell volume. The mean signal per cell was then expressed 
as a factorial value; total lipid engorgement could give a signal of one and 
no lipid a signal of zero. Quantitative measurements of BODIPY 493/503 
were made using the processing package Lucidia (Kinetic Imaging, NC, 
USA).
Glucose uptake
3T3-L1 and 3T3-F442A cells were differentiated as described above, 
using dexamethasone, IBMX, insulin and BRL 49653. Once fully 
differentiated (assessed by microscopy) cells were treated for 24-72 h in 
Cell-gro, in the absence or presence of 10ng/ml IL-6. Media was 
replaced every 24 h, where necessary. Cells were then washed with 
Krebs Ringer phosphate buffer, pH 7.4 (KRP: 128 mM NaCI, 4.7 mM KCI, 
1.25 mM CaCfe, 1.25 mM MgS04 and 1 mM Na2HP0 4, at pH 7.4) warmed 
to 37°C, and incubated for 30 minutes at 37°C with Cell-gro, in the 
presence or absence of 2 pg/ml insulin. Ten minutes prior to the end of 
this incubation, 1 pi tritiated deoxyglucose (3H-DOG) per ml media was 
added to each mixture. Following the incubation, cells were placed on ice 
and washed twice with ice-cold KRP buffer. Adipocytes were lysed with 
0.1% SDS by incubating for 30 minutes at 37°C and homogenised by 
repeat pipetting. 800 pi of the homogenate was added to 8 ml scintillation 
fluid and the internalised 3H-DOG measured by scintillation counting [171, 
263].
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A modified version of this protocol was used to measure protein 
levels by western blotting. No 3H-DOG was used and instead of being 
lysed with 0.1% SDS, the cells were immediately flash frozen in liquid 
nitrogen and stored at -80°C. Protein levels were measured as described 
below.
Further details on these methods are described in Chapter 5. 
Lipolysis
3T3-F442A or 3T3-L1 adipocytes were differentiated as described above, 
using dexamethasone, IBMX and insulin until > 90% of cells were lipid- 
containing adipocytes (as assessed by light microscopy). Adipocytes 
were then incubated at 37°C and 10% CO2 for 8-72 h in Cell-gro, in the 
absence or presence of 10 ng/ml IL-6, re-feeding every 24 h, as required. 
Following this pre-incubation, cells were incubated (37°C, 10% CO2) for 
6 h in Cell-gro containing 1 pM dobutamine, 1 nM clenbuterol, 1 
CL316243, 1^ iM noradrenaline, 2.5 mM dbcAMP or with no additive. The 
adipocytes that were pre-incubated with IL-6 were also incubated with 
10 ng/ml IL-6 during the 6 h lipolysis incubation. After 6 h, the media was 
removed from the cells and assayed for glycerol accumulation [286]. The 
adipocytes were stored for RNA isolation. Further details are described in 
Chapter 5.
Animal explants
C57BL6/J or ob~y~ mice were housed, fed, maintained and killed by 
Biological Services, UCL, according to Government guidelines. Weight 
measurements were made on live mice and blood collected by tail bleed. 
Subcutaneous or epididymal adipose tissue (the latter representing 
visceral or omental fat), or liver, was removed from recently killed 
animals, and washed twice in phosphate-buffered saline (PBS). Obvious 
blood vessels were avoided; however, adipose tissue contains a 
significant fraction of non-adipocyte cells, notably macrophages and 
stromal-vascular cells, the former of which increases with obesity (in 
which up to 60% of cells could be macrophages) [23]. The experiments
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reported here do not differentiate between the release of IL-6 from the 
individual cell sources (the intention was also to study isolated adipocytes 
[235], but time constraints meant that this was not possible). Tissues 
were cut into small fragments and weighed prior to experimentation. 
Tissue fragments were incubated for 5 h or 24 h in Cell-Gro, containing 
5pg/ml IL-1p, 1 pM CL316243, 100pg/ml cycioheximide or 0.5pg/ml 
brefeldin A [166, 287, 288]. Following incubation, media was removed 
and retained for assay, and tissue was flash frozen in liquid nitrogen and 
stored at -80°C for RNA isolation. See Chapter 3 for further detail.
RNA isolation
To preserve the labile RNA, all products used for RNA isolation were 
treated with di-ethyl pyrocarbonate (DEPC). Water was sterilised by 
adding 0.01% DEPC, incubating overnight at 45°C and autoclaving. 
Chloroform, isopropanol and ethanol were prepared by adding 1% DEPC 
to each solution [289].
RNA was isolated from cultured cells using Tri-reagent and a 
phenol/chloroform method [290]. To each well of a 6-well tissue-culture 
plate 400 jul of Tri-reagent was added, mixed and incubated at room 
temperature for five minutes. Cells were homogenised by repeated 
pipetting and equivalent cells were pooled (where necessary). Samples 
were centrifuged at 12000xg for ten minutes at 4°C. The supernatant 
solution was transferred to a fresh centrifuge tube and DEPC-chloroform 
was added (200 pi chloroform per 1 ml Tri-reagent used to digest the 
cells). Samples were mixed by vortexing and incubated at 4°C for 15 
minutes. Samples were then centrifuged at 12000xg for 15 minutes at 
4°C and the supernatant solution removed. A 1/i0 volume of DEPC- 
isopropanol was added, vortexed and incubated at room temperature for 
two minutes, prior to centrifugation at 12000 xg for ten minutes at 4°C. 
The supernatant solution was again removed to a fresh tube and DEPC- 
isopropanol was added (500 pi isopropanol per 1 ml Tri-reagent used to 
digest the cells). Samples were incubated overnight at -20°C, and
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subsequently centrifuged at 14000 xg for 30 minutes at 4°C. All liquid 
was removed and the pellet was washed in 1 ml (per 1 ml of Tri-reagent 
used to digest the cells) 75% DEPC-ethanol. Following further 
centrifugation at 14000 x g for 10 minutes at 4°C, the pellet was air-dried 
and reconstituted in 50 pi nuclease-free water.
Animal tissue RNA was extracted using 1 ml TRI reagent per 
(approximately) 500 mg tissue. Frozen tissue was crushed under liquid 
nitrogen to a fine powder and added to TRI reagent for homogenisation. It 
was subsequently isolated as described above.
cDNA synthesis
The concentration and purity of isolated RNA was assessed by 
measuring optical density at 260 nm (OD26o) and 280 nm (OD28o) [289]. A 
dilution of the sample of 4 pi in 1 ml DEPC-water was made in a crystal 
cuvette and measured at both OD26o and OD28o (using pure water as a 
blank for each measurement). At OD26o, an optical density of 1 
corresponds to approximately 40 pg/ml RNA in an undiluted sample. 
Therefore, with the above dilution, an OD of 1 would correspond to 
10 mg/ml. Thus, multiplication of the measured OD26o by 10 provides the 
RNA concentration in pg/pl. Purity of the RNA preparation was assessed 
as a ratio of OD26o:OD280, in which a value of 2 indicates pure RNA, and a 
reading between 1.7 and 2.1 is considered acceptable purity.
A volume of RNA sample containing 10pg RNA (as calculated 
using the method above) was used to synthesise cDNA, according to the 
standard method indicated by Promega. To this, a mixture of 14 pi 5x 
reverse transcriptase buffer, 7 pi 0.1 M DTT, 4 pi 20 mM dNTP, 2 pi 
40 U/pl RNAse inhibitor and 1 pi 50 pmol random oligonucleotide primers 
was added, and a total volume of 66 pi was prepared (using nuclease- 
free water). The mixture was heated to 65°C for ten minutes and 4 pi 
200 U/pl reverse transcriptase added, and the sample incubated at 42°C 
for 90 minutes. cDNA samples were stored at -80°C until required for rt- 
PCR analysis.
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End-point rt-PCR analysis
End-point rt-PCR was carried out using specific primers for p-actin, 
PPARy, C/EBPa, adipsin, IL-6 and the leptin. To 5 pi cDNA was added 
10 pi 10x Taq polymerase buffer, 2 pi 5 mM dNTP, Mg2+ and 50pmol 
each of forward and reverse primers (Figure 2.1), made up to 100 pi in 
H2O. Samples were denatured at 95°C for 5 minutes, 0.5 pi Taq 
polymerase and 20 pi paraffin oil added, and cDNA amplified using 
specific primer conditions (Figure 2.1). Cycle lengths were: dissociation, 
95°C, 30 seconds; annealing, primer specific (Figure 2.1), 1 minute; 
elongation, 72°C, 1 minute.
rt-PCR products were visualised on a 2% agarose gel. 2 g agarose 
was dissolved in 100 ml TBE buffer (89 mM Tris, 89 mM boric acid and 
2 mM EDTA), 4 pi ethidium bromide was added, and the gel was enabled 
to set [289]. Samples were loaded as 25 pi rt-PCR product mixed with 
5 pi DNA loading buffer, and run at 80 V for 30 minutes. Agarose gels 
were visualised using a UVP ultraviolet lamp, box and software 
(Cambridge, UK).
Real-time rt-PCR analysis
Specific primer sequences for Taq-man® rt-PCR analysis were (i) 
purchased directly from the supplier (Applied Biosystems), (ii) designed 
using the software package Primer Express (Applied Biosystems), 
fulfilling all the criteria of primer design for this application or (iii) 
sequences from previously published papers [291-293]. Details of the 
primers used are shown in Figure 2.2. Real-time rt-PCR primers differ 
from those used for end-point rt-PCR because of the conditions used to 
carry out the reactions; whereas end-point rt-PCRs can be carried out at 
a range of temperatures (generally 56-64°C), for a varied number of 
cycles (determined by running the primers with a positive control through 
a number of cycles to find the linear growth period) and with different 
MgCI concentrations (generally < 5 mM), real-time rt-PCR conditions are 
fixed and require more stringent primer selection (which includes limits to
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Primer Sequence (5’ -  3’) [MgCI]
mM
Tm
°C
No. of 
cycles
Actin F AAGTACT CCGT GT GG AT CGG 5 58 30
Actin R CACCTT CACCGTT CCAGTTT
Adipsin F T GCACAGCT CCGT GTACTT C 0.5 56 30
Adipsin R CACCTGCACAGAGT CGT CAT
C/EBPa GGGACTTAGGTGTTGGGGAT 0.5 56 35
C/EBPa GG AAACCT GGCCT GTT GTAA
IL-6F CCGGAGAGG AGACTT CACAG 2 58 30
IL-6R CAG AATT GCCATT GCACAAC
ob F CTCATGCCAGCACTCAAAAA 1 58 30
ob R AGCACCAC AAAACCTGAT CC
PPARy F TTTT CAAGGGTGCCAGTTT C 3 58 30
PPARy R TTATT CAT CAGGGAGGCCAG
Figure 2.1 -  Primer sequences and running conditions for end point 
rt-PCR amplification of adipocyte gene products.
Forward (F) and reverse (R) primers for end point rt-PCR designed from 
published mRNA sequences and internet-based primer-design software. 
Shown are the sequences, magnesium chloride concentration, melting 
temperature (Tm) and number of cycles.
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Primer Sequence (5’-3 ’)
Adipsin F GCTATCCCAGAATGCCTCGTT
Adipsin R GTTCCACTTCTTTGTCCTCGTATTG
P2-AR F TGCCTATCCAGATGCACTGGTA
P2-AR R CACAGCAAGT CT CCT CGGT GTA
P3-AR F CCT CCT CCGTCT CCTT CTACCT
P3-AR R CGCTTAGCCACAACGAACACT
C/EBPa F T GCGCAAGAGCCGAGATAA
C/EBPa CGGTCATTGTCACTGGTCAACT
GAPDHF T CAACTACATGGT CTACAT GTT CCAGTA
GAPDHR CGCTCCT GGAAGATGGT GAT
IL-6F CAG AATT GCCAT CGTACAACT CTTTT CT CA
IL-6R AAGTGCATCATCGTTGTTCATACA
ob F ACCGCT CACCCACTTTT C AA
ob R CGACCACTATCAGCAGCTACACA
PPARy F GGGT G AAACT CT GGG AG ATT CT C
PPARy R TGCTCATAGGCAGTGCATCAG
Figure 2.2 -  Primer sequences for real time rt-PCR.
Forward (F) and reverse (R) primers designed using Primer Express 
software for Taq-man rt-PCR, or from previously published papers.
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the GC content, their positions within the primers and the number of 
contiguous Gs). Therefore, although the latter primers might work for end­
point PCRs, the reverse is unlikely to be true. The Primer Express 
software often provides more than one possible set of primer pairs. As 
long as the sequence is unique, the set of primer pairs chosen should not 
affect the reaction.
Primers were prepared individually to a concentration of 
80 nmol/ml, and forward and reverse primers were mixed 1:1 to give a 
final concentration of 40 nmol/ml of each primer. Reconstituted primers 
were stored at -20°C. Samples were run (at least) in duplicate, as 25 pi 
total volume per well in 96-well rt-PCR microtitre plates. This final volume 
consisted of 12.5 pi SYBR-green solution, 1.25 pi specific primer, 1 pi 
cDNA and 10.25 pi nuclease-free water. For each sample, a control 
mRNA, GAPDH (glyceraldehyde-phosphate dehydrogenase) [294], was 
run concurrently in duplicate. A negative control, nuclease-free water, for 
each set of primer pairs used was also included in each rt-PCR reaction. 
For each reported result, a minimum of three separate samples (i.e. the 
tissue or cells from three individual wells) were tested in duplicate. 
Amplification conditions using this method remain constant independent 
of the primer sequences used, providing the initial criteria are met. 
Reactions were run using the standard procedure specified by the ABI 
Prism 7000 software.
Data were analysed using a method described by Livak and 
Schmittgen for the relative quantification of real-time rt-PCR data [295]. 
This method, known as 2“^°*, calculates the relative changes in gene 
expression between two or more samples, in which one sample is 
nominated as a (BaselineD(or calibrator) and all remaining samples are 
compared with this. Mathematical data and methods are shown in the 
appendix.
Northern analysis
RNA was isolated and quantified as described above. A 1% agarose gel 
was prepared by boiling 1 g agarose in 95 ml MOPS buffer (20 mM
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MOPS, 5 mM sodium acetate and 1 mM EDTA), allowing the mixture to 
cool to approximately 60°C, adding 5 ml formaldehyde, and pouring. 
Once set, the gel was transferred to an electrophoresis tank in TBE 
buffer. RNA samples (20 pg total) were mixed with RNA loading buffer 
[50% formamide, 17% formaldehyde (36%), 6% glycerol in MOPS buffer, 
containing 1% ethidium bromide and bromophenol blue] to a total of 
30 pi, denatured at 65°C for 10 minutes and loaded onto the gel. The gel 
was run at 80 V for 45 minutes, visualised under ultraviolet (UV) light, and 
washed for 30 minutes in DEPCCH2O to remove excess formaldehyde. 
Concurrently, a gel-sized piece of nylon transfer membrane was soaked 
for 30 minutes in 2x SSC buffer (3 M sodium chloride and 0.3 M sodium 
citrate). The gel was removed from the DEPCCH2O and placed upon five 
sheets of Whatmann filter paper, which had been pre-soaked in 10x SSC 
buffer, on a platform above a reservoir of 10x SSC buffer, with a paper 
towel wick connecting the gel to the buffer. The nylon membrane was 
placed upon the gel, ensuring that no air bubbles were present. On top of 
the membrane five sheets of Whatmann filter paper, also pre-soaked in 
10x SSC, and two dry blotting pads were placed. The gel/membrane was 
left to contact blot during an overnight incubation at room temperature 
[289].
The gel and membrane were removed from the blotting structure. 
Transfer of RNA was assessed by UV photography, and the membrane 
cross-linked twice in an UV crosslinker. The membrane was then baked 
dry at 80°C for 1 h and stored for northern analysis.
Plasmids for p2- and p3-adrenoceptors were cultured overnight in 
an Escherichia coii host in LB broth (1% tryptone, 0.5% yeast extract and 
1% NaCI, in water), at 37°C and isolated by alkaline lysis. The culture 
was centrifuged at 4000 rpm for 10 minutes, and the pellet reconstituted 
in an ice-cold solution of 50 mM glucose, 25 mM Tris-HCI and 10 mM 
EDTA. 1% SDS in 0.2 N NaOH was added, and the sample was mixed 
and stored on ice. An ice-cold solution of 5 M potassium acetate and 
glacial acetic acid was added, and the mixture incubated on ice for five 
minutes. This was centrifuged at 10000 rpm for five minutes at 4°C, and
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the supernatant solution added to an equal volume of 
phenol:chloroform:isoamylalcohol 25:25:1. This was centrifuged for two 
minutes at 10000 rpm at 4°C and the double-stranded DNA from the 
upper phase was precipitated with two volumes of absolute ethanol. The 
sample was centrifuged at 10000 rpm for ten minutes, the pellet was air- 
dried for ten minutes and then dissolved in 50 pi TBE buffer. The nucleic 
acid content was assessed by OD260 measurement. The DNA probes 
were isolated from the plasmids using restriction enzymes. The plasmid 
containing the p2-adrenoceptor insert was incubated overnight with 
EcoR1 and Pst1, and the f33-adrenoceptor plasmid with EcoR1 and Xba1. 
The products were separated on a 1% agarose gel (1 g agarose in 
100 ml TBE buffer). Samples were loaded as 25 pi sample and 5 pi DNA 
loading buffer (30% glycerol and 70% water, containing bromophenol 
blue and 1% ethidium bromide), and the gel was run at 80 V for 1 h [289]. 
Following visualisation, the insert bands were excised and the agarose 
that had been removed was weighed. The agarose was digested using a 
Qiagen plasmid kit (Qiagen, Crawley, UK) and the insert liberated. The 
final pellet was dissolved in 10 mM Tris-CI pH 8.5. Nucleic acid content 
was assessed by measurement at OD260.
The RNA membrane was placed in a hybridisation tube with 10 ml 
of hybridisation buffer (consisting of 50 mM PIPES pH 6.5, 100 mM NaCI, 
50 mM sodium phosphate, 1 mM EDTA, 5% SDS) and 120 pi sheared 
salmon sperm DNA (Ambion). The membrane was pre-hybridised for 1 h 
at 65°C. The hybridisation probe mixture was prepared as 1 pi plasmid 
insert in 9 pi H2O, and boiled for five minutes. 1 pi each of dATP, dGTP 
and dTTP and 2 pi hexanucleotides in 10x reaction buffer was added on 
ice. To this, 5 pi 32P-dCTP and 1 pi klenow enzyme was added, and the 
mixture incubated for 1 h at 37°C. The probe was then purified using a 
spin column, washed with STE buffer (10 mM Tris-HCI pH 8, 1 mM EDTA 
and 150 mM NaCI), and spun at 2000 rpm for two minutes. The purified 
probe was boiled for ten minutes, and added to the membrane and 
hybridisation buffer. The probe and membrane were incubated overnight
57
at 65°C, rotating. Following incubation, the membrane was washed for 
ten minutes in wash buffer (5% SDS in 0.5x SSC) at room temperature, 
and twice at 65°C for 15 minutes. The membrane was wrapped in 
Clingfilm, and taped inside an x-ray film cassette adjacent to unexposed 
x-ray film. The cassette was stored at -80°C for two weeks, before the 
film was developed. The membrane was stripped of probe by incubating 
in boiling wash buffer for ten minutes, and ensuring that all radioactive 
label was removed. The hybridisation process was then repeated for the 
second probe.
Protein isolation
Protein for western blotting was isolated from 3T3-L1 adipocytes using 
two methods. For proteins of the insulin signalling machinery (insulin 
receptor subunit-p (IRp), IRS-1 or the phosphorylation of IRS-1) the 
adipocytes were digested and homogenised using RIPA buffer (50 mM 
Tris-HCI, pH 7.4, containing 1% NP-40, 0.25% sodium deoxycholate, 
150 mM NaCI, 1 mM EDTA, 1 mM pefabloc, 1 mM activated NA3V04, 
1 mM sodium fluoride, 1 pg/ml aptotinin, 1 pg/ml leupeptin and 1 pg/ml 
pepstatin). Homogenates were centrifuged at 13000 rpm for 15 minutes 
at 4°C and the supernatant solution retained [296, 297].
Subcellular isolation of the glucose transporters GLUT1 and 
GLUT4 was carried out by digesting 3T3-L1 adipocytes with 5 ml per 
flask HES buffer (20 mM HEPES pH 7.4 containing 1 mM EDTA, 255 mM 
sucrose and a cocktail of pre-prepared protease inhibitors). Homogenised 
cells were centrifuged at 19 000 g for 20 minutes at 4°C (Figure 2.3). The 
supernatant solution (total internal membranes) was removed and 
centrifuged at 150 000 g for 60 minutes at 4°C and the pellets were gently 
reconstituted in 100 pi HES buffer. The pellets from the original 19 000 g 
spin were resuspended in 2 ml HES buffer, and layered onto 1 ml 1.12 M 
sucrose in HES buffer. This was centrifuged at 100 000 g for 1 h at 4°C. 
The interface was collected and resuspended in HES buffer, and
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Figure 2.3 -  Centrifugal separation of the internal and plasma 
membranes of3T3-L1 adipocytes
Homogenised 3T3-L1 adipocytes (in HES buffer) were centrifuged 
appropriately to separate both the internal and plasma membranes. 
Where required, pellets and interfaces were reconstituted in HES buffer, 
at volumes described within the text.
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centrifuged at 41 000 g for 20 minutes at 4°C. The pellets were 
reconstituted in 50 jul HES buffer [298].
Protein concentration was assessed using the Lowry method 
[299]. 5 )j.l of sample or standard (BSA in HES buffer at concentrations of 
2 mg/ml, 1 mg/ml, 0.5 mg/ml, 0.25 mg/ml, 0.125 mg/ml, 0.0625 mg/ml 
and 0.0313 mg/ml) was added to a microtitre plate, incubated with Bio- 
Rad protein assay reagent A for 15 minutes and 200 pi reagent B for a 
further 15 minutes. Absorbance was measured at 650 nm.
Western analysis
Protein detection was performed using ECL (enhanced 
chemiluminescence), according to the manufacture’s instructions. Briefly, 
the system uses the emission of light from luminol in the presence of 
HRP (horseradish peroxidase) and hydrogen peroxide, as well as 
chemical enhancers (such as phenol). Exposure of autoradiography 
paper to the reaction enables the visualisation of light emission (following 
development of the paper). To achieve this, protein is bound to a 
membrane and incubated with a primary antibody. A secondary HRP- 
conjugated antibody binds to the primary antibody, and this is exposed to 
detection reagents containing luminol and hydrogen peroxide.
Protein samples extracted using either of the methods described 
above were diluted to a concentration of 20 pg/pl in RIPA or HES buffer 
(as appropriate). A sodium dodecyl sulphate polyacrylamide (SDS-PAGE) 
separating gel was prepared (10% polyacrylamide, 0.375 M Tris-HCI 
pH 8.8, 0.1% SDS, 0.05% ammonium persulphate and 0.05% TEMED), 
with a stacking gel (5% polyacrylamide, 0.125 M Tris-HCI pH 6.8, 0.1% 
SDS, 0.05% ammonium persulphate and 0.05% TEMED). A 20 jxl volume 
of sample was mixed with 5 nl of sample loading buffer (63 mM Tris-HCI, 
pH 6.8, 2% SDS, 10% glycerol, 0.25% bromophenol blue and 5% 
|3-mercaptoethanol) and either boiled for three minutes (samples in RIPA 
buffer) or incubated at 37°C for ten minutes (samples in HES buffer) prior 
to loading onto the gel. Gels were run at 100 V until sufficient migration
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had occurred, in a running buffer of 25 mM Tris-base, 0.192 M glycine 
and 0.1% SDS [289].
The gei was removed, briefly washed in distilled water and soaked 
in transfer buffer (48 mM Tris-base, 39 mM glycine and 0.037% SDS) for 
20 minutes. A gel-sized piece of ECL membrane was also incubated for 
20 minutes in transfer buffer. Protein was transferred from the gel to the 
membrane using a semi-dry electrophoretic method (Multiphor II, 
Pharmacia, Uppsala, Sweden). The membrane was placed upon the 
electrode on top of six sheets of filter paper that had been soaked in 
transfer buffer, the gel was placed on top of the membrane and covered 
with a further six sheets of soaked filter paper. The negative electrode 
was placed upon the construct and the transfer run at 20 V for 30 minutes 
[289].
The membrane was blocked for 1 h at room temperature in a 
mixture of phosphate buffered saline/Tween 20 (PBST, PBS containing 
0.5% Tween) with 5% Marvel powdered milk, and washed twice in PBST 
(ten minutes per wash). The primary antibody, diluted 1:1000 in PBST, 
was incubated with the membrane overnight at room temperature. The 
membrane was washed three times in PBST (ten minutes per wash) and 
incubated for 2 h with a secondary antibody (HRP-conjugated, 1:5000 in 
PBST) at room temperature. The membrane was washed three times as 
before and incubated with ECL+plus reagent for two minutes. Excess 
reagent was removed by enabling it to run off the membrane, which was 
wrapped in Clingfilm. The membrane was exposed to x-ray film for 15 
seconds to two minutes (depending on the antibody used) and the film 
developed.
Assays
Assays for IL-6 and leptin were carried out in accordance with the 
manufacturer’s instructions. Both assays are two-site ELISAs, with 
polyclonal antibodies pre-bound to the microtitre plate. Standards and 
samples are incubated and a second, HRP-conjugated antibody is added. 
A colour chromogen solution (tetramethylbenzidine) is added, and colour
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change (equivalent to target concentration) is measured at 450 nm, with 
wavelength correction at 540 nm. The published intra- and inter- assay 
variability for these assays are 4.7% and 6.8% (IL-6) and 3.8% and 5.8% 
(leptin), with sensitivities of < 3.1 pg/ml (IL-6) and < 20 pg/ml (leptin).
Glycerol accumulation was used as a measure of lipolysis, using 
the reagent GPO Trinder according to the manufacturer’s instructions. 
40 pi sample or standard (625, 312.5, 156.3, 78.1, 39.1, 19.5 and 
9.8 pg/ml Sigma glycerol standard) was added to 200 pi GPO Trinder, 
incubated for five minutes and absorbance measured at 570 nm.
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Chapter 3 -  Adipose Tissue Release of IL-6
introduction
Adipocytes are unusual among endocrine tissues in that they are not 
specialised for the release of one major hormone, as, for example, 
pancreatic (3-cells are for insulin or adrenal glands are for adrenalin, but 
they release numerous adipokines. Furthermore, the release of 
adipokines is also dependent upon the location of the adipose tissue 
depot, as well as the fat content of the organism. Finally, adipokines do 
not appear to have a single mechanism of release, but each investigated 
thus far has a unique pattern of control and secretion.
Leptin, for example, is expressed in significantly greater amounts 
in subcutaneous depots compared with visceral [300, 301]. A variety of 
stimuli have a differential effect on the expression and secretion of leptin 
from these depots: dexamethasone increases release from visceral tissue 
only, despite increasing the level of mRNA in both depots; insulin 
increases subcutaneous release without affecting expression in either 
depot [119]; and transforming growth factor-(31 (TGF-(31) inhibits leptin 
release more effectively from visceral depots than it does from 
subcutaneous [120]. In spite of this difference in release and expression, 
leptin secretion does appear to be closely linked with mRNA levels, and 
to the lipid volume of the adipocyte [34].
Investigation into the secretory pathway of leptin revealed the 
many different pathways that are used in the adipocyte. Prior to release, 
leptin is stored in intracellular pools within the adipocyte, as are 
numerous other proteins, but these pools are separate from those 
containing GLUT4, LPL or angiotensinogen [287, 288, 302]. This 
indicates a number of different mechanisms through which adipocytes 
can transport products to the cell surface, even after the same stimulus 
(insulin is an effective stimulant for the release of each of these 
examples) [303]. Furthermore, adiponectin release (also stimulated by 
insulin) follows a different pathway to that seen for GLUT4 [187]. Leptin 
secretion from adipocytes is a steady-state process (under normal
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conditions) [288], and does not require de novo synthesis of the protein. 
This implies that, although leptin is released at a constant rate, significant 
stores are maintained within the adipocyte to enable a response to 
stimulation [166],
Clearly, therefore, adipocytes use a variety of secretory pathways 
to release adipokines. Although the different secretory pathways for leptin 
and adiponectin have been identified, the molecular control of release for 
other adipokines, including IL-6, has not been investigated. In spite of a 
range of knowledge concerning factors that affect its release, including 
|3-adrenoceptor agonists or IL-ip (both of which have been reported to 
stimulate IL-6 release from adipocytes) [235, 256], little is known about 
the mechanism by which this release occurs. Increased IL-6 release is 
observed from the visceral tissue of obese subjects, but whether this is 
true of normal weight subjects is unknown [236].
Studies in humans have shown that obese subjects have higher 
circulating levels of IL-6 [243] and that in the obese, visceral adipose 
tissue releases greater levels of IL-6 than does subcutaneous [236]. If a 
murine model is to recapitulate human obesity, at least for the purposes 
of autocrine/paracrine IL-6 release, a similar pattern of IL-6 release must 
be confirmed. Therefore, the studies presented here were designed to 
confirm whether this was true. Furthermore, an investigation into IL-6 
release from lean-animal-derived adipose tissue was carried out to 
determine whether release was affected by the obese state of the animal, 
which might be expected considering that circulating IL-6 is higher in the 
obese. Finally, the mechanism of release of IL-6 from adipose tissue was 
examined, to test whether IL-6 is stored within adipocytes prior to release, 
as are a number of other adipokines.
Thus, the aims of this chapter are to investigate:
(i) The effect of obesity on IL-6 levels in a rodent model of obesity.
(ii) The depot specific difference in IL-6 release from lean and obese 
animals.
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(iii) The mode of secretion of IL-6, both constitutive and regulated, using 
the Golgi-disrupting molecule brefeldin A to abolish intracellular transport 
and, therefore, secretion, as well as an inhibitor of transcription, 
cycloheximide, to prevent protein production.
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Methods
As described in Chapter 2, 12-week-old ob“/_ mice, or their wild-type 
cousins (C57BL6/J), were weighed, tail bled and killed. Unfortunately, 
facilities were not available for the accurate measurement of body-fat 
distribution, such as magnetic resonance imaging (MRI) or DEXA. Both 
these techniques enable an accurate analysis of whole-body tissue 
distribution; the adipose tissue weight measurements presented here are 
crude analyses of easily removed tissue, to give an indication of relative 
adiposity. Adipose tissue was removed from two major sources: 
subcutaneous tissue was extracted from beneath the skin, but without 
entering the body cavity, and epididymal adipose tissue (or omental or 
visceral: these three terms are used in this thesis and refer, in mice, to 
the same tissue depot) was removed from the body cavity and 
surrounding all the visceral organs. Obvious blood vessels within the 
adipose tissue were avoided. Tissue from up to six weight-matched 
animals was pooled (to minimise inter-animal variation) and washed in 
warm PBS to remove any non-adipose tissue, and fragments of tissue 
weighing between 50 mg and 130 mg were separated and placed in 12- 
well plates. Tissue fragments were incubated in 2 ml per well Cell-gro, 
supplemented with the cytokine IL-ip, the |33-adrenoceptor agonist 
CL316243, the Golgi-disrupting brefeldin A or the transcription inhibitor 
cycloheximide, or with a combination of IL-1(3 or CL316243 with either 
brefeldin A or cycloheximide. A subset of tissue was also incubated in 
Cell-gro alone to act as a basal control. Tissue was incubated for 5 h or 
24 h, after which the media was removed for assay, and tissue stored for 
RNA isolation, as described in Chapter 2. In addition to adipose tissue, 
fragments of liver were removed and incubated for 5 h in Cell-gro to 
measure the basal release of IL-6 from another tissue source.
A similar set of experiments was also carried out on mature 
3T3-L1 adipocytes, differentiated using dexamethasone, IBMX, insulin 
and BRL 49653, as described in Chapter 2. Cells were differentiated in 6-
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well plates, and treated for 24 h with 1 ml of Cell-gro containing the same 
treatments as the tissue fragments.
The blood and supernatant solutions were assayed using a 
commercially available murine IL-6 ELISA (R & D Systems). The IL-6 
concentrations from the tissue supernatant assay were divided by the 
weight of the original tissue fragment, to give the total IL-6 release per 
gram of tissue. Adipose tissue was homogenised and RNA isolated for 
real-time rt-PCR analysis as described in Chapter 2. All data are shown 
as median and interquartile range, and were obtained from a minimum of 
six individual tissue fragments per treatment, and a minimum of two 
separate experiments. The n values for the IL-6 release graphs from 
explanted adipose tissue refer to the number of individual wells from 
which samples were taken. Significance was calculated using the Mann- 
Whitney U test, with two-tailed p values below 0.05 considered 
significant.
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Results
Murine adiposity and circulating IL-6
As with humans, an increase in body mass in mice was accompanied by 
an increase in circulating IL-6 levels (Figure 3.1). Leptin-deficient obv“ 
animals were significantly heavier than wild-type counterparts of the 
same age [55.6 (48.9-60.9) vs. 27.1 (24.8-37.1) g, p< 0.001], and had 
significantly higher plasma IL-6 levels [8.6 (4.6-24.5) vs. 2.8 (2.5-5.9) 
pg/ml, p< 0.001]. The total mass of adipose tissue obtained from each set 
of animals indicated that a considerable proportion of the weight increase 
observed in the o/rA animals was due to an increase in adipose tissue, 
as opposed to other sources. A crude estimation of subcutaneous and 
visceral adipose tissue from lean animals comprised a mean of 0.8% and 
1.7% of total mass, respectively, whereas in obese animals these figures 
were 6.1% and 6.8%, respectively. Because this measurement was 
obtained only through a measurement of the mass of removed tissue, it 
cannot be compared with more accurate calculations of adipose tissue 
distribution.
Depot- and obesity-specific differences in IL-6 secretion
Having established that obese mice had a higher concentration of 
circulating IL-6 than did lean animals, the release of IL-6 from adipose 
tissue depots in both lean and obese mice was measured. As shown in 
Figure 3.2, basal (unstimulated) IL-6 release differed depending on both 
the location of the depot and the total body mass of the animal. Adipose 
tissue release of IL-6 from lean animals during a 24 h incubation showed 
no significant difference between subcutaneous and visceral tissue [16.7 
(13.3-30.5) vs. 27.3 (25.0-39.3) ng/ml per gram of tissue, p=0.37], 
whereas visceral tissue from obese animals released significantly more 
IL-6 over 24 h than did subcutaneous [58.1 (48.8-66.3) vs. 20.9 (11.5- 
24.2) ng/ml per gram tissue, p= 0.004].
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Figure 3.1 -  Weight and circulating IL-6 levels of C57BL6/J and ob"/_ 
mice.
Total body weight (columns, left hand axis) and circulating IL-6 (points, 
right hand axis) of 12-week-old C57BL6/J and ob^~ mice. Data presented 
as median and interquartile range.
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Figure 3.2 -  24 h accumulation of IL-6 release from unstimulated 
C57BL6/J and ob~~ adipose tissue explants.
Basal (unstimulated) release of IL-6 from C57BL6/J and ob_A adipose 
tissue explants from visceral (O) or subcutaneous (A ) depots. Data 
presented as median and interquartile range of IL-6 released into 
supernatant over 24 h, corrected to 1 g of tissue.
* p= 0.004 vs. o/T/_ subcutaneous, and p= 0.015 vs. C57BL6/J visceral.
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When comparing the depot-specific release from lean and obese 
animals, clear location-dependent differences were observed. IL-6 
release from subcutaneous tissue did not vary significantly, immaterial of 
whether the animal was obese or not (16.7 vs. 20.9 ng/ml per gram tissue 
lean vs. obese, p= 1). Visceral release from obese animals, however, was 
more than twice that of lean animals (68.1 vs. 27.3 ng/ml per gram, 
p= 0.015).
The incubation of tissue from C57BL6/J animals for 5 h follows a 
similar pattern to that of the 24 h incubation (Figure 3.3), with no 
significant difference between IL-6 release from subcutaneous or visceral 
depots (6.4 ng/ml per gram tissue subcutaneous vs. 6.3 ng/ml per gram 
tissue visceral, p= 0.903). Notably, the rate of IL-6 release differs 
between the tissues during these incubation periods. Assuming a steady- 
state release of IL-6, subcutaneous tissue from C57BL6/J animals is 
1.28 ng/h per gram of tissue over 5 h, compared with 0.69 ng/h per gram 
of tissue over 24 h and, from obese animals, 0.87 pg/h per gram of 
tissue. Visceral tissue from C57BL6/J mice released 1.26 pg/h IL-6 per 
gram of tissue over 5h  and 1.13 pg/h per gram of tissue over 24 h, 
whereas obese mice released 2.42 pg/h per gram of tissue over 24 h.
As a comparison with other cellular sources of IL-6, fragments of 
liver (from C57BL6/J) were also incubated for 5 h in Cell-gro to assess 
relative levels of release. Liver (0.346 ng/ml per gram tissue) released 
significantly less IL-6, in the absence of stimulation, than either 
subcutaneous (6.4 ng/ml per gram tissue, p= 0.034) or visceral (6.3 ng/ml 
per gram tissue, p= 0.009) adipose tissue.
Stimulated IL-6 release
The incubation of adipose tissue for 24 h with the immunological 
stimulant IL-1(3 or the (33-adrenoceptor agonist CL316243 affected IL-6 
release, depending on both the adipose tissue depot and the obese state 
of the host animal.
In lean animals (Figure 3.4), the only observed effect was from 
visceral tissue in response to IL-1(3 [27.3 ng/ml per gram tissue basal, vs.
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Figure 3.3 -  5 h accumulation of IL-6 release from C57BL6/J adipose 
tissue explants incubated with IL-1J3 or CL316243.
The release of IL-6 from C57BL6/J adipose tissue explants from visceral
(O) or subcutaneous (A ) depots exposed to 5 h incubation with IL-1 p, 
CL316243 or no stimulation (basal). Data presented as median and 
interquartile range of IL-6 released into supernatant over 2 h, corrected to 
1 g of tissue.
* p= 0.001; ** p= 0.017; both vs. basal (same depot).
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Figure 3.4 -  24 h accumulation of IL-6 release from C57BL6/J 
adipose tissue explants incubated with IL-1p or CL316243.
The release of IL-6 from C57BL6/J adipose tissue explants from visceral
(O) or subcutaneous (A ) depots exposed to 24 h incubation with IL-ip, 
CL316243 or no stimulation (basal). Data presented as median and 
interquartile range of IL-6 released into supernatant over 2 h, corrected to 
1 g of tissue.
*p= 0.009 vs. basal.
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99.5 (59.4-136.4) ng/ml per gram tissue IL-1(3 stimulated, p= 0.009]. 
There was no significant effect of IL-1 p on subcutaneous tissue [52.5 
(15.9-105.8) ng/ml per gram tissue stimulated, vs. 16.7 ng/ml per gram 
tissue basal, p= 0.347]. Using CL316243 as a |3-adrenoceptor stimulant 
affected neither subcutaneous [7.3 (6.7-7.9) ng/ml per gram tissue, 
p= 0.121] nor visceral [26.8 (18.1-42.3) ng/ml per gram tissue, p= 0.85] 
tissue release of IL-6.
Tissue from the obv“ animals was more responsive than that from 
lean animals (Figure 3.5). Incubation with IL-1 (3 caused an increase in 
IL-6 release from both visceral [58.1 ng/ml per gram tissue basal vs. 91.3 
(79.7-103.7) ng/ml per gram tissue IL-1 p stimulated, p= 0.004] and 
subcutaneous [20.9 ng/ml per gram tissue basal vs. 56.5 (44.1-87.1) 
ng/ml per gram tissue IL-1 p stimulated, p= 0.006] depots over 24 h. In 
contrast to the lack of effect on tissue from lean mice, CL316243 
significantly increased IL-6 release from visceral tissue from obese 
animals [89.6 (80.7-90.4) ng/ml per gram tissue, p= 0.01]. It had no effect 
on subcutaneous tissue from the same animals [22.3 (16.8-24.2) ng/ml 
per gram tissue, p= 0.873].
A similar pattern was observed in the response of adipose tissue 
from C57BL6/J adipose tissue exposed to the agents for 5 h (Figure 3.3). 
IL-6 release from visceral depots was stimulated by IL-1 (3 (basal 6.3 vs. 
IL-1 p 14.2 ng/ml per gram tissue, p= 0.001) but subcutaneous depots 
were unaffected (basal 6.4 vs. IL-1 p 13.0 ng/ml per gram tissue, 
p= 0.149). 5h incubation with CL316243 also stimulated visceral IL-6 
release (10.9 ng/ml per gram tissue, p= 0.017) but not subcutaneous 
(8.1 ng/ml per gram tissue, p= 0.564).
Inhibition of IL-6 release
The incubation of adipose tissue from either depot or animal source with 
the Golgi-disrupting brefeldin A or transcription-inhibitor cycloheximide 
completely abrogated IL-6 release (Figures 3.6 and 3.7). C57BL6/J 
release was reduced to 1.8 (1.7-2.2) ng/ml per gram tissue (p= 0.009) for
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Figure 3.5 -  24 h accumulation of IL-6 release from ob~y~ adipose 
tissue expiants incubated with IL-1 p or CL316243.
The release of IL-6 from ob~ adipose tissue explants from visceral (O) or
subcutaneous (A ) depots exposed to 24 h incubation with IL-1 p, 
CL316243 or no stimulation (basal). Data presented as median and 
interquartile range of IL-6 released into supernatant over 24 h, corrected 
to 1 g of tissue.
* p= 0.004; ** p= 0.006; *** p= 0.01; all vs. basal (same depot).
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Figure 3.6 -  24 h accumulation of IL-6 release from C57BL6/J 
adipose tissue explants incubated with brefeldin A or 
cycloheximide.
The release of IL-6 from C57BL6/J adipose tissue explants from visceral 
(O) or subcutaneous (A ) depots exposed to 24 hr incubation with 
brefeldin A, cycloheximide or no stimulation (basal). Data presented as 
median and interquartile range of IL-6 released into supernatant over 
24 h, corrected to 1 g of tissue.
* p= 0.002; ** p= 0.009; both vs. basal (same depot).
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Figure 3.7 -  24 h accumulation of IL-6 release from ob~ ~ adipose 
tissue explants incubated with brefeldin A or cycloheximide.
The release of IL-6 from ob_A adipose tissue explants from visceral (O) or
subcutaneous (A ) depots exposed to 24 h incubation with brefeldin A, 
cycloheximide or no stimulation (basal). Data presented as median and 
interquartile range of IL-6 released into supernatant over 24 h, corrected 
to 1 g of tissue.
*p= 0.02
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subcutaneous and 1.9 (1.1-2.5) ng/ml per gram tissue (p= 0.002) for 
visceral by brefeldin A, and to 0.4 (0.4-0.5) ng/ml per gram tissue 
(p= 0.009) and 1.1 (0.7-1.6) ng/ml (p= 0.002) per gram tissue 
respectively by cycloheximide. The effect was the same in tissue from 
obv“ animals, in which brefeldin A reduced IL-6 release to 3.9 (3.0-4.8) 
ng/ml per gram tissue (p= 0.02) from subcutaneous and 3.0 (2.5-3.4) 
ng/m! per gram tissue (p= 0.02) from visceral, and cycloheximide to 1.9 
(1.6-3.1) ng/ml per gram tissue (p= 0.02) and 1.7 (1.6-2.1) ng/ml per 
gram tissue (p= 0.02).
The incubation of C57BL6/J explants with brefeldin A or 
cycloheximide for 5 h produced similar results. Subcutaneous tissue IL-6 
release was reduced to 0.12 (0.09-1.14) ng/ml per gram (basal 6.4 ng/ml 
per gram, p= 0.021) by brefeldin A, and to 0.17 (0.15-0.19) ng/ml per 
gram (p= 0.021) by cycloheximide. Release by visceral tissue was 
reduced to 0.07 (0.06-0.08) ng/ml per gram (basal 6.3 ng/ml per gram, 
p< 0.001) by brefeldin A and to 0.20 (0.17-0.29) ng/ml per gram tissue 
(p< 0.001) by cycloheximide.
Subcutaneous tissue from obese animals that was incubated with 
IL-1 p and brefeldin A released 3.8 (3.7-6.6) ng/ml IL-6 per gram tissue 
(p= 0.07); with IL-1 p and cycloheximide, 2.0 (1.7-2.2) ng/ml per gram 
tissue (p= 0.02); with CL316243 and brefeldin A, 3.7 (2.8-4.0) ng/ml per 
gram tissue (p= 0.02); and with CL316243 and cycloheximide, 1.6 (1.5- 
1.6) ng/ml per gram tissue (p= 0.02). IL-6 release from visceral tissue 
from the same animals was also significantly inhibited; IL-1 p and brefeldin 
A reduced release to 6.4 (6.3-6.6) ng/ml per gram; IL-1 (3 and 
cycloheximide, to 1.7 (1.7-4.8) ng/ml per gram; CL316243 and brefeldin, 
to A 3.5 (3.0-5.5) ng/ml per gram; and CL316243 and cycloheximide, to
1.6 (15-2.2) ng/ml per gram (all p= 0.02).
Cell-line release of IL-6
In addition to measuring IL-6 release from adipose tissue explants, the 
murine cell line 3T3-L1 was used to measure IL-6 release. Fully
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differentiated adipocytes were treated with Cell-gro supplemented with 
IL-1 (3, CL316243, brefeldin A or cycloheximide. Incubation with IL-1 p 
significantly increased IL-6 release over 24 h [basal 1.3 (0.9-1.6) vs. 
IL-1 p 1.8 (1.8—2.0) ng/ml, p=0.02], whereas CL316243 had no effect 
[1.56 (1.1-1.7) ng/ml, p= 0.79]. Both brefeldin A [0.61 (0.54-0.64) ng/ml, 
p= 0.046] and cycloheximide [0.027 (0.024-0.042) ng/ml, p= 0.02] 
significantly inhibited 3T3-L1 IL-6 release.
IL-6 expression in adipose tissue
The expression of IL-6 in adipose tissue closely mirrored its release 
(Figure 3.8). There was no significant difference in visceral expression 
compared with subcutaneous in lean adipose tissue [visceral expression
1.6 (0.5-6.2) fold that of subcutaneous, p= 0.309]. Nor was there a 
difference between the expression of IL-6 from subcutaneous tissues of 
lean or obese animals [obese subcutaneous expression 1.7 (1.0-1.9) fold 
that of lean, p= 0.944]. As with the release data, however, IL-6 expression 
was significantly greater in visceral tissue from obese animals compared 
with mRNA levels from both lean [3.6 (2.7-4.0) fold that of C57BL6/J 
subcutaneous, p= 0.001] and obese subcutaneous depots (p= 0.001), but 
not compared with lean visceral (p= 0.139).
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Figure 3.8 -  C57BL6/J and ob~~ adipose tissue expiant expression of 
IL-6.
The semi-quantitative expression of IL-6 from C57BL6/J and ob~y~ 
subcutaneous (A)  and visceral (O) adipose tissue. Expression is 
corrected to GAPDH mRNA levels and displayed as median (interquartile 
range) fold-increase compared with C57BL6/J subcutaneous levels.
* p= 0.001 vs. ob~~ subcutaneous.
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Discussion
Prior to making any comparisons to the situation in humans, it was 
important to establish that obesity in mice is characterised by the same 
rise in circulating IL-6 levels that is observed in human obesity [103, 304, 
305], This study demonstrates that mice do exhibit increased circulating 
IL-6 in the obese state. Furthermore, these data establish that adipose 
tissue is a source of significant IL-6 production, which is likely to 
contribute to increased circulating levels. Calculations in human subjects, 
which were based on an assumption that subcutaneous adipose tissue 
released similar amounts of IL-6 to other depots -  which the data here 
(and elsewhere [236]) show not to be the case (in the obese) -- indicated 
that up to 35% of circulating IL-6 was adipose tissue derived [103]. 
Whether similar arterio-venous sampling of adipose tissue is possible in 
mice has not been examined. Visceral adipose tissue from obese animals 
not only had an alteration in the production of IL-6 but also had altered 
sensitivity to the stimulation of IL-6 production. These data demonstrate 
that IL-6 production by adipose tissue is constitutive, requires 
transcription and is trafficked through the adipocyte in a Golgi-dependent 
manner, although, unlike other adipokines, it is not stored within the cell 
prior to release.
The studies described here have used the leptin-deficient ob_/" 
mouse as a model for murine obesity. These animals exhibit weight gain 
and hypertrophy from weaning compared with wild-type C57BL6/J [306]. 
In spite of being the product of a gene knockout, the ob~y~ mouse is a 
good model of obesity to investigate the release of IL-6. A lack of leptin 
has a number of serious consequences for the organism, in addition to 
the increase in body weight and accompanying insulin resistance, such 
as infertility [307], reduced metabolic rate [308], impaired liver function 
[309] and increased anxiety [310], However, leptin appears to be a true 
endocrine factor, although its autocrine/paracrine effects on adipose 
tissue are disputed, and might depend on the adipose tissue source [126, 
311, 312]. The data presented here clearly indicate that IL-6 release is
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unaffected by leptin deficiency, or demonstrate that any effect is 
insufficient to inhibit the rise in circulating IL-6 that is observed in obesity. 
Therefore, despite the inherent physiological deficiencies, the ob~y~ model 
of obesity might be an acceptable alternative to diet-induced obesity for 
the purposes of measuring adipose tissue IL-6 release. Nevertheless, 
had the resources and time been available, an investigation into the 
effects of diet-induced obesity on adipose tissue IL-6 release would be 
desirable.
Studies on IL-6 release from human adipose tissue have focused 
primarily on differences that occur as a result of obesity. As with the 
murine data presented here, human obesity is characterised by an 
increase in circulating IL-6, with omental adipose tissue depots releasing 
significantly more IL-6 than does subcutaneous tissue [236]. There is an 
absence of data on depot-specific differences in adipose tissue from lean 
humans, but if consistent with the murine data, they suggest a functional 
change in adipose tissue as the organism becomes obese. The increased 
basal IL-6 release from omental adipose tissue from obese animals 
compared with lean indicates that the physiology of this tissue is affected 
by obesity. Subcutaneous adipose tissue mass is also greater in obese 
individuals but, unlike omental tissue, releases similar levels of IL-6 per 
gram of tissue as does tissue from lean animals. The real-time rt-PCR 
data from the adipose tissue further indicate that constitutive release of 
IL-6 from adipose tissue is greater from omental depots in the obese 
animal than from subcutaneous depots, and that there is no such 
difference between the depots in lean mice. This increase in IL-6 release 
from omental tissue in obesity might have serious implications for the risk 
of obesity-related diseases, such as insulin resistance, coronary heart 
disease (CHD) and diabetes, all of which are correlated with visceral 
adiposity and increased circulating levels of IL-6.
One interesting observation concerns the rate of IL-6 release. The 
hourly rate of release of IL-6 from visceral tissue is similar during both the 
5 h and 24 h incubation periods, suggesting that visceral tissue can 
release appreciable quantities of IL-6 over a relatively long period of time
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in the absence of stimulation. (Notably, visceral tissue from obese 
animals was releasing almost double the amount of IL-6 per hour than 
was the tissue from lean animals. Despite not having data for 5 h release 
from obese tissue, because of a lack of access to the animals, the data 
indicate that obese tissue rate-of-release is greater than that of lean.) By 
contrast, the rate of subcutaneous tissue IL-6 release is lower over 24 h 
(from lean animals) than it is from visceral tissue. Although this could be 
the result of a lower release per hour, it could also derive from a reduction 
in release during the time course; that is, IL-6 release would initially be 
similar (for example, during the first 5 h), but would then decrease. In 
contrast to the visceral adipose tissue, therefore, subcutaneous depots 
do not appear to be able to continue releasing IL-6 at a high rate for long 
periods of time, further indicating a physiological difference between the 
two adipose tissue sources. However, because no assessment was 
made of the viability of the subcutaneous tissue after 24 h ex vivo, it is 
possible that the accumulation rate slowed as a result of cell death. To 
ensure that this was not the reason for the reduction in IL-6-release rate, 
an assay of cell viability, such as 125l-insulin binding, or simpler methods, 
such as cell counting, cell size or trypan-blue exclusion [313], should 
have been carried out after 24 h in culture. Previous reports have 
suggested that explanted adipocytes are fully functional for up to 72 h 
[313], but this cannot be assumed in this case. Hourly (or similarly 
frequent) sampling of the supernatants would also be a valuable 
measurement of rate of release.
Furthermore, the stability of IL-6 is also important. Two general 
mechanisms should be considered: the breakdown of released IL-6 in the 
supernatant, and the reuptake and degradation of IL-6 by adipocytes (and 
other cells within the adipose tissue). The former might be a factor in the 
24 h cultures; it is unlikely that there is a significant effect over 5 h, 
because IL-6 is stable for at least 6 h in the absence of blood cells [314] 
(although macrophages are likely to be present in the adipose tissue, as 
discussed below). Moreover, there were still significant quantities of 
measurable IL-6 in the supernatant from obesity-derived visceral adipose
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tissue, which contains more macrophages than subcutaneous tissue [23]. 
The latter possibility, the re-uptake of IL-6 by adipocytes, could also be 
occurring. Adipocytes are known to express the IL-6 receptor system 
[267], and data presented in Chapters 4 and 5 describe functional effects 
of IL-6 on the adipocyte, indicating that IL-6 is likely to be internalised and 
degraded following its binding to the cell surface. This, however, is 
unavoidable, although frequent (e.g. hourly) sampling of the supernatant 
(replacing the removed media with an equivalent volume of fresh media 
to avoid concentrating the supernatant) during the incubation might 
represent a reasonable method to obtain continuous rate of release 
data.Of course, IL-6 release is not the only function of adipose tissue that 
changes in obesity. Insulin resistance is one of the best-studied disorders 
that is related to excess weight, and one which, with other markers of the 
metabolic syndrome, is closely related to fat-cell size and distribution [30, 
315, 316]. Although it might seem obvious, adipocytes in obese 
individuals are larger than those in the lean [30], but it is important to 
differentiate this observation from obesity merely being due to an 
increase in the number of adipocytes within the depot. If obesity were 
characterised solely by an increase in the number of adipocytes, it would 
be difficult to explain how visceral adipose tissue could behave differently 
in the obese than in lean individuals. Changes to adipocyte size and 
volume are known to affect the release of adipocyte-derived factors. For 
example, leptin expression is proportional to the size of the lipid vacuole 
within the adipocyte [317], and circulating adiponectin levels are inversely 
related to fat mass [318, 319]. It seems likely, therefore, that IL-6 release 
is similarly controlled, with more secreted from omental adipose tissue in 
the obese state. Thorough investigations into the physiology of the 
hypertrophic adipocytes and adipose tissue, based upon the data 
collected concerning leptin, adiponectin and now IL-6, are likely to reveal 
the ‘obese’ adipocytes and tissues as functionally deviant for a number of 
mechanisms, some of which will result in an obesity-related disease 
phenotype. Furthermore, the infiltration of macrophages into adipose 
tissue during obesity [23] and/or the conversion of adipocytes into
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macrophage-like cells [24] might explain the increased response to 
stimuli in the adipose tissue of the obese animals.
The reports by Weisberg et al. [23], Xu et a\. [320] and Charriere 
etal. [24] raise interesting points concerning the source of adipose- 
tissue-derived IL-6. The two former papers describe the infiltration of 
adipose tissue, especially in the obese, by macrophages, and the latter 
the conversion of adipocytes into macrophage-like cells in obesity. 
Although unstimulated macrophages do not release IL-6 [235, 256], it is 
probable that the macrophages that have infiltrated adipose tissue are 
stimulated, and therefore can release IL-6. Furthermore, the expression 
of IL-6 was detected in both the macrophage and stromal vascular 
fractions, although the largest portion was expressed by adipocytes [23]. 
Nevertheless, a significant non-adipocyte release of IL-6 from adipose 
tissue has been reported [321]. Therefore, it is probable that a large 
portion of the IL-6 that was measured in the supernatants in this study 
was not specifically adipocyte derived. However, adipocyte-derived IL-6 is 
not insignificant; isolated adipocytes are known to release IL-6 [256, 267], 
and IL-1 p does not affect the release of IL-6 from macrophages [235, 
322]. This indicates that the IL-1p-induced release of IL-6 that was 
reported here was from adipocyte (or the unmeasured stromal vascular 
fraction). Unfortunately, time constraints prevented the isolation of 
adipocytes from adipose tissue to provide a definitive answer to the 
comparative release from each fraction in this study, and comparisons 
with the release from 3T3 cells is not a reasonable measure because of 
the relatively low level of IL-6 from cell lines [256]. Nevertheless, although 
adipocytes themselves are not the only source of IL-6 in adipose tissue, 
they do contribute to the release, especially stimulated release.
The release of IL-6 from adipocytes differs from numerous other 
adipokines in one important respect. Factors such as leptin [287, 302], 
adiponectin [187] and LPL [302, 323] are stored in secretory vesicles 
prior to release. The release of these molecules occurs following an 
external stimulus, for example insulin binding, inducing exocytosis. IL-6, 
however, does not appear to be stored within the adipocyte before
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secretion. Stored adipokines are, at least partially, insensitive to 
cycloheximide treatment; sufficient product is present within the cell that 
further synthesis is not required for release following stimulation. IL-6 
release was acutely sensitive to cycloheximide, even in the presence of 
stimulation by IL-1p, indicating a requirement for de novo production. 
Because the levels of IL-6 that were measured in the supernatant were 
barely above the background limits for the assay, it is highly unlikely that 
significant IL-6 was present intracellularly. Constitutive release of IL-6 is 
further implied by the relationship between the 5 h and 24 h incubations 
of C57BL6/J-derived adipose tissue. Basal release of IL-6 over 5 h is 
approximately one-fifth that of the 24 h release, indicating a constant and 
steady release. It seems, therefore, that IL-6 is constitutively expressed 
and released from murine adipose tissue, as it is in humans [235]. The 
intracellular pathway of IL-6 secretion, given that it does not correspond 
to those of other adipokines, needs to be determined.
Just as intriguing as the fact that basal secretion of IL-6 differs in 
the lean and the obese is the observation that obese visceral adipose 
tissue is also more responsive to stimulated IL-6 release. Omental fat 
from obese mice releases greater levels of IL-6 following incubation with 
the p3-adrenoceptor agonist CL316243. Omental tissue from lean 
animals and subcutaneous tissue from either lean or obese mice are 
unresponsive to CL316243. This discrepancy implies that omental tissue 
in obesity contains a greater number of, or more active, {33- 
adrenoceptors. However, previous studies have indicated a significant 
reduction in p3-adrenoceptors expression in ob~y~ adipocytes compared 
with controls [324, 325]. Additionally, C57BL6/J mice fed high-fat diets to 
induce obesity, and other genetically obese strains also have reduced p3- 
adrenoceptor expression [326, 327]. These studies also described a 
reduction in function, as well as expression, of the receptors, which 
makes the increase in IL-6 secretion observed in these experiments when 
ob~y~ visceral adipose tissue was treated with CL316243 difficult to 
explain. The changes in expression that were observed by Collins et ai
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[326] and Breslow et al. [325] were on epididymal and/or perirenal fat 
pads: depots included in the omental tissue used in this study. One final 
observation from these previous studies that is of relevance here is the 
fact that subcutaneous adipose tissue expression of p3-adrenoceptor was 
identical to that of perirenal adipose tissue in lean animals (with both 
lower than that of epididymal), and diet-induced obesity reduced 
expression in all three depots to similar levels [326]. Following these 
findings, one might predict that treatment with a p3-specific agonist would 
have less effect on adipose tissue from obese animals compared with 
lean, with no significant difference between subcutaneous and visceral 
depots. Unfortunately the data obtained here does not enable a 
conclusive explanation of the mechanism of increased IL-6 release. One 
possibility is that, despite being classed as a (33-specific agonist, 
CL316243 (as with other adrenoceptor agonists) might also affect other 
(3-adrenoceptors. Therefore, with fewer (33-adrenoceptors present, 
stimulation could be through (32-adrenoceptor, an adrenoceptor that is 
increased in the obese state [328]. Further studies are required to identify 
the precise mechanisms occurring in (3-adrenoceptor-stimulated IL-6 
release, possibly starting with measurement of (32-adrenoceptor 
(clenbuterol) agonist effects.
In comparison with CL316243, IL-1 p was a more potent effector of 
IL-6 release from adipose tissue, with visceral tissue secreting more IL-6 
(independent of the mass of the animal), whether incubated for 5 h or 
24 h. Subcutaneous adipose tissue had no statistically significant 
response to IL-1 p, barring those from obese sources, but the data 
reported here spans a wide range. Human subcutaneous adipocytes 
have been shown to respond to IL-1 p in vitro [235], and, in light of the 
data presented here, murine adipocytes might be expected to respond 
similarly.
Having established that adipose tissue constitutively releases IL-6 
in the basal state, and that this release can be upregulated by a variety of 
signals, it is worth comparing this release to that from other tissues. The
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data obtained from the liver samples show that minimal amounts of IL-6 
are released from hepatocytes in the absence of stimulation. Monocytes 
and macrophages are able to release IL-6 following stimulation with 
IL-1 p, but not basally [235]. Furthermore, skeletal muscle does not 
release IL-6 in the absence of a stimulant, such as exercise [232]. 
Therefore, of the major IL-6-releasing organs and tissues, only adipose 
tissue, and particularly visceral depots, releases IL-6 constitutively and in 
significant amounts in the absence of a stimulatory signal.
The experiments presented here provide a better understanding of 
the mechanisms of the release of IL-6 from adipose tissue. As in humans, 
murine adipose tissue releases IL-6 constitutively [235], and this is 
increased in obesity. Unlike numerous other adipokines, IL-6 is not stored 
within the adipocyte until secretion is stimulated, but is synthesised de 
novo. The immune modulator IL-1 (3 is a powerful stimulator of IL-6 
release from adipose tissue, but adrenoceptor stimulation is only effective 
in visceral tissue from obese animals. The importance of adipose-tissue- 
derived IL-6 as an autocrine/paracrine signal is discussed further in 
Chapters 4 and 5.
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Chapter 4 -  Adipogenesis
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Introduction
The total mass of adipose tissue is determined by both the number of 
adipocytes and the volume of these cells within the tissue. Under normal 
conditions, the number of adipocytes is regulated by the formation of new 
adipocytes through the differentiation of preadipocyte precursors 
(adipogenesis, Figure 1.3) and apoptosis of existing adipocytes. The 
volume of the cells, itself dependent upon lipid content, is regulated by 
metabolic processes such as lipogenesis and lipolysis. A number of 
cytokines and adipokines have important roles in the adipogenic and 
apoptotic regulation of adipocytes. However, whether IL-6 can alter 
adipocyte numbers, by the regulation of adipogenesis and apoptosis 
and/or adipocyte size, through effects on glucose uptake, lipogenesis and 
lipolysis, is not known.
The best-characterised adipokine affecting these adipocyte 
functions is TNFa, a potent anti-adipogenic factor. The incubation of 
adipocytes with TNFa reverses differentiation, probably owing to an 
inhibition of the adipogenic mediator PPARy [99, 171]. TNFa also initiates 
apoptosis in mature adipocytes [93]. By contrast, the majority of studies 
using leptin have reported no significant autocrine/paracrine effects on 
adipocyte differentiation [126] (although a pro-adipogenic effect has been 
reported in rodents [329]). However, leptin has been implicated in the 
apoptosis of adipocytes [311], although this is likely to be mediated 
through indirect central effects rather than an autocrine/paracrine 
response [127, 330]. Resistin has been reported to inhibit adipocyte 
differentiation [175], although there are very little data available 
concerning this adipokine and its molecular function.
Previous studies have shown that IL-6 inhibits the expression of 
PPARy [265], and inhibits adipocyte differentiation under certain 
conditions in bone marrow stroma [331], However, IL-6 has also been 
reported to increase adipogenesis at the expense of osteoblastogenesis 
in SAMP6 mice [332], and other members of the class I cytokine family
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have been reported to increase adipogenesis via the MAPK cascade 
[333], which can also be activated by IL-6. IL-6 is also a growth and 
differentiation factor for a number of other cell types [334, 335]. The direct 
role of IL-6 in adipogenesis has not been studied, however.
Early changes in cellular morphology during adipogenesis, with a 
rounding of cells, can be observed microscopically. Lipid droplets are also 
visible within 72 h after the induction of adipogenesis, and these lipid 
deposits accumulate until it accounts for over 80% of the cellular 
contents. These morphological and biochemical changes are 
accompanied by changes in gene expression. Leptin release from these 
cells also increases, and its secretion is directly related to the lipid 
content of the cells [34, 35].
The initial experiments described in this chapter were loosely based on 
the studies of TNFa and adipocyte differentiation. With both IL-6 and 
TNFa being pro-inflammatory cytokines, and TNFa potently inhibiting 
adipogenesis, the hypothesis for the research was that IL-6 would have a 
similar effect.
This chapter will investigate the effect of IL-6 on adipocyte differentiation 
using the conversion of 3T3-F442A preadipocytes to mature adipocytes 
as an in vitro model of adipogenesis. Adipogenesis, initiated using a 
number of frequently cited methods, was monitored by investigating 
changes in cellular morphology, lipid accumulation, gene expression and 
leptin release.
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Methods
The effects of IL-6 on in vitro adipogenesis were measured using the 
preadipocyte cell line 3T3-F442A, which can differentiate in the absence 
of thiazolidinedione stimulation, and release appreciable levels of leptin 
when mature. By contrast, 3T3-L1 adipocytes are more difficult to 
differentiate, frequently requiring the addition of a thiazoiidinedione to 
ensure adipogenesis. Time constraints precluded the investigation of 
other cell types and sources, such as cell lines of uncommitted stem cells 
that can differentiate into adipocytes, or primary preadipocytes.
3T3-F442A cells were seeded onto 6-well plates at a concentration 
of 6 x 104 cells/well in DMEM/10% BCS (supplemented, as was all cell- 
culture media, with 1% penicillin/streptomycin). Following a 24 h 
incubation (at 37°C, 5% CO2) after seeding, cells were fed with 1.5 
ml/well DMEM/10% CCS and grown until the cells were approximately 
90% confluent (assessed by eye using light microscopy). The cells were 
then differentiated using the methods described in Chapter 2. These 
were:
(i) DMEM/10% CCS, supplemented with dexamethasone (1 jiM), IBMX 
(0.5 mM) and insulin (5 pg/ml).
(ii) DMEM/10% CCS, supplemented with IBMX (1 mM) and insulin 
(5 pg/ml).
(iii) DMEM/10% CCS, supplemented with indomethacin (125 pM) and 
insulin (5 pg/ml).
(iv) DMEM/10% CCS, supplemented with T3 (2 nM) and insulin (17 nM).
Methods (i), (iii) and (iv) are based on previously reported 
adipogenesis techniques (see Chapters 1 and 2), whereas method (ii) 
was included as a novel method that excluded dexamethasone, which is 
a multi-functional potentiator, to test differentiation with fewer adipogenic 
compounds.
For methods (i), (ii) and (iii), the cells were incubated (37°C, 5% 
CO2) for 72 h in 1.5 ml/well induction media (the time of addition
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designated day 0), whereupon the ceils were fed with fresh media with all 
supplements withdrawn, bar insulin. Cells were re-fed in this manner 
every 48 h. Media that was removed prior to feeding was retained and 
stored at -80°C for subsequent assay. The protocol for method (iv) 
differed in that T3 was maintained in the media at every feeding. A final 
set of cells served as a negative control, with cells fed only DMEM/10% 
CCS (Figure 4.1). In addition to the methods above, each was repeated 
in the presence of 10 ng/ml IL-6, included as a supplement in the media 
at each feeding. A concentration of 10 ng/ml IL-6 was chosen because it 
is within the physiological concentration range of the cytokine in the 
adipose tissue [256] (and unpublished data). Had more time been 
available, a range of IL-6 concentrations would have been investigated, 
from ~0.1-100 ng/ml IL-6 (which is still below the concentration used in 
other studies [267]).
A subset of cells, treated identically to those in method (i), in the 
absence or presence of IL-6, was used for RNA isolation and rt-PCR. 
Media was removed and retained for assay, and the 6-well plates were 
flash frozen in liquid nitrogen and stored at -80°C prior to RNA isolation. 
RNA isolation, cDNA synthesis and rt-PCR were carried out as described 
in Chapter 2. End-point rt-PCRs were carried out for p-actin, PPARy, 
C/EBPa, ob and adipsin. Additionally, to enable a comparison with cells 
treated with IL-6 for a considerably shorter time period, cells differentiated 
for 15 days using method (i) were treated for 48 h in Cell-gro, in the 
absence or presence of 10 ng/ml IL-6. The media from these cells was 
assayed for leptin release, and rt-PCR was carried out.
A final subset of cells was differentiated, on cover slips using 
method (i) in the absence or presence of IL-6, and used to assess lipid 
accumulation. Cells were loaded with BODIPY 493/503 and the lipid 
content of a random selection of cells assessed by confocal microscopy 
(see Chapter 2). A total of 82 randomly selected control cells and 40 IL-6- 
treated cells were analysed.
Data are presented as median and interquartile range, and were 
obtained from a minimum of six individual samples from at least two
94
T3
(a)
(b)
(c)
(6)
(e)
72h
fh
( \ )
( \ )
rn
( \ \ )
(£
( \ )
fh
( \ )
fil
( \ \ )
( \ )
( \ )
(\)
m
( \ \ )
o;
48h 48h 48h
Figure 4.1 -  Time line of adipogenesis cell culture.
3T3-F442A preadipocytes were treated at day 0 with: (a)
dexamethasone, IBMX and insulin; (b) IBMX and insulin; (c) 
indomethacin and insulin; (d) T3 and insulin; or (e) no treatment, all in the 
absence or presence of 10 ng/ml IL-6. After 72 h, supernatant was 
removed for assay (and cells for RNA extraction) and cells re-fed with: (i) 
insulin-supplemented media or (ii) T3 and insulin (as day 0), with or 
without IL-6. This removal and re-feeding was repeated every 48 h until 
the cessation of the experiment (day 17)
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separate experiments (n values refer to the number of individual wells 
from which measurements were obtained). Significance was calculated 
using the Mann-Whitney U test, with two-tailed p values below 0.05 
considered significant. Real-time rt-PCR data are expressed as changes 
in expression compared with an arbitrary baseline (described for each 
individual message investigated), using the method described by Livak 
and Schmittgen [295].
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Results
Differentiation assessed by microscopy
Changes in the morphology of the cells during differentiation were 
assessed by microscopy. Using light microscopy, it was evident that 
within 72 h of induction of differentiation using the dexamethasone or 
indomethacin containing protocols [methods (i), (ii) and (iii)], the majority 
(> 90%) of cells had changed from the preadipocyte spindle shape to the 
rounded morphology of the adipocyte. At 7-9 days post-induction of 
differentiation small lipid droplets were visible, which continued to expand 
until > 90% of the cell volume was lipid (by day 17 post-induction). The 
changes observed during the T3 protocol were less pronounced; fewer 
cells adopted the adipocyte morphology within 72 h, lipid droplets were 
not visible until much later post-induction of differentiation and the lipid 
vacuoles were smaller. Preadipocytes that were not incubated with any of 
the traditional adipogenic agents did not adopt an adipocyte-like 
morphology or accumulate lipid, with the exception of a tiny minority of 
cells that underwent spontaneous differentiation.
The inclusion of 10 ng/ml IL-6 to the dexamethasone- or 
indomethacin-containing protocols resulted in larger lipid droplets within 
the cell when compared with non-IL-6-treated cells at the same time 
point. There was no visible effect of IL-6 on the cells that were 
differentiated using T3 and insulin, or on untreated cells.
Treating adipocytes with the neutral lipid dye BODIPY 493/503 
confirmed the observation that IL-6 increased the lipid content of 
adipocytes during differentiation with dexamethasone, IBMX and insulin 
(Figures 4.2 and 4.3). The mean index of BODIPY staining for cells 
differentiated in the absence of IL-6 was 0.49 (0.42-0.53), compared with
0.68 (0.57-0.77) for IL-6-treated cells (p< 0.01).
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Figure 4.2 -  Confocal Microscopy of cells differentiated with and 
without IL-6.
Representative adipocytes at 13 days post-induction, differentiated in the 
absence (A) or presence (B) of 10 ng/ml IL-6 using the dexamethasone, 
IBMX and insulin protocol. The left-hand panels show the transmitted 
images; right hand panels are images of the cells dyed with the neutral 
lipid-staining BODIPY 493/503.
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Figure 4.3 -  Index of BODIPY 493/503 staining of 3T3-F442A cells 
differentiated in the presence or absence of IL-6.
The index of BODIPY 493/503 staining, representing cellular lipid content, of 
3T3-F442A adipocytes differentiated using dexamethasone, IBMX and insulin 
in the absence (basal, n= 82) or presence (n= 40) of 10 ng/ml IL-6.
p< 0.01
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Differentiation assessed by leptin release
The secretion of the adipocyte-derived protein leptin was used for an 
assessment of adipogenesis. Although leptin is not a marker of 
adipogenesis per se, its expression and release is related to the volume 
of the lipid vacuole within the cell [34], and, as such, it is a useful 
measure of adiposity and differentiation. Depending upon the 
differentiation method used, leptin accumulation in the media increased 
significantly 5-9 days post-induction of differentiation, compared with 
dayO (Figures 4.4-4.8). Leptin levels from cells differentiated using 
dexamethasone, IBMX and insulin rose above preadipocyte levels nine 
days after induction [day 0, 25.9 (17.6-31.4) pg/ml leptin vs. 52.0 (38.3- 
144.6) pg/ml day 9, p< 0.001], whereas in the presence of IL-6 the 
difference was observed at day 7 [32.7 (26.6-38.1) pg/ml, p= 0.005]. 
Preadipocytes that were treated with IBMX and insulin released 
significantly more leptin at day 9 compared with day 0, whether IL-6 was 
present or not [day 0, 13.9 (13.5-14.6) pg/ml leptin vs. day 9 no IL-6, 17.7 
(15.2-19.4) pg/ml, p= 0.037; day 9 + IL-6, 75.6 (42.6-188.4) pg/ml, 
p= 0.004]. Changes in leptin release from indomethacin-treated cells 
were noticeable even earlier during the time course, at day 7 in the 
absence of IL-6 [day 0, 22.0 (19.9-23.6) pg/ml leptin vs. 52.1 (40.2-67.9) 
pg/ml, p= 0.004] and day 5 in its presence [23.8 (23.7-24.9) pg/ml, 
p= 0.025]. Interestingly, both untreated cells and those that were treated 
with T3 had significant differences in leptin levels from day 5, despite 
having very few differentiated cells or lipid vacuoles visible. Notably, 
although the differences in release were significant, the actual levels of 
leptin were considerably lower throughout the time-course of the 
experiment than those measured at comparable time points using the 
other methods of differentiation [T3 day 0, 7.9 (7.5-8.1) pg/ml leptin vs.: 
day 5 no IL-6, 24.0 (19.7-30.0) pg/ml, p= 0.004; day 5 + IL-6, 19.7 (18.7- 
-20.7) pg/ml, p= 0.004; and no intervention day 0, 20.4 (18.4-22.2) pg/ml 
leptin vs.; day 7 no IL-6, 29.3 (26.3-35.0) pg/ml, p= 0.025; day 5 + IL-6, 
27.5 (25.0-34.7) pg/ml, p= 0.017]. With the exception of untreated cells
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Figure 4.4 -  Leptin release from 3T3-F442A cells differentiated using 
dexamethasone, IBMX and insulin, +l -  IL-6.
The accumulation of leptin in the media of differentiating 3T3-F442A 
adipocytes treated for 72 h (at day 0) with dexamethasone, IBMX and 
insulin in the absence (unbroken line) or presence (broken line) of 
10ng/ml recombinant murine IL-6. Data presented as median and 
interquartile range (n£ 22 for each sample).
* p< 0.001, no IL-6 vs. dO; ** p= 0.005, IL-6 treated vs. dO; *** p< 0.026, 
IL-6 treated vs. untreated.
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Figure 4.5 -  Leptin release from 3T3-F442A cells differentiated using 
IBMX and insulin, +1- IL-6.
The accumulation of leptin in the media of differentiating 3T3-F442A 
adipocytes treated for 72 h (at day 0) with IBMX and insulin in the 
absence (unbroken line) or presence (broken line) of 10ng/ml 
recombinant murine IL-6. Data presented as median and interquartile 
range (n= 6 for each sample).
* p= 0.037, no IL-6 vs. dO; ** p= 0.004, IL-6 treated vs. dO; *** p< 0.016, 
IL-6 treated vs. untreated.
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Figure 4.6 -  Leptin release from 3T3-F442A cells differentiated using
indomethacin and insulin, +/- IL-6.
The accumulation of leptin in the media of differentiating 3T3-F442A 
adipocytes treated for 72 h (at day 0) with indomethacin and insulin in the 
absence (unbroken line) or presence (broken line) of 10ng/ml 
recombinant murine IL-6. Data presented as median and interquartile 
range (n= 6 for each sample).
* p= 0.004, no IL-6 vs. dO; ** p= 0.025, IL-6 treated vs. dO; *** p< 0.016, 
IL-6 treated vs. untreated.
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Figure 4.7 -  Leptin release from 3T3-F442A cells differentiated using 
T3 and insulin, +1- IL-6.
The accumulation of leptin in the media of differentiating 3T3-F442A 
adipocytes treated for 72 h (at day 0) with T3 and insulin in the absence 
(unbroken line) or presence (broken line) of 10 ng/ml recombinant murine 
IL-6. Data presented as median and interquartile range (n= 6 for each 
sample).
* p= 0.004, both IL-6 treated and untreated vs. dO.
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Figure 4.8. Comparison of leptin release into the supernatant from 
3T3-F442A cells differentiated using various methods.
The accumulation of leptin (in pg/ml) into the supernatant during the 
differentiation of 3T3-F442A cells with: dexamethasone (dex), IBMX and 
insulin (ins); IBMX and insulin; indomethacin (indo) and insulin; or T3 and 
insulin. Day indicates day of differentiation.
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(in the presence or absence of IL-6), leptin release continued to rise as 
the cells differentiated further, until the cessation of the experiment (17 
days post-induction).
The effect of the inclusion of 10 ng/ml IL-6 in the induction media 
depended on the differentiation method used. Levels of leptin in the 
media were greater in cells that were differentiated with dexamethasone, 
IBMX and insulin, or IBMX and insulin in the presence of IL-6 when 
compared with equivalent cells without IL-6. This was evident from day 11 
post-induction in the former method [no IL-6, 260.3 (102.2-460.1) pg/ml 
leptin vs. + IL-6, 466.8 (231.5-1593.4) pg/ml, p= 0.016] and from day 9 in 
the latter [no IL-6, 17.7 (15.2-19.4) pg/ml leptin vs. + IL-6, 75.6 (42.6- 
188.4) pg/ml, p= 0.004]. This trend continued until the end of the time- 
course, with the exception of day 15 post-induction in the 
dexamethasone-based method [no IL-6, 1398.8 (798.7-3014.1) pg/ml 
leptin vs. + IL-6, 2512.4 (1278.7-3036.5) pg/ml, p= 0.137] and day 17 in 
the IBMX and insulin method [no IL-6, 1762.8 (671.3-2127.7) pg/ml leptin 
vs. + IL-6, 3224.9 (1922.9-4598.7) pg/ml, p= 0.201]. The release of leptin 
during differentiation using indomethacin and insulin appeared to have 
the opposite effect when IL-6 was present, with IL-6-treated cells 
releasing less leptin [day 9 no IL-6, 294.5 (209.6-268.7) pg/ml leptin vs. 
day 9 + IL-6, 106.1 (89.5-127.7) pg/ml, p= 0.004]. This trend continued at 
days 11 and 13 post-induction. However, at both day 15 and day 17 post­
induction, the difference in leptin release between the two treatments was 
not significant [day 15 no IL-6, 3894.1 (3404.1-4215.6) pg/ml leptin vs. 
day 15 + IL-6, 3090.2 (2962.2-3328.5) pg/ml, p= 0.109; and day 17 no 
IL-6, 4179.3 (3917.4-4394.4) pg/ml vs. day 17 + IL-6, 3310.9 (3255.7- 
3712.3) pg/ml, p= 0.078]. Leptin release during differentiation by T3 and 
insulin was unaffected by the presence of IL-6. Untreated adipocytes 
release very little leptin [a peak of 56.9 (49.9-62.2) pg/ml at 13 days post­
induction], but IL-6-treated cells appeared to release more leptin at day 
11 post-induction, and less at day 13 [day 11 no IL-6, 43.0 (41.6-44.0) 
pg/ml leptin vs. day 11 + IL-6, 49.3 (46.1-52.2) pg/ml, p= 0.025; and day
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13 no IL-6, 56.9 (49.9-61.2) pg/ml vs. day 13 + IL-6, 31.6 (29.1-44.8) 
pg/ml, p= 0.025].
Comparisons of leptin release from the different methods tended to 
mirror the differences observed by light microscopy. In the absence of 
IL-6, indomethacin-treated cells released the greatest amount of leptin at 
every time point from day 7 post-induction onwards. There was little 
discernable difference between the two methods using IBMX, both of 
which, in addition to the indomethacin method, tended to release more 
leptin than either the untreated or T3-treated cells. Despite releasing lower 
levels of leptin than the other methods, cells differentiated using T3 still 
released significantly more leptin than untreated cells. Among the IL-6- 
treated cells, the leptin release from the dexamethasone, IBMX and 
insulin, the IBMX and insulin and the indomethacin and insulin protocols 
were similar, and all significantly higher than untreated or T3 and insulin 
treated cells.
Gene expression during adipogenesis
End-point rt-PCR was used to assess the expression of PPARy, C/EBPa, 
ob, adipsin and IL-6 during differentiation that was induced with 
dexamethasone, IBMX and insulin. p-Actin expression was used as a 
control. The correct number of cycles was determined to ensure that the 
rt-PCR was stopped during the linear range of replication (cycle numbers 
are shown in Figure 2.1). The level of p-actin expression remained the 
same throughout the differentiation process (Figure 4.9). The increase in 
expression of both adipsin (an early adipocyte marker) and leptin as the 
differentiation time-course continued indicated that the cells were 
becoming mature adipocytes. IL-6 appeared to have no effect on adipsin 
expression, but there seemed to be a slight reduction in ob expression at 
day 17 post-induction, in the presence of IL-6.
PPARy expression increased from the preadipocyte state to 17 
days post-induction. Conversely, IL-6 expression appeared to become 
slightly lower. Investigation of the two major differentiation factors PPARy
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Figure 4.9 -  End-point rt-PCR of adipocyte genes during 
differentiation.
The expression of adipocyte gene-products days (A) or hours (B) 
following the induction of differentiation, in the absence (-) or presence 
(+) of 10 ng/ml IL-6.
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and C/EBPa in the hours immediately following treatment with the 
differentiation agents showed an immediate upregulation of both genes 
(within 1 h). IL-6 appeared to have no effect on the expression of 
C/EBPa, but increased the transcription of PPARy at 12 h and 24 h post­
induction of differentiation, and possibly also at three days post-induction.
Owing to the difficulty in quantitatively assessing the data that 
were produced by end-point rt-PCR, a semi-quantitative method of rt- 
PCR was used. Therefore, to validate the observations made using end­
point rt-PCR, the adipogenesis experiments were repeated with real-time 
rt-PCR. Specific primers were designed for PPARy, C/EBPa, ob and 
adipsin, with GAPDH as a control. During the first 72 h of adipogenesis, 
PPARy expression rose rapidly, reaching a peak at 48 h of 11.2 (9.0- 
19.0) times that of the preadipocyte (Figure 4.10). This expression was 
subsequently reduced, but remained greater than the preadipocyte level 
(all samples were significantly greater than the preadipocyte expression, 
p= 0.004). Incubation with IL-6 had no significant effect on PPARy 
expression during the initial 48 h, but resulted in reduced expression at 
72 h post-induction [expression compared with preadipocyte (day 0); no 
IL-6, 4.8 (4.6-S.8) fold vs. +IL-6, 3.0 (2.9-3.2) fold, p= 0.004]. The rise in 
transcription of C/EBPa was less marked than that of PPARy (Figure 
4.11), reaching a peak of 2.3 (0.8-2.3) times greater expression than the 
preadipocyte at 48 h post-induction, although this rise was not statistically 
significant (p= 0.055), whereas the 1.4 (1.4-1.7) fold increase in 
expression at 72 h was (p= 0.025). The inclusion of IL-6 in the induction 
media caused a significant inhibition of C/EBPa expression during the 
first 24 h [+IL-6, 0.7 (0.6-0.7) fold expression compared with 
preadipocyte (day 0), p= 0.037; vs. no IL-6,1.5 (1.2-17.1) fold, p= 0.006]. 
IL-6 had no effect on C/EBPa expression at 48 h or 72 h post-induction. 
The expression of adipsin (Figure 4.12) increased throughout 
adipogenesis up to and including day 17 post-induction [7.5 (6.7-8.7) fold 
increase in mRNA compared with preadipocyte, p= 0.004]. It was at this 
time point that the IL-6-treated cells had a significantly lower expression
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Figure 4.10 -  Real-time rt-PCR analysis of PPARy expression during 
adipogenesis.
The semi-quantative expression of PPARy during adipogenesis 
stimulated with dexamethasone, IBMX and insulin in the absence (-, O) 
or presence (+, A) of 10 ng/ml IL-6. Expression is corrected to GAPDH 
mRNA levels and displayed as median (interquartile range) fold-increase 
compared to preadipocyte levels (day 0), which are valued (arbitrarily) at
1.
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Figure 4.11 -  Real-time rt-PCR analysis of C/EBPa expression 
during adipogenesis.
The semi-quantative expression of C/EBPa during adipogenesis 
stimulated with dexamethasone, IBMX and insulin in the absence (-, O) 
or presence (+, A) of 10 ng/ml IL-6. Expression is corrected to GAPDH 
mRNA levels and displayed as median (interquartile range) fold-increase 
compared with preadipocyte levels (day 0), which are valued (arbitrarily)
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Figure 4.12 -  Real-time rt-PCR analysis of adipsin expression during 
adipogenesis.
The semi-quantative expression of adipsin during adipogenesis 
stimulated with dexamethasone, IBMX and insulin in the absence (-, O) 
or presence (+, A) of 10 ng/ml IL-6. Expression is corrected to GAPDH 
mRNA levels and displayed as median (interquartile range) fold-increase 
compared with preadipocyte levels (day 0), which are valued (arbitrarily) 
at 1.
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of adipsin compared with those cells that were differentiated without IL-6 
[p= 0.006; expression of adipsin in IL-6 treated cells, compared with 
preadipocyte, 3.2 (2.7-3.8) fold greater]. Comparison of the expression of 
ob, the leptin gene, in cells treated with or without IL-6 during 
differentiation indicated that, in spite of the increase in leptin release that 
was observed in the presence of IL-6, transcription was not affected 
(Figure 4.13). No significant difference occurred at 11-, 15- or 17-days 
post-induction of differentiation.
Short-term IL-6 incubation with adipocytes
In order to investigate the acute effects of IL-6 on leptin expression and 
release in adipocytes, 3T3-F442A preadipocytes were differentiated using 
dexamethasone, IBMX and insulin. At 15-days post-induction (when they 
were mature adipocytes), the cells were treated with Cell-gro in the 
absence or presence of 10 ng/ml IL-6, for up to 48 h. There was no 
significant difference in leptin release over 48 h between the IL-6 treated 
[2531.2 (2265-3326) pg/ml] and untreated [2392.3 (2314-2925) pg/ml, 
p= 0.827] cells. This was matched by the expression of ob, measured by 
real-time rt-PCR [IL-6 treated expression was 1.1 (0.6-1.6) fold that of 
untreated cells, p= 0.873].
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Figure 4.13 -  Real-time rt-PCR analysis of ob expression during 
adipogenesis.
The semi-quantative expression of ob during adipogenesis stimulated 
with dexamethasone, IBMX and insulin in the absence (-, O) or presence 
(+, A) of 10 ng/ml IL-6. Expression is corrected to GAPDH mRNA levels 
and displayed as median (interquartile range) fold-change in expression 
with IL-6 treatment compared to the corresponding untreated levels (day 
0), which are valued (arbitrarily) at 1.
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Discussion
Even the use of the most basic technique available, light microscopy, 
indicated that there was a clear, discernable difference between the 
adipocytes that were differentiated in the presence of IL-6 and those that 
were not. The initial observation that increased cell size and lipid-vacuole 
volume occurred in the presence of IL-6 was confirmed by using leptin as 
an adipocyte marker, dramatically disproving the original hypothesis, 
which predicted the opposite. Leptin is produced almost exclusively by 
adipocytes, and circulating levels are strongly correlated with indices of 
obesity, such as BMI, percentage body fat, total fat mass and body 
weight, as well as increasing age [114-116, 336]. Its release from 
adipocytes is dependent upon the volume of lipid within the cell, such that 
lipid-engorged adipocytes secrete significantly more leptin than smaller 
adipocytes [34]. This corresponds to data showing that more leptin is 
expressed and released from the larger subcutaneous adipocytes than 
from visceral depots [300, 337]. It is important to distinguish between the 
observation that IL-6-treated adipocytes were larger and contained more 
lipid but were not more numerous. The number of differentiating 
adipocytes in each sample, IL-6 treated and untreated, was 
approximately the same. Therefore, the increase in leptin secretion 
observed as a consequence of incubating IL-6 was related directly to the 
increased cell volumes in these cultures.
To determine a mechanism for the effect of IL-6 on adipogenesis, 
two rt-PCR techniques were used. Initially, end-point rt-PCR, a non- 
quantitative measure of expression, which amplifies a message a fixed 
number of times, was used. This provided some interesting results, and it 
was decided to confirm these with a more accurate and semi-quantitative 
method, real-time rt-PCR. Immediately noticeable was the fact that the 
results obtained by the latter method did not correlate with the original 
end-point data. End-point rt-PCR has a number of fallibilities that might 
affect the results: (i) it is not quantitative, therefore relying on a subjective 
observation of an agarose gel. This can be minimised by using computer-
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based colour-density analysis of the image, but this method still requires 
a clear gel with clean bands; (ii) it is difficult to be certain that reactions 
have run correctly, in spite of the fact that analyses of the message are 
made prior to running samples to ensure that the number of cycles is 
within the linear phase of expansion. The difference in band intensity 
between one cycle and the next is often minimal, and the difference 
between obtaining no visible message and a plateaued intensity can be 
difficult to assess; and (iii) although reactions are repeated a number of 
times, only trends can be inferred. Data cannot be effectively pooled and 
compared to provide intra-sample variation and, again, results can 
depend on the success of the gel. Therefore, because these problems 
are not encountered when using real-time rt-PCR, the semi-quantitative 
data (which does not rely on gels or visual determination, or an arbitrary 
cycle number, and that provides clear mathematically serviceable results) 
are likely to be more reliable.
Therefore, using data obtained from real-time rt-PCR, it appears 
that IL-6 treatment does not increase the secretion of leptin by altering 
the expression of its mRNA. Although increasing expression would seem 
to be the most obvious method of increasing release, it is not the only 
possibility. As described in Chapter 3, leptin is stored in intracellular pools 
prior to secretion [287], and IL-6 might be directly affecting the exocytosis 
of these. This possibility is excluded, however, by the fact that shorter- 
term (48 h) incubation of mature adipocytes with IL-6 does not directly 
promote an increased secretion of leptin. It might be that leptin release is 
increased as a consequence of the effects of chronic exposure to IL-6 on 
adipogenesis. Continuous exposure to IL-6 had the effect of increasing 
the lipid content of the adipocyte (an effect not noticeable following 48 h 
exposure in mature adipocytes), and it could be through this that 
secretion is increased. A mechanism for this must be established, but it is 
possible to speculate that an increase in the post-transcriptional 
production of leptin occurs (or a reduction of proteasome-based 
degradation), or that leptin is stored in such excess in the intracellular 
pools that, although the increase in release is significant, it is not
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sufficient to deplete these pools. The latter possibility warrants an 
investigation of the dynamics and kinetics of leptin secretion, especially 
considering that TNFa, at least in acute treatments, can upregulate leptin 
release without affecting expression [166]. The former depends upon the 
activity of leptin-degrading systems in the adipocyte, which are poorly 
reported (although leptin is degraded by this system [338], as are other 
components in the adipocyte [339-341]).
Although there was no significant effect on the expression of ob, 
other genes were affected by incubation with IL-6. Notably, the chronic 
exposure of differentiating adipocytes to IL-6 inhibits the expression of the 
potent adipogenic transcription factor PPARy. A similar conclusion has 
previously been reached concerning the effects of adipokines and insulin 
resistance, in a study suggesting that IL-6, in addition to other cytokines, 
decreased the expression of PPARy in adipocytes [266]. This discovery 
seems to contradict the observation that the morphology of IL-6 treated 
adipocytes is more lipid engorged, and that adipogenesis, at least in 
terms of lipid accumulation and leptin release, is driven primarily by 
PPARy [59, 342, 343]. IL-6 is not completely inhibiting PPARy expression, 
however, and C/EBPa, the second main protagonist of adipocyte 
differentiation, is unaffected. Therefore adipogenesis will still occur, and 
whereas the reduction in PPARy has not negatively affected 
differentiation, it might have had a secondary effect on the expression of 
other adipocyte genes. PPARy affects the expression of other genes; 
microarray and other methods of detection have revealed a massive list 
of targets for PPARy [344-347]. Obviously these include a number of 
genes required for adipogenesis and the function of the mature 
adipocyte. Among those that are upregulated include: C/EBPa [54, 61]; 
LPL [348]; fatty acid binding protein-4 [105]; adipsin [28, 349, 350]; IR 
and IRS-1 [351]; aP2 [342]; STATS 1, 5A and 5B [352]; the glucose 
transporters GLUT1 [353] and GLUT4 [28]; aquaporin adipose [354]; and 
ApoA I and II [29]. A number of other adipocyte and metabolic genes are 
downregulated by PPARy, including ob [53, 355, 356], ApoCIII [348, 357]
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and resistin [358] and, in the case of adiponectin, there is still confusion 
as to whether it is up- [194, 359, 360] or downregulated [358] by PPARy. 
Two of these gene products are of particular interest, leptin and adipsin.
Adipsin is an adipocyte marker, homologous to human 
complement factor D, that is expressed in adipocytes but not 
preadipocytes [72, 361]. The data presented here show that adipsin 
mRNA is significantly greater in adipocytes compared with preadipocytes 
from as early as three-days post-induction of differentiation; however, in 
the mature adipocyte its expression is reduced following exposure to IL-6. 
This might be as a consequence of the IL-6 reduction of PPARy 
expression, which in turn results in a down regulation of adipsin 
expression. That this does not happen with ob expression is more of a 
quandary, as less PPARy would be expected to equate with more leptin. 
However, although an increase in PPARy has been demonstrated to 
decrease leptin secretion and expression [355, 356], the control of ob is 
also regulated by C/EBPa [53, 117, 362], which is the only predictor of 
leptin mRNA in vivo [363], and thus might preserve leptin gene 
expression [364]. This suggests that ob expression in mature adipocytes 
is more explicitly controlled by C/EBPa, which is unaffected by the 
presence of IL-6, than it is by PPARy.
In addition to the use of dexamethasone, IBMX and insulin, a 
number of other methods are frequently used to differentiate 3T3-F442A 
cells. The most commonly cited method (after the adipogenic cocktail of 
dexamethasone, IBMX and insulin) is indomethacin and insulin, with T3 
and insulin also noteworthy. The protocols that are used vary in the 
mechanisms used to promote adipogenesis. In each case, insulin is used 
to enhance glucose uptake, and therefore lipid deposition. Insulin also 
has an effect on C/EBPa, with an upregulation of the expression of 
C/EBPa in the presence of insulin [364] (although the opposite effect has 
also been described [365]), but this is not the primary reason that insulin 
is included in the adipogenic cocktail. Insulin also increases the 
expression of glycerol-3-phosphate dehydrogenase [366, 367], ob [303,
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364, 368] and HSL [369], and decreases the expression of adipsin [366] 
and resistin [178]. T3 is used as a potentiator of insulin action, increasing 
glucose uptake [370] and lipogenic factors for lipid deposition [283, 371]. 
In contrast to the other methods described, the T3 and insulin protocol 
does not contain a factor specifically included to enhance the expression 
of differentiation-related genes, instead relying on the spontaneous 
conversion of preadipocytes and the possible effect of insulin on C/EBPa. 
Indomethacin, a cyclooxygenase inhibitor and non-steroidal anti­
inflammatory drug, is a potent activator of the adipogenic transcription 
factor PPARy [87], and subsequently enhances fatty acid and triglyceride 
synthesis [86]. Dexamethasone enhances the expression of the early 
adipogenic transcription factor C/EBP5 [73], causes growth arrest [75] 
and downregulates the expression of the anti-adipogenic factor pref-1 
[78], as well as potentiating the effects of cAMP [77], the target of IBMX. 
IBMX itself is used as a non-specific phosphodiesterase inhibitor, to 
increase the activity of glycerophosphate dehydrogenase and, therefore, 
lipid deposition [80, 372]. The aim of all the protocols described is to 
increase the expression of adipogenic genes and to enhance lipid 
deposition.
Of the protocols investigated here, which also included one 
method eschewing dexamethasone in favour of a double dosage of 
IBMX, the success in differentiating 3T3-F442A cells differed 
considerably. It is clear that IL-6 alone is not sufficient to induce 
adipogenesis, as demonstrated by its failure to induce the expression of 
either PPARy or C/EBPa. In this study the use of T3 and insulin was 
relatively ineffective at differentiating 3T3-F442As, in terms of both 
adipose conversion and Jeptin release. This is probably owing to the lack 
of a dedicated agent (as with cells treated with only IL-6) designed to 
induce C/EBPa or PPARy expression. Similarly, the IBMX method in the 
absence of dexamethasone was less effective than that using 
dexamethasone, probably for the same reasons. By contrast, 
differentiation using indomethacin was more effective, in terms of both the 
recruitment of adipocytes and leptin release, than the ‘baseline’ standard
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of dexamethasone and IBMX. This is probably a result of its direct 
interaction with the potent adipogenic transcription factor PPARy, 
increasing the recruitment of the preadipocytes and enabling more cells 
to differentiate quickly and efficiently.
The results reported here are noticeably different to the only 
published comparison of differentiation-dependent leptin release from cell 
lines [284], which observed virtually the opposite of what was seen here. 
In the previous study, T3-treated cells released the greatest levels of 
leptin, and indomethacin-treated cells secreted the least. Additionally, 
greater leptin release was observed from 3T3-L1 adipocytes compared 
with 3T3-F442A cells. This is unusual, because a number of studies have 
investigated leptin expression or release from 3T3-F442A adipocytes 
differentiated using dexamethasone, IBMX and insulin, and have 
recorded appreciable levels [368]. It does appear that the conditions of 
differentiation significantly affect leptin release [373]. Previous studies 
have consistently identified insulin as a promoter of leptin secretion and 
expression [281, 303, 374]. This appears to be contradicted in the Slieker 
et al. study [284], in which extremely low levels of insulin (as used in the 
T3 and insulin protocol) promote increased ob expression when compared 
with the methods using a higher concentration of insulin. Furthermore, 
high concentrations of glucose reduce the expression of ob and inhibit the 
action of insulin on adipocytes [375]. The Slieker study involved a glucose 
concentration of 25 mM. This is equivalent to 4500 mg/L, considerable 
greater than the 2500 mg/L concentration that was used in this study: a 
concentration that is described as ‘high’ by its manufacturer. 
Unfortunately, Slieker et al. [284] provided no data concerning the 
differentiation state of the adipocytes in their study. If the indomethacin- 
or dexamethasone-containing protocols resulted in adipocytes that were 
less lipid engorged, as would be expected if insulin function was 
impaired, then the lower expression of leptin would not be surprising [34]. 
The inclusion of T3, an insulin potentiator, in the more successful protocol 
might negate the inhibitory effects of excess glucose on insulin. This 
would enable greater lipid deposition and, consequently, greater ob
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expression. In the absence of data concerning the adipocyte morphology, 
very little information concerning a possible mechanism can be gleaned. 
In the data presented here, leptin release broadly corresponds to the size 
of the adipocytes (assessed by microscopy), in agreement with previously 
published reports.
The effect of IL-6 on the various differentiating methodologies is 
curious. The pattern that was established with the dexamethasone, IBMX 
and insulin protocol, in which leptin release was increased when the cells 
are co-incubated with IL-6, was preserved for the dexamethasone-free 
IBMX treatment. There was no effect of IL-6 on leptin secretion from the 
cells that were differentiated using T3 and insulin, and the presence of 
IL-6 resulted in a decrease in leptin release from cells that were treated 
with indomethacin and insulin. The T3 observation could be attributed to 
the low levels of leptin recorded. The effect of IL-6 on leptin release from 
adipocytes that were differentiated using dexamethasone, IBMX and 
insulin was more prominent as differentiation continued: the adipocytes 
were larger (i.e. more lipid engorged) and released considerably greater 
levels of leptin. Had the time-course of the T3 protocol been extended and 
the volume of the adipocytes increased, with a corresponding increase in 
leptin release, a difference might have emerged. The reduction in leptin 
secretion that was observed when IL-6 was present during differentiation 
with indomethacin and insulin might be as a result of the IL-6 effect on 
PPARy, in which PPARy expression was marginally inhibited by IL-6. This 
would imply that IL-6 is interfering with the indomethacin-mediated 
upregulation of PPARy, with a minor reduction in PPARy levels affecting 
adipose conversion rates. Confirmation by way of measuring mRNA 
levels is required to confirm this.
Therefore, adipocytes differentiated using dexamethasone, IBMX 
and insulin that were also treated with 10 ng/ml 1L-6 exhibit increased 
lipid deposition and leptin secretion without directly affecting 
adipogenesis. IL-6 had no explicit effect on the expression of ob, the 
gene that encodes leptin, but reduced the mRNA levels of the 
transcription factor PPARy, possibly affecting adipsin expression. 1L-6
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also appears to hinder indomethacin-induced differentiation, and although 
the mechanism of this is unknown, the IL-6 effect on PPARy might be 
involved. There appears to be no direct genetic mechanism for the 
observed increase in leptin release, although the data reported in Chapter 
5 pose some more possibilities.
Cell volume is a significant risk factor for pathologies associated 
with obesity. One such pathology, insulin resistance, is caused (at least in 
part) by adipokines, and is related to an increase in adipocyte volume 
rather than number [31, 32], Significantly, IL-6 has been shown here to 
increase the lipid content of differentiating adipocytes. Similarly, the work 
of Mattacks et al. [376] suggests that adipocytes in close proximity to 
lymph nodes are susceptible to HIV or lipopolysaccharide-associated 
hypertrophy. It is possible, especially when considering the data 
presented here, that IL-6 might be responsible (at least partially) for this 
adipocyte hypertrophy, because levels of IL-6 are significantly increased 
(from non-adipocyte sources) following LPS challenge or in HIV.
Adipocyte hypertrophy is relevant because insulin resistance is 
more closely related to visceral adipose tissue than subcutaneous [30]. 
As described in Chapter 3, visceral adipose tissue from obese individuals 
releases more IL-6 than does subcutaneous. Therefore, although it 
appears unlikely that IL-6 has a direct mechanistic effect on insulin 
resistance (Chapter 5), the strong correlation between the two might be 
as a result of the feedback relationship in visceral tissue.
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Chapter 5 -  Glucose Uptake and Lipolysis
Introduction
To fulfil its role as an energy store for the body, adipose tissue must be 
able to satisfy three criteria: it must have the ability to take up substrates 
in times of excess energy input, the ability to release substrates for 
peripheral tissues in times of fasting and have an effective method of 
storing energy to implement both uptake and release. This third capability 
is achieved by the use of triglyceride (also known as triacylglycerol) as 
the predominant long-term storage molecule in the body. Triglycerides 
consist of three long-chain fatty acid moieties bound to a glycerol 
backbone. They are non-polar, and are thus stored in an anhydrous form 
(glycogen, the storage form of glucose is stored in a hydrated form, 
requiring up to twice its dry weight in water), meaning that the energy 
storage to weight ratio is very high. Additionally, the lower oxidation state 
of carbon in fats when compared with carbohydrates results in greater 
energy release upon oxidation than from carbohydrates [377]. When the 
organism is in a fed state (i.e. a positive energy state), triglycerides are 
formed within the adipocyte, from fatty acids or glucose taken up from the 
bloodstream. When the organism is in the fasted state (a negative energy 
state), the triglycerides are hydrolysed into their constituent fatty acids 
and glycerol and are released from the adipocyte into the circulation.
Lipids are stored within the adipocyte in a specialised lipid vacuole, 
which is characterised by its high triglyceride content, with the remainder 
of the droplet consisting of protein and phospholipids [378]. 
Approximately 5% of the lipid-droplet mass is phospholipid, which forms 
the surface monolayer of the vacuole. A further 5% of the mass is protein, 
predominantly perilipins and adipose differentiation-related protein 
(ADRP), which share amino-terminus homology, and their presence 
depends upon the stage of differentiation [379]. Perilipins are found on 
the periphery of lipid vacuoles in mature adipocytes [380, 381] and 
appear to be involved in the packaging of lipids [382]. Perilipin levels 
correspond to those of triglycerides [383] and the expression of perilipins 
might be under the control of lipids in a similar mechanism to ADRP
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[384]. In addition to the packaging role, perilipins are involved in HSL- 
related lipolysis. The remainder of the lipid content is triglyceride, with 
small quantities of free fatty acids and (3-carotene also present [385].
Lipogenesis and glucose uptake
Lipogenesis, which is the formation of triglycerides within the adipocyte, is 
controlled by a number of enzymatic processes. Very little triglyceride is 
taken up by the adipocyte directly. Instead, triglyceride from the 
bloodstream is digested by the enzyme LPL into fatty acids, which can 
diffuse into the cell. A second enzyme, fatty acyl-CoA synthase, is then 
responsible for converting these fatty acids to triacylglycerol, to prevent 
diffusion from the cell and for storage. This is the preferential form of 
triglyceride synthesis in the cell and the mechanism by which most is 
formed [377].
Alternatively, triglycerides can be formed de novo from acetyl-CoA 
and malonyl-CoA precursors. For this synthesis, glucose is the base 
substrate for acetyl-CoA, as well as the glycerol-3-phosphate backbone. 
Glucose is metabolised via the glycolysis pathway, and is converted to 
acetyl-CoA in the Krebs cycle or to glycerol-3-phosphate by 
glyceraldehyde-3-phosphate during glycolysis. Subsequently, the 
multifunctional enzyme fatty acid synthase adds malonyl-CoA (itself 
formed from acetyl-CoA by acetyl-CoA carboxylase) sequentially to an 
acetyl-CoA substrate, to form palmitic acid, which is the predominant fatty 
acid used for storage in triglycerides (Figure 5.1) [386]. Other fatty acids 
are produced by the elongation or desaturation of this palmitic acid 
precursor [387]. These fatty acids are then transferred to a molecule of 
glycerol-3-phosphate to form monoacylglycerols, with the addition of a 
second and third fatty acid moiety producing a diacylglycerol and 
triacylglycerol respectively. These reactions are controlled by various 
acyl-transferases [388].
However, unlike fatty acids, glucose is unable to passively diffuse 
through the cell membrane. Instead, glucose uptake is mediated by a 
family of membrane-bound channels known as the glucose transporters
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(GLUTs). Six members of the GLUT family have been described (GLUTs 
1-5 and GLUT 7) [389], all of which are transmembrane proteins with a 
membrane-spanning region providing an aqueous pore for glucose 
transport [390]. In adipocytes, the predominant transporters are GLUT1 
and GLUT4, which are insulin independent and insulin dependent, 
respectively. In an unstimulated adipocyte, the majority (95%) of GLUT4 
is located in intracellular pools, as is 30-40% of GLUT 1, where they are 
non-functional. Their redistribution to the plasma membrane is necessary 
for function [391],
The best-studied mechanism for the stimulation of glucose uptake 
is that which occurs in response to insulin. Insulin is produced by the 
(3-cells of the pancreas in response to the dietary intake of carbohydrate. 
Insulin binds to IRs on the adipocyte membrane and this complex 
interacts with IRS-1. This results in the tyrosyl phosphorylation of IRS-1 
and the subsequent phosphorylation and activation of intracellular 
kinases, such as phosphatidylinositol-3-kinase [392, 393]. The relocation 
of GLUT4 to the plasma membrane enables glucose translocation, 
providing the substrate for lipogenesis [394-396]. However, chronic 
exposure to insulin downregulates the expression of GLUT4 but 
upregulates GLUT1 transcription, causing an increase in constitutive 
glucose uptake and reducing the capacity for insulin-stimulated uptake.
Interest in the effects of adipokines on glucose uptake and 
(specifically) insulin action developed from the discovery that adipocyte- 
derived TNFa affects insulin action. Insulin-stimulated glucose uptake is 
severely restricted in the condition of insulin resistance, which is 
observed in many cases of obesity and type-2 diabetes. Even prior to the 
identification and naming of the molecule, TNFa was implicated in the 
pathogenesis of insulin resistance [397]. Correlations between adipocyte 
expression of TNFa and insulin resistance were subsequently reported 
[102, 161]. TNFa directly inhibits insulin signalling in adipocytes by a 
variety of mechanisms, specifically by reducing the protein or mRNA 
levels of GLUT4 [168, 171, 398, 399] or by inhibiting the tyrosine 
phosphorylation of IR and IRS-1 [167, 296, 400-402]. Subsequently, other
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adipokines have been reported to affect insulin action. Leptin, under 
certain conditions (the excess levels of leptin that are observed in obesity 
appear to result in leptin resistance, thus severely reducing its functions 
[133]), enhances insulin action and reverses insulin resistance [403-406]. 
More recently, adiponectin has been shown to alleviate insulin resistance 
and to increase glucose uptake [188, 407-409]. The effects of IL-6 are 
currently disputed (see discussion).
Lipolysis
During times of fasting, tissues, such as cardiac and skeletal muscle and 
the liver, require substrate for energy production. Adipocytes can respond 
to these requirements by hydrolysing triglyceride into its component 
glycerol and fatty acids. Fatty acids are then free to diffuse out of the cell 
to be transported to where required. The rate-limiting step of lipolysis is 
controlled by HSL, a multi-enzyme complex that hydrolyses individual 
fatty acid moieties from glycerol. As its name suggests, HSL is influenced 
by endocrine signals, increasing or reducing lipolysis as necessary.
HSL appears to be controlled by the phosphorylation and 
dephosphorylation of serine residues on the enzyme [410]. Site-directed 
mutagenesis has identified a number of serine residues that, when 
phosphorylated, will activate or inactivate the protein [411]. A second 
mechanism that controls HSL is the intracellular location of the enzyme. 
Following stimulation with a lipolytic signal and subsequent 
phosphorylation, HSL is translocated from the cytoplasm to the lipid 
droplet [412]. Further control is imparted by perilipin, the lipid vacuole 
protein, which is associated with HSL following its translocation. A 
number of mechanisms are related to the function of perilipin in lipolysis. 
Concurrent phosphorylation of perilipin A with HSL appears to enable the 
hydrolysis of triglycerides [413], but perilipins also have a role in 
preventing lipolysis [414], possibly by preventing HSL from coming into 
contact with stored lipids [285]. The inhibition of lipolysis conferred by 
perilipin is so significant that animals lacking perilipin are immune to diet- 
induced obesity [415]. Therefore, the control of the lipolytic function of
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HSL occurs at many levels and many of the mechanisms remain 
unresolved.
The stimulation of lipolysis is caused by many effectors, including 
catecholamines, prostaglandins, TNFa, IL-1, IFNa, IFN(3 and IFNy. 
Catecholamines act through (3-adrenoceptors, resulting in the activation 
of adenylate cyclase, thus increasing intracellular cAMP and activating 
cAMP-dependent protein kinase (PKA). PKA phosphorylates the serine 
residues on HSL that are required to activate the enzyme. The cytokines 
appear to stimulate lipolysis by inducing prostaglandin synthesis, 
because their effect is inhibited by the prostaglandin inhibitor 
indomethacin [270]. Conversely, glucose can inhibit the action of HSL by 
decreasing the expression of the enzyme [416]. Insulin reduces PKA 
activity and, therefore, HSL phosphorylation, although prolonged 
exposure to both insulin and glucose increases HSL expression, which 
might explain the increased lipolysis that is observed in diabetic patients 
with hyperglycaemia and hyperinsulinaemia [369]. As with glucose 
uptake, IL-6 has been reported to have a variety of effects on lipolysis.
As with the adipogenesis methods, the hypothesis was that IL-6 would 
act similarly to TNFa; that is, increase lipolysis and inhibit glucose uptake 
(although one report, Stouthard et al. [263], appeared to indicate the 
opposite: this was to be confirmed or rejected by this study).
The aims of this chapter, therefore, were to investigate:
(i) The effect of IL-6 on basal and insulin-stimulated glucose uptake.
(ii) The effect of IL-6 on basal and adrenoceptor-stimulated lipolysis.
(iii) The possible mechanisms of these actions.
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Methods
Glucose Uptake
Differentiated 3T3-L1 and 3T3-F442A adipocytes were used to assess 
glucose uptake. Cells that were used for 3H-DOG uptake measurement 
were grown and differentiated in 6-well plates. Insulin was withdrawn from 
the DMEM/CCS (to re-sensitise the cells to insulin) for 24 h or 48 h, 
followed by treatment in the absence or presence of 10 ng/ml IL-6 in 
1.5 ml/well Cell-gro for a further 24 h or 48 h. The media was refreshed 
every 24 h, where necessary. Following incubation, cells were washed 
and treated for 30 minutes with or without 1 pg/ml insulin in Cell-gro 
(volumes as before). For the final ten minutes of the uptake-measurement 
experiment, 1 pl/ml media 3H-DOG was added to each well. After the 30- 
minute incubation, the media was removed and discarded (Figure 5.2). 
Adipocytes were washed with ice-cold KRP buffer and digested using 
0.1% SDS. 800 pi of the cell homogenate was removed, added to 8 ml 
scintillation fluid and counted.
Data for glucose uptake are expressed as mean fold-increase 
(standard deviation) in uptake of 3H-DOG compared with basal (no IL-6), 
and significance was assessed by Mann-Whitney U test, where two-tailed 
p values below 0.05 were considered significant. Experiments were 
repeated a minimum of three times.
Insulin receptor signalling
Because 3T3-L1 adipocytes responded better to insulin than did 
3T3-F442A cells, western-blot analysis for insulin signalling proteins, and 
the phosphorylation state of these proteins using immunoprecipitation, 
was carried out only with 3T3-L1 cells. Adipocytes for insulin-receptor 
signalling were grown in 75-cm2 tissue culture flasks. Using a method 
similar to that for glucose uptake, insulin was withdrawn for the 
DMEM/CCS culture media for 48 h, followed by treatment in the absence
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‘Fully’ differentiated adipocytes
Insulin washout 
DMEM/CCS
48h
Pre-treatment
Cell-gro +/-IL-6
24 h 48h
Treatment for glucose uptake
Cell-gro + insulin 30 min
. +3H-D0G 10 min
Assay/protein isolation
Figure 5.2 -  Time line of glucose uptake experiments.
Differentiated adipocytes were treated for 24 h or 48 h in DMEM/CCS to 
re-sensitise the cells to insulin. Cells were then pre-treated for an equal 
length of time in Cell-gro, in the absence or presence of 10 ng/ml IL-6. 
Glucose uptake treatment was 30 minutes in the presence of insulin, with 
3H-DOG added for the final 10 minutes. Cells were then solubilised for 
assay and protein isolation.
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or presence of 10 ng/ml IL-6 in 10 ml Cell-gro. After 48 h, the cells were 
treated for glucose uptake as described above, the culture media was 
aspirated and the flasks flash-frozen in liquid nitrogen Flasks were stored 
at -80°C prior to analysis.
Western blotting of IRp and IRS-1, and IRS-1 phosphorylation, as 
well as subcellular localization of GLUT 1 and GLUT4, was carried out as 
described in Chapter 2. Exposure times for each of the products were: 
IRp, IRS-1 and IRS-1 phosphorylation, 1 minute; GLUT1, 15 seconds; 
GLUT4, 45 seconds.
Lipolysis
Lipolysis was measured as glycerol concentration released into the cell- 
culture supernatant of 3T3-F442A adipocytes. The experiments were also 
carried out on 3T3-L1 cells, but this cell line did not release sufficient 
levels of glycerol for assay. Adipocytes were grown, differentiated and 
treated in 6-well plates. The majority of the experiments were carried out 
on adipocytes differentiated using dexamethasone, IBMX and insulin. As 
a comparison, a subset of experiments was carried out on cells 
differentiated using IBMX and insulin, or indomethacin and insulin. Prior 
to the lipolysis experiment, cells were pre-treated for 8 h, 12 h, 24 h, 48 h 
and 72 h in 1.5 ml/well Cell-gro, in the absence or presence of 10 ng/ml 
IL-6. Cells were then treated for 6 h with 1.5 ml/well Cell-gro containing 
1 pM dobutamine (a pi-adrenoceptor agonist), 1 pM clenbuterol (a p2- 
adrenoceptor agonist), 1 pM CL316243 (a p3-adrenoceptor agonist), 
1 pM noradrenaline (a non-specific a/p agonist), 2.5 pM dbcAMP (cAMP 
analogue) or with no additives, in the absence or presence of 10 ng/ml 
IL-6. Following 6 h incubation, the media was removed and assayed for 
glycerol release as described in Chapter 2 (Figure 5.3). The adipocytes 
were homogenised in TRI-reagent for RNA isolation (see Chapter 2). 
RNA was used for northern analysis of the samples, using probes for p2- 
adrenoceptors and p3-adrenoceptors, and to synthesise cDNA for rt-PCR 
analyses of both p2- and p3-adrenoceptor message.
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Pre-treatment 
Cell-gro +/- IL-6
I 8h I I2h 24 h 48 h 72h
Treatment for lipolysis
Cell-gro + agonist 
(+/- IL-6) I 6h
Assay and RNA isolation
Figure 5.3 -  Time line of lipolysis experiments.
Differentiated adipocytes were pre-treated for 8-72 h in Cell-gro, in the 
absence or presence of 10 ng/ml IL-6. Cells were then subjected to a 6 h 
treatment with adrenergic agonists or without stimulant (in the absence or 
presence of IL-6, as in the pre-treatment). Supernatants were assayed for 
glycerol release and cells used for RNA isolation.
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Data are presented as percentage increase (interquartile range) in 
glycerol levels compared with basal (no IL-6) for each pre-incubation time 
period, unless otherwise stated (n values refer to the number of individual 
wells from which measurements were obtained). Significance was 
assessed by Mann-Whitney U test, and two-tailed p values below 0.05 
were considered significant. Real-time rt-PCR data are expressed as 
relative difference in expression (interquartile range) compared with basal 
(no IL-6), using the method described by Livak and Schmittgen [295]. All 
experiments were repeated a minimum of three times.
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Results
The effect of IL-6 on glucose uptake
Changes in insulin-stimulated glucose uptake in 3T3-L1 adipocytes after 
48 h of insulin withdrawal (that is, 24 h in Cell-gro followed by 24 h in the 
absence or presence of IL-6) were variable. However, a total of 96 h of 
insulin withdrawal rendered the adipocytes insulin responsive. Insulin 
treatment resulted in a mean (standard deviation) 4.1 (1.3)-fold increase 
in glucose uptake compared with basal (p< 0.031; Figure 5.4). IL-6 pre- 
treatment increased glucose uptake 3.1 (2.4) fold (p= 0.05) and insulin 
treatment following incubation with IL-6 caused a 14.7 (3.4)-fold increase 
in glucose uptake compared with basal (p< 0.001).
The F442A adipocytes were considerably less responsive to insulin. 
Following 96 h insulin withdrawal, glucose uptake compared with basal 
was enhanced 1.9 (0.1) fold in response to insulin (p< 0.001), 1.5 (0.2) 
fold with IL-6 treatment (p< 0.001) and 3.0 (1.0) fold in response to insulin 
after IL-6 pre-treatment (p< 0.001).
Notably, the basal uptake of glucose was similar in both cell lines, at both 
time points [3T3-L1 48 h insulin withdrawal, median (interquartile range) 
24371 (19001-29231) counts per minute (cpm); 3T3-L1 96 h insulin 
withdrawal, 25480 (15215-43320) cpm; 3T3-F442A 48 h insulin 
withdrawal, 28294 (21953-30164) cpm; 3T3-F442A 96 h insulin 
withdrawal, 31751 (29502-36020) cpm. All p= ns, with the exception of 
3T3-L1 48 h vs. 3T3-F442A 96 h, p= 0.01].
The effect of IL-6 on proteins related to glucose uptake
To investigate possible mechanisms for the effect of IL-6 on glucose 
uptake, changes in the protein levels of components of the insulin- 
signalling pathway were measured. Figure 5.5 shows the comparative 
protein levels of IRp, IRS-1 protein and IRS-1 phosphorylation following 
each of the treatments that were used to induce glucose uptake. 
Treatment with insulin appeared to increase the levels of IRS-1 compared
135
Basal Insulin IL-6
Treatment
Insulin + 
IL-6
Figure 6.4 -  The effect of IL-6 on basal and insulin-stimulated 
glucose uptake in 3T3-L1 adipocytes.
The effect of 48 h pre-incubation (following a 48 h insulin washout period) 
with 10 ng/ml IL-6 on basal and insulin stimulated glucose uptake in 
3T3-L1 adipocytes, shown as mean fold increase compared with basal 
(no IL-6), + SD (n= 9 for each sample).
*p= 0.031; **p= 0.05; ***p< 0.001 (compared with basal).
1 3 6
+ -  + Insulin
Figure 5.5 -  The effect of IL-6 on insulin signalling during glucose 
uptake.
The effect of 48 h (following a 48 h insulin washout period) pre-incubation 
with 10 ng/ml IL-6 on IRS-1 (A) and insulin receptor-p (B) protein, and 
IRS-1 phosphorylation (C), during basal (insulin -)  and insulin-stimulated 
(insulin +) glucose uptake.
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with basal, and clearly upregulated its phosphorylation without affecting 
the levels of IRp. IL-6 pre-treatment had no effect on any of these 
proteins, whether adipocytes were treated with insulin or not. Therefore 
another mechanism must be involved.
Glucose transport into adipocytes is facilitated by the two glucose 
transporters GLUT1 and GLUT4, which are only functional when located 
at the plasma membrane. Incubation with IL-6 had no effect on the 
protein levels of either GLUT1 or GLUT4 in the adipocyte (Figure 5.6). 
Unfortunately, attempts to analyse GLUT translocation in response to 
insulin and/or IL-6 were not successful during the time available.
The effect of IL-6 on basal and stimulated lipolysis
A comparison of the basal (unstimulated) release of glycerol is shown in 
Figure 5.7. The peak release of glycerol was observed following 12-24 h 
pre-treatment with serum-free media. At both of these time points, 
significantly more glycerol was accumulated than after 8 h [167.9 (149.4-
193.7) pg/ml; vs. 12 h, 275.4 (11.2; mean and standard deviation, owing 
to the lower sample number) pg/ml, p= 0.02; vs. 24 h, 276.1 (227.1- 
360.1) pg/ml, p= 0.012], 48 h [110.4 (99.6-183.2) pg/ml; vs. 12 h, 
p= 0.007; vs. 24 h, p< 0.001] or 72 h pre-incubation [22.9 (17.3-31.7) 
pg/ml; vs. 12 h, p= 0.02; vs. 24 h, p= 0.001]. There was no significant 
difference in glycerol accumulation between pre-treatment for either 12 h 
and 24 h or 8 h and 48 h. Levels of glycerol release following 72 h pre- 
incubation were barely above background, and also significantly below 
both 8h (p= 0.004) and 48 h (p= 0.001) pre-incubation. This indicates 
that 48 h was the maximum pre-incubation period for viable lipolysis 
experiments carried out in these studies.
Unstimulated and stimulated lipolysis in the absence and presence 
of 10 ng/ml IL-6 following a 12 h serum starvation is shown in Figure 5.8. 
Treatment with any of the adrenoceptor agonists increased lipolysis 
(measured by glycerol secretion) compared with basal. Incubation with 
IL-6 during the pre-incubation and treatment had no effect on the
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Figure 5.6 -  The effect of IL-6 on glucose transporter levels during 
glucose uptake.
The effect of 48 h pre-incubation with 10 ng/ml IL-6 on GLUT1 (A) and 
GLUT4 (B) protein levels during basal (insulin -) and insulin-stimulated 
(insulin +) glucose uptake.
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Figure 5.7 -  Glycerol accumulation from unstimulated 3T3-F442A 
adipocytes.
The release of glycerol over 6 h from fully differentiated 3T3-F442A 
adipocytes, pre-treated in serum-free media for 8 h to 72 h. Data 
presented as median and interquartile range (12 h data presented as 
mean and standard deviation, owing to the lower sample number) of 
glycerol accumulated in the supernatant, without stimulation (n> 6 for 
each sample: 12 h, n - 3). 
p values: see text.
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Figure 5.8 -  Glycerol accumulation from 3T3-F442A adipocytes pre­
treated for 12 h +/- IL-6.
The release of glycerol from 3T3-F442A adipocytes pre-treated in serum- 
free media for 12 h in the absence (♦) or presence (A)  of 10 ng/ml IL-6, 
prior to 6 h incubation with a (31- (dobutamine), (32- (clenbuterol), p3- 
(CL316243) or a non-specific a/p-adrenoceptor agonist (noradrenaline), 
or no stimulant. Data presented as percentage stimulation (mean and 
standard deviation, owing to the low sample number) of glycerol 
accumulation compared with basal (no IL-6). Cells differentiated using 
dexamethasone, IBMX and insulin, n - 3 for each sample.
*p= 0.05 compared with basal, no IL-6.
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stimulated release of glycerol but significantly increased glycerol release 
in unstimulated samples [IL-6 treated 116.1% (4.1; mean and standard 
deviation) of basal, p= 0.05].
A pre-incubation of 24 h produced dramatically different results 
(Figure 5.9). In contrast to the results obtained following the 12 h pre­
incubation, there was no significant effect of IL-6 on basal lipolysis [IL-6 
treated release 105% (102.5-113.3) of basal, p= 0.198], whereas all 
stimulated glycerol release was inhibited following IL-6 treatment [IL-6 
treated vs. untreated; dobutamine, 136.7% (124.7-153.9) vs. 173.6% 
(168.9-174.5), p= 0.004; clenbuterol, 211.4% (197.7-248.0) vs. 291.7% 
(279.1-320.8), p< 0.001; CL316243, 228.8% (195.1-286.6) vs. 339.6% 
(291.8-356.5), p= 0.013; and noradrenaline, 173.8% (159.4-211.8) vs. 
225.1% (191.0-256.4), p= 0.028].
Following 48 h pre-incubation, only clenbuterol-stimulated lipolysis 
was significantly inhibited by IL-6 (IL-6 treated vs. untreated; 174.8% 
(159.2-186.3) vs. 251.4% (223.2-276.3), p< 0.001), with no other 
agonists affecting glycerol accumulation. Pre-incubation with IL-6 for 8 h 
had no effect on the lipolysis that was stimulated by any of the agonists, 
and the levels of glycerol release following 72 h pre-incubation were too 
low for meaningful analysis.
The effect of differentiation method on lipolysis
A similar series of experiments to those described above were carried out 
on 3T3-F442A adipocytes, which were differentiated using IBMX and 
insulin, or indomethacin and insulin. Pre-treatment in the presence or 
absence of IL-6 was for either 16 h or 24 h. Differentiation with IBMX and 
insulin resulted in adipocytes releasing significantly less glycerol than did 
cells that were differentiated with dexamethasone, IBMX and insulin 
(measured following 12 h or 24 h pre-incubation) following either 16 h or 
24 h pre-incubation in serum-free media. Levels of unstimulated release 
after 16 h were barely above measurements of background glycerol 
secretion. After 24 h pre-incubation, significant responses (in the absence 
of IL-6) were only recorded in cells that were treated with clenbuterol
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Figure 5.9 -  Glycerol accumulation from 3T3-F442A adipocytes pre­
treated for 24 h +/- IL-6.
The release of glycerol from 3T3-F442A adipocytes pre-treated in serum- 
free media for 24 h in the absence (♦) or presence (A)  of 10 ng/ml IL-6, 
prior to 6 h incubation with a (31- (dobutamine), p2- (clenbuterol), p3- 
(CL316243) or a non-specific a/p-adrenoceptor agonist (noradrenaline), 
or no stimulant. Data presented as percentage stimulation (median and 
interquartile range) of glycerol accumulation compared with basal (no 
IL-6). Cells differentiated using dexamethasone, IBMX and insulin. n= 11 
for each sample (n= 13 for basal no IL-6).
*p= 0.004; **p<  0.001; ***p =  0.013; fp =  0.028.
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[287.1% (186.0-438.2) of basal, p= 0.043] and CL316243 [340% (245.5-
444.7) of basal, p= 0.021], and there was no significant effect of IL-6.
Adipocytes differentiated using indomethacin and insulin were 
more responsive to lipolytic stimuli than those that were differentiated 
using IBMX and insulin. At both 16 h and 24 h, a significant response to 
each of the agonists was observed, and unstimulated release was greater 
than that of IBMX and insulin differentiated cells [glycerol release from 
indomethacin vs. IBMX treated cells, 24 h pre-treatment; 140.6 (136.8-
176.3) vs. 44.3 (21.9-71.6) pg/ml, p= 0.021]. There was no significant 
difference in unstimulated glycerol release following 24 h pre-incubation 
from cells differentiated using indomethacin and insulin when compared 
with those differentiated using dexamethasone, IBMX and insulin 
(glycerol release, 276.1 pg/ml, p= 0.065). Additionally, the increase in 
glycerol release that was stimulated by the adrenoceptor agonists in the 
indomethacin-differentiated adipocytes was similar when compared with 
the percentage changes observed for dexamethasone, IBMX and insulin 
treated cells. Pre-treatment with IL-6 for 16 h had no effect on lipolysis. 
Glycerol release from adipocytes differentiated using indomethacin and 
insulin, following 24 h pre-treatment in serum-free media, is shown in 
Figure 5.10. No inhibition is observed in the presence of IL-6, with the 
exception of CL316243-treated adipocytes, which have significantly 
reduced glycerol release when incubated with IL-6 [IL-6 treated vs. 
untreated; 305.2% (202.2-346.4) vs. 390.5% (375.5-467.1), compared 
with basal (no IL-6), p= 0.017].
Mechanisms of the IL-6 effect on lipolysis
To investigate the possibility that IL-6 was affecting lipolysis at the post- 
receptor level, possibly by altering the activity of HSL, adipocytes were 
incubated with the cell-permeable cAMP homologue dbcAMP, following 
24 h of pre-incubation in the absence or presence of IL-6. There was no 
significant difference in glycerol release in the presence of IL-6 [IL-6 
treated vs. untreated; 176.4% (166.2-177.7) vs. 170.1% (167.3-175.1) of 
unstimulated, p= 0.513].
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Figure 5.10 -  Glycerol accumulation from 3T3-F442A adipocytes pre­
treated for 24 h *1- IL-6, differentiated with indomethacin and insulin.
The release of glycerol from 3T3-F442A adipocytes pre-treated in serum-
free media for 24 h in the absence (♦) or presence (A)  of 10 ng/ml IL-6, 
prior to 6 h incubation with a p i- (dobutamine), (32- (clenbuterol), p3- 
(CL316243) or non-specific a/p-adrenoceptor agonist (noradrenaline), or 
no stimulant. Data presented as percentage stimulation (median and 
interquartile range) of glycerol accumulation compared with basal (no IL-
6). Cells differentiated using indomethacin and insulin. n= 4 (no IL-6); 
n= 6 (+ IL-6).
*p=  0.017.
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Another possible mechanism is cytokine-induced alteration of 
(3-adrenoceptor expression, which has been shown for TNFa [417]. 
Therefore, levels of adrenoceptor mRNA were examined. Probes for (32- 
and p3-adrenoceptors were used to measure the levels of the two 
receptors in adipocytes that were differentiated using dexamethasone, 
IBMX and insulin, and which had been pre-incubated for 24 h prior to the 
lipolysis experiments. There appeared to be no effect of IL-6 on receptor 
levels when measured by northern blot (Figure 5.11). The resolution of 
the blots made it difficult to make a quantitative assessment, however, so 
semi-quantitative real-time rt-PCR was used to measure the mRNA levels 
of the adrenoceptors. The expression of p2-adrenoceptors (Figure 5.12) 
in cells that were not treated with adrenoceptor agonists did not differ 
from the expression in cells that were treated with clenbuterol, either 
without [0.85 (0.52-1.2) fold (median and interquartile range) of basal 
levels, p= 0.423] or with [2.1 (0.6-2.5) fold, p= 0.337] IL-6 pre-treatment; 
expression levels following CL316243 treatment were similarly unaffected 
(without IL-6, 0.8 (0.7-0.9) fold, p= 0.078; with IL-6, 0.9 (0.7-1.5) fold, 
p= 0.522). There was also no difference in expression between IL-6 
treated and untreated cells following either clenbuterol (p= 0.749) or 
CL316243 (p= 1) incubation. CL316243 treatment in the absence of IL-6 
appeared to downregulate the expression of p3-adrenoceptors (Figure 
5.13) compared with basal [0.36 (0.35-0.41) fold of basal, p=0.01], 
although no significant differences were observed following the remaining 
treatments; clenbuterol [without IL-6, 1.2 (0.7-1.8), p= 0.631; with IL-6, 
1.0 (0.6-1.3), p= 0.631], and CL316243 with IL-6 pre-treatment [0.9 (0.6-
1.3), p= 0.749]. IL-6 treatment of the cells had no effect the expression of 
p3-adrenoceptors (clenbuterol, p= 0.631 and CL316243, p= 0.078).
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Figure 5.11 -  Northern blots of (32- and (33- adrenoceptors.
Northern blots of p2- (C) and p3-adrenoceptors (D) following basal (1),
and dobutamine (2), clenbuterol (3), dobutamine (4) and noradrenaline 
(5) stimulation, following 24 h pre-incubation in the absence (-) or 
presence (+) of 10 ng/ml IL-6. A shows the original RNA gel, and B the 
membrane to confirm transfer.
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Figure 5.12 -  Real time rt-PCR analysis of [32-adrenoceptor 
expression following IL-6 treatment.
The semi-quantative expression of [32-adrenoceptors following lipolysis 
stimulated with either clenbuterol (clen) or CL316243. Prior to incubation 
with the lipolysis agonists, adipocytes had been incubated in the absence 
(-, O) or presence (+, A) of 10 ng/ml IL-6. Expression is corrected to 
GAPDH mRNA levels, and presented as fold change in expression 
compared with basal [32-adrenoceptor expression (not shown), median 
and interquartile range.
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Figure 5.13 -  Real time rt-PCR analysis of (33-adrenoceptor 
expression following IL-6 treatment.
The semi-quantative expression of (33-adrenoceptors following lipolysis 
stimulated with either clenbuterol (clen) or CL316243. Prior to incubation 
with the lipolysis agonists, adipocytes had been incubated in the absence 
(-, O) or presence (+, A) of 10 ng/ml IL-6. Expression is corrected to 
GAPDH mRNA levels, and presented as fold change in expression 
compared to basal (33-adrenoceptor expression (not shown), median and 
interquartile range.
*p= 0.01 compared with CL316243 no IL-6.
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Discussion
As with the results from adipogenesis, the chronic incubation of 
differentiated adipocytes with IL-6 appears to have a lipid-enhancing 
effect. Both basal and insulin-stimulated glucose uptake was increased 
following treatment with IL-6, therefore increasing fat deposition within the 
adipocyte. Furthermore, the effect of p-adrenoceptor-related lipolytic 
signals is attenuated, preventing the loss of lipids from the adipocyte. 
These results, therefore, led to the immediate rejection of the initial 
TNFa-based hypothesis. This implicates IL-6 in the retention of adipose 
tissue, and might help to explain some of the observations from Chapter
4.
Owing to the strong correlations between adipokines and insulin 
resistance [161, 244, 254, 304, 418-422], there has been considerable 
interest in the effects of these cytokines on glucose uptake in the 
adipocyte. Early studies on adipocytes suggested, as the results here do, 
that the direct incubation of mature 3T3-L1 cells with IL-6 enhances 
glucose uptake [263], and also that this effect was not mediated via the 
traditional insulin-related pathway. Unfortunately, time constraints 
prevented a categorical answer to the question of whether IL-6 affects the 
intracellular trafficking of GLUT1. Total protein levels of either GLUT1 or 
GLUT4 remained unchanged in the presence of IL-6, but the increase in 
glucose uptake observed might have been due to an increase in GLUT1 
at the plasma membrane.
No effect of IL-6 was observed following a more acute stimulation 
(less than 24 h) implying, as with adipogenesis, that only chronic 
incubation with IL-6 significantly affects adipocytes. This observation has 
been confirmed by a number of other studies [263-265]. These data also 
provide a mechanism for the differentiation-dependent effects of IL-6. 
Chronic incubation of mature adipocytes with IL-6 resulted in the increase 
of both basal and insulin-stimulated glucose uptake, and therefore lipid 
deposition. The occurrence of this during adipogenesis, although not
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affecting the actual mechanism of differentiation, would increase the lipid 
contents within the differentiating cells. The features of IL-6 treatment that 
were observed during adipogenesis using dexamethasone, IBMX and 
insulin correspond to this: lipid vacuoles with a greater volume, and an 
increase in secreted leptin, which is related to lipid content of fat cells 
[34].
The difference in glucose uptake between 3T3-L1 adipocytes and 
3T3-F442A adipocytes, and between the 48 h and 96 h insulin-withdrawal 
periods, might be due to a number of reasons. Concerning the period of 
insulin-withdrawal prior to the experiments, it must be noted that the 
concentrations of insulin used during the differentiation period is far 
higher than physiological levels could ever reach. Insulin has a potent 
downregulatory effect on the expression and protein levels of the glucose 
transporters and components of the insulin-signalling machinery [297, 
423, 424]. Therefore, prior to measuring glucose uptake in these cells, 
this inhibitory effect of insulin must be negated. It is possible that, after 
48 h, maximal basal function of the insulin-signalling system is not 
recovered, whereas 96 h is sufficient. The difference between the cell 
types might be because, although they are derived from the same source, 
they are fundamentally different for a number of physiological processes 
(also evidenced by the poor response of 3T3-L1 adipocytes for the 
measurement of lipolysis). For this reason alone, it is not surprising that 
the response to insulin might differ. It is also possible that the numbers of 
cells within the cultures could differ, although this has been corrected for 
as much as is possible in an adherent cell culture through the seeding of 
identical numbers of cells prior to growth and differentiation. Notably, it 
can be inferred that the 3T3-L1 cells are responding to insulin because 
the level of glucose uptake is similar to that observed in other studies 
[263].
The appearance of an almost synergistic response to glucose 
uptake in 3T3-L1 adipocytes treated with both IL-6 and insulin might be 
due to a number of factors. Whether the response is synergistic, and 
whether it is the result of transporter relocation to the plasma membrane
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or increased GLUT activity cannot be concluded without further 
experimentation. However, the fact that the response was not observed in 
the less insulin-responsive 3T3-F442A cells leads to the possibility that 
insulin responsiveness has an effect on IL-6-induced glucose uptake in 
the presence of insulin (or, alternatively, on insulin-induced glucose 
uptake in the presence of IL-6).
These findings appear to challenge the reports of a number of 
studies concerning insulin resistance, which described the negative 
effects of IL-6 on glucose uptake. These range from associative studies, 
in which circulating IL-6 levels are positively correlated with numerous 
indices of insulin resistance [254, 255, 265, 304, 420, 421], to direct 
effects of IL-6 on cell lines and tissues [265, 421]. The first of these 
observations, concerning plasma IL-6 concentrations, in relation to 
studies on glucose clearance, circulating glucose levels and the effects of 
insulin, does not necessarily contradict the data presented here. There 
can be no dispute that IL-6 and insulin resistance are closely linked; 
adipose tissue releases IL-6 and this is closely related to body fat and 
obesity [103, 425-427], and obesity is a direct cause of insulin resistance 
[108, 316, 428-430]. If IL-6 increases glucose uptake, and thus lipid 
deposition, it is further contributing to excess fat deposition within the 
adipocyte and, therefore, indirectly causing insulin resistance. A further 
consequence of this is the release of more IL-6 from the excess adipose 
tissue, providing the circulating cytokine that enables these associations 
to be made. Whether IL-6 is inducing insulin resistance by other direct 
means, or through the IL-6-related involvement of other molecules, 
remains to be established.
IL-6 has also been reported to have a direct negative effect on 
adipocyte and other tissue glucose uptake [265, 421]. IL-6 appears to 
have no direct effect on glucose metabolism in muscle, at least with acute 
incubation [431], which is in agreement with the acute effects observed 
here. The effect on hepatocytes, in which the acute (< 1.5 h) incubation 
with IL-6 inhibits insulin action [421], might be ascribed to tissue specific 
differences. How to interpret the data obtained here in relation to the
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report by Rotter et al. [265] is more difficult. Their data, based on similar 
methodologies applied here, suggest almost the opposite effects. Chronic 
(24 h) exposure of 3T3-L1 adipocytes to IL-6 resulted in the decrease of 
insulin-stimulated glucose uptake, as well as in the expression and 
protein levels of IRS-1 and GLUT4. Clearly, this is in direct conflict with 
the findings presented here, in which (in addition to the increase in basal 
and insulin-stimulated glucose uptake) IRS-1 and GLUT4 levels were 
unaffected. As with the data presented here, acute incubation with IL-6 
had no effect. There are a number of differences between the 
experiments, although the relevance of these differences is questionable: 
The Rotter et al. [265] study used double the IL-6 concentration that was 
used in the studies presented here (20 ng/ml compared with 10 ng/ml), 
although both are within reasonable physiological concentrations for 
adipose tissue. In the data presented in this thesis, no effect of IL-6 was 
observed following 24 h pre-incubation, and subsequently no further 
investigation of this time-point was undertaken. Therefore, the effect of 
IL-6 on the GLUT and insulin signalling proteins was measured only after 
48 h pre-incubation with IL-6. Finally the pre-treatment described in this 
study involved the complete removal of all serum and a defined minimal 
media (Cell-gro), whereas the Rotter et al. study used DMEM. Whether 
these differences are significant enough to explain the disparity in results 
cannot be known with the current data. The original intention of using 
different IL-6 concentrations might have helped to resolve this. Findings 
are further complicated by the fact that, independent of the apparent 
effects of IL-6 on glucose uptake in the tissues, there might be no net 
effect on total body glucose disposal caused by IL-6 [431].
Similar disparities in the effects of IL-6 on lipolysis in adipocytes 
have been published, although there is more variation in the methods 
used (compared with the relatively similar techniques that are used to 
measure glucose uptake). The data presented here indicate that, as with 
other effects of IL-6, acute incubation has no significant effect on 
adipocyte lipolysis, with one caveat. Following 12 h pre-incubation with 
IL-6, basal lipolysis was slightly, but significantly, increased. This is in
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agreement with previous studies that have described an increase in basal 
lipolysis [267, 271]. Although this indicates that IL-6 might stimulate fat 
oxidation in adipocytes, the evidence is far from conclusive. As with the 
data presented here, which imply that an increase in glycerol release only 
results from an acute incubation with IL-6, neither of the two other studies 
reported an increase in lipolysis in all cells investigated. Mattacks et al. 
[271] noted that lipolysis was only stimulated by IL-6 in adipocytes from 
lymph nodes, which exhibit far lower levels of basal lipolysis than other 
adipocytes (and significantly greater responses to stimulators), and not 
from gonadal or perirenal depots. Furthermore, the action of IL-6 was 
modulated considerably by the co-incubation of IL~4, which resulted in an 
inhibition of glycerol release. This indicates that the source of adipocytes 
appears to be crucial in the effect of adipokines on lipolysis and must be 
considered in future studies. How the data from Path et al. [267] compare 
with that presented here is open to debate, because the 10 nmol/L IL-6 
concentration they used was considerably greater than the 10 ng/ml 
(approximately 0.3 nmol/L) used here. Significantly, 24 h incubation of 
breast adipocytes with lower concentrations of IL-6 had no effect on 
lipolysis.
The fact that lipolysis is differentially affected following acute and 
chronic incubation is not necessarily paradoxical. IL-6 is released from 
muscle in response to exercise and is believed to maintain glucose 
homeostasis by inducing lipolysis [432, 433]. Notably, in both exercise 
and immune responses, the increase in IL-6 levels is large and transient. 
In these situations it might be beneficial to release substrate for energy 
production and IL-6 might be involved in the acute control of lipolysis in 
some tissues [434]. The situation in obesity is quite different to this; IL-6 
levels are elevated but (at least in terms of initiating the acute phase 
response or activating immune responses) are subclinical. Furthermore, 
serum concentrations remain at these elevated levels chronically, as 
opposed to being cleared from the circulation within 48 h. This results in a 
very different response to IL-6, and could help to explain why studies 
have failed to pinpoint the precise role of IL-6 in adipocyte lipolysis. The
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data presented here imply that, irrespective of its acute actions, chronic 
exposure to mildly elevated levels of IL-6 inhibits p-adrenoceptor- 
stimulated lipolysis. Whether this is a mechanism for maintaining stores 
of adipose tissue is unknown, but remains a possibility. Because basal 
lipolysis is not affected over longer time periods, these findings suggest 
that IL-6 is not directly affecting the lipolytic machinery within the 
adipocyte.
Unfortunately, attempts at identifying a definitive mechanism for 
the IL-6 effect on either glucose uptake or lipolysis were not completed. 
Possibilities were rejected, however: IL-6 does not affect glucose uptake 
by acting through IR or IRS-1 (although IRS-2 might be affected), or by 
increasing either GLUT1 or GLUT4 protein levels; the anti-lipolytic actions 
are not through the modulation of HSL function, because the IL-6 effect is 
cAMP insensitive, or by the downregulation of the (3-adrenoceptors. 
Recent work in the laboratory has provided an interesting potential 
resolution, in combination with research published by other groups. The 
signalling molecule nitric oxide (NO) inhibits adrenoceptor-stimulated 
lipolysis in a similar manner to that of IL-6 in the data presented here 
[435, 436], without effects on basal lipolysis. Previous studies have 
suggested that NO can initiate the translocation of the insulin-dependent 
glucose transporter GLUT4 to the plasma membrane in the absence of 
insulin [437]. Preliminary data have suggested that IL-6 induces NO 
release in adipocytes (V. Mohamed-Ali, personal communication). If this 
is confirmed, and it is shown that IL-6 does initiate translocation of the 
insulin-sensitive glucose transporter GLUT4 to the plasma membrane, it 
would appear to be compelling evidence for a mechanism of chronic IL-6 
stimulation of the adipocyte.
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Chapter 6 -  Conclusions and Future Directions
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Adipokines and disease
Cytokines have been implicated in the pathogenesis of numerous 
diseases, in addition to their role in the immune response. Of note, 
obesity and its related disorders, including insulin resistance, are 
increasingly being correlated with adipose-tissue-derived factors. The 
direct mechanisms of how adipokines cause a disease state have yet to 
be established, although significant progress has been made in recent 
years concerning the effects of TNFa on insulin resistance [102]. 
Furthermore, correlations with insulin resistance have also been reported 
for IL-6, adiponectin, leptin and resistin [254, 438]. However, despite 
adipose tissue releasing considerable amounts of IL-6, especially in 
obesity [103], relatively little is known about its mechanism of action and 
its effects on adipose tissue.
Circulating IL-6 is correlated with obesity and insulin resistance, 
but the reported effects of IL-6 on muscle, adipose tissue and liver do not 
appear to implicate it in a mechanism for insulin resistance. Instead, the 
data presented here suggest that IL-6 does not have a direct effect on 
insulin resistance per se, but that it has profound effects on the biology of 
adipose tissue, particularly visceral adipose tissue, such that lipid 
retention is encouraged. From this pro-adipogenic state, insulin 
resistance and other pathologies are indirectly promoted.
The results from Chapter 3 showed that a proportion of IL-6 
release from adipose tissue is constitutive, with considerable secretion in 
the absence of stimulation. This is not true for all tissue types that release 
IL-6; macrophages, skeletal muscle and liver all require stimulation to 
release appreciable amounts of IL-6. Furthermore, the constitutive 
release of IL-6 from adipose tissue increases in obesity, possibly 
reflecting changes in the composition of the tissue. Therefore, although 
the acute regulated release of IL-6 -  which adipose tissue is also capable 
of -  during infection or exercise is beneficial for anti-inflammatory and 
energy homeostatic effects, the constitutive release from adipose tissue 
is potentially harmful.
157
In Chapter 4, it was shown that IL-6 has a significant effect on lipid 
accumulation during adipogenesis. It must be noted that, although leptin 
release was increased and the adipocytes that were treated with IL-6 
were larger than untreated cells, IL-6 was not directly affecting 
adipogenesis. Rather, IL-6 was promoting an increase in lipid deposition 
within adipocytes that were already committed to differentiation. 
Therefore, it appears that IL-6 is acting as a hypertrophy-promoting agent 
resulting in large adipocytes. This is important, because hypertrophic 
adipocytes are more likely to be involved in the pathogenesis of obesity- 
related disorders. Visceral adipose tissue correlates better with obesity- 
related disease states than does subcutaneous tissue [8, 439-441]. 
Previous studies have already implicated hypertrophy as the most 
significant factor in obesity (that is, the increased size of existing 
adipocytes is more significant in obesity and its diseases than is the 
differentiation of new adipocytes), although a degree of hyperplasia does 
occur [442-444]. This increased adipocyte size might also affect the 
production, release and function of other adipokines and cytokines -  
leptin release is significantly greater from large adipocytes, as has been 
shown in this study. Adiponectin, which appears to be protective against 
insulin resistance [445, 446], is reduced in obesity. Therefore, an 
increase in IL-6 and, subsequently, adipocyte size might affect insulin 
resistance indirectly, by inhibiting the production of adiponectin through a 
hypertrophy-related mechanism.
The studies described in Chapter 5 provide a possible mechanism 
for how IL-6 results in adipocyte hypertrophy. The chronic incubation of 
differentiated adipocytes with IL-6 results in an increase in both basal and 
insulin-stimulated glucose uptake and an inhibition of adrenoceptor- 
stimulated lipolysis. Both of these effects have serious implications for the 
lipid content of adipocytes because both will promote the production and 
retention of lipid within the cell. Therefore, the lipid deposition that was 
observed during adipogenesis in the presence of IL-6 might be 
attributable to these two mechanisms. Unfortunately, no molecular 
mechanism for this was obtained (although a number were ruled out). It is
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possible that glucose uptake is enhanced by an increased translocation 
of the insulin-independent glucose transporter GLUT1 to the plasma 
membrane, although this remains to be determined. Again, the distinction 
between the acute and chronic effects of IL-6 must be defined. The high 
levels of circulating IL-6 that occur in acute disease responses and during 
exercise result in the release of lipids from stores within the liver and 
muscle [434, 447] (although even reports on the acute effects of IL-6 are 
conflicting: individual tissue depots might be affected by acute IL-6 
infusion, but total body levels of glucose disposal might not be affected 
[431]). As presented here, the incubation of a (relatively) low level of IL-6 
has no acute effect but reduces lipolysis and increases glucose uptake 
over a longer period of time.
Therefore, the release of IL-6 from adipose tissue can have 
serious consequences on the physiology of the adipocytes in the tissue, 
as a result of autocrine and paracrine responses. IL-6 is released 
constitutively in the absence of a signal, and this release is greater in the 
obese state. Because the adipocytes in this situation are surrounded by a 
chronically raised level of IL-6, they become further stimulated to store 
lipid: IL-6 increases basal (and insulin-stimulated) glucose uptake and 
inhibits lipolysis. One hypothetical possibility is that a positive-feedback 
mechanism of increased hypertrophy and increased secretion of IL-6 
occurs, especially in visceral tissue depots. In this situation, IL-6 levels 
would be related to obesity, but the correlation that occurs with insulin 
resistance would be indirect, because IL-6 does not appear to have any 
direct negative effect on insulin action, especially in adipocytes. To test 
whether a positive-feedback mechanism occurs, experiments need to be 
performed that can differentiate between exogenously added IL-6 and 
that which is produced by the tissue being stimulated (for example, by 
labelling the exogenous IL-6 with a radioactive label that can be assayed 
separately and subtracting this measurement from the total IL-6 levels, or 
by adding a moiety to the exogenous protein so that it can be removed 
prior to assay, such as by filtering through antibodies directed against the 
moiety). Alternatively, an increase in adipocyte hypertrophy might have a
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beneficial effect against insulin resistance; lipid storage in sites other than 
the adipocyte (such as the liver [448] or muscle [449]) are strongly 
correlated with complications such as insulin resistance and 
cardiovascular disease [450]. The prevention of this, through the 
preferential deposition of lipid into the adipocyte, might help to alleviate 
the severity of insulin resistance. However, this must be balanced against 
potential harmful effects, such as increased levels of adipokines that are 
related to insulin resistance, including TNFa. A third possibility is that IL-6 
is acting as a macrophage factor in the adipose tissue. Infiltrated 
macrophages are likely to be activated, and the release of cytokines from 
macrophages [451] might further affect adipose tissue biology. 
Macrophage-derived products, particularly TNFa [452], could be involved 
in numerous adipocyte functions, including lipolysis [286] and apoptosis 
[93]. Furthermore, this might be one explanation for some of the 
anomalies observed in the effects of IL-6 on adipose tissue: (i) the 
incubation of IL-6 with adipose tissue, including resident macrophages, 
might affect the release of TNFa and the effects associated with it; (ii) 
some adipose tissue depots are less infiltrated by macrophages than 
others [23] and, accordingly, this might be responsible for the differential 
effect on different adipose tissues [267, 271]; and interventions on 
adipocytes in isolation, as reported here, would not be subject to these 
extra-adipocyte effects, and would only measure the direct effect of IL-6 
on adipocytes themselves. Of course, these remain hypotheses and 
considerable work is required before the effect of IL-6 on adipocytes, and 
on adipose tissue, can be fully determined.
Overall, how does adipose-tissue (and adipocyte)-derived IL-6 fit 
into the scheme of adipokines and obesity-related disorders? As yet, 
there is too little information to make much more than educated 
guesswork; the data provided here give an idea of the effects of IL-6 in an 
autocrine/paracrine setting in adipose tissue, but also raise numerous 
questions and, in some cases, controversy. I would suggest that IL-6 has 
a pro-hypertrophic effect on adipocytes (in isolation), promoting the 
retention of lipid, and that it is a marker for adiposity in otherwise healthy
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individuals. However, there are two significant caveats. First, IL-6 is 
unlikely to be as potent as, for example, TNFa with its effects on 
adipocytes. The IL-6-related responses are likely to be rather modest in 
comparison, without the dramatic immediate change in adipose tissue 
(i.e. de-differentiation [259] and apoptosis [93]) that follows TNFa 
incubation. However, because of the chronic timescales involved, it might 
have a longer-term effect on adipose tissue depot size and function, 
relating to an increase in adiposity over a period of months or even years. 
Second, the recent data concerning the composition of adipose tissue 
indicates that macrophages are likely to be important mediators of any 
adipose tissue effects involving inflammatory cytokines, such as IL-6. 
This might explain some of the differences observed in response to 
lipolysis (for example) between adipocytes alone and adipose tissue. 
Nonetheless, adipose tissue releases considerable IL-6, and the major 
differences observed in the responses of adipose tissue depots to IL-6 
(both in this study and by Mattacks et al. [271], as well as the fact that 
IL-6-deficient mice are obese [274], indicate that IL-6 does have a role in 
adipose tissue biology. For these reasons, the effects of IL-6 on adipose 
tissue deserve further investigation.
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Future directions
Adipose tissue releases numerous different adipokines, and these are 
regulated in many different ways. Studies on the individual products and 
their effects are ongoing, and knowledge of the interaction between them 
is relatively poor. Furthermore, although IL-6 is related to insulin 
resistance, it does not appear to directly affect insulin action. The data 
presented here suggest an indirect mechanism, possibly through one or 
more of the other adipokines. The metabolism of the adipocyte appears 
to be affected by the chronic influence of IL-6, and the molecular 
mechanisms causing this must be established to fully understand the 
autocrine and paracrine effects of IL-6 on adipocytes. The endocrine 
effects of adipocyte-derived IL-6, especially on the liver and skeletal 
muscle, need to be determined. Moreover, the interactions between 
adipocytes and the tissue immediately surrounding them could have a 
profound effect on the function of adipocytes, as shown by the effect of 
lymph nodes on adipose tissue physiology. It must also be noted that IL-6 
might have a significant central effect on body mass. IL-6-knockout mice 
develop mature-onset obesity [274], which can be reversed by the central 
administration of IL-6 [275]. IL-6 levels in the central nervous system are 
inversely correlated with adiposity, the opposite of what is observed in the 
periphery [453]. Therefore, IL-6 released from adipose tissue must be 
considered as an autocrine, a paracrine and an endocrine and central 
signal in its effects on fat mass.
One important factor that must be determined is the actual 
composition of adipose tissue, especially the differences between the 
cellular constituents in the lean and the obese states. Studies have 
reported the infiltration of macrophages into adipose tissue in obesity 
[23]. Furthermore, an inflammatory state develops within the adipose 
tissue of the obese through changes in gene expression, resulting in 
macrophage-derived messages being expressed by adipocytes [24, 320]. 
Therefore, it is important to identify the cellular source of IL-6; because 
macrophages do not release significant quantities of IL-6 under basal
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conditions, the release in lean animals might be solely adipocyte derived. 
During obesity, IL-6 might be released by adipocytes, by adipocytes with 
macrophage-like expression patterns or by infiltrating macrophages 
(which are likely to be activated and therefore releasing cytokines). The 
inflammatory-like state in obesity might also explain the increased 
sensitivity of adipose tissue to stimulators such as IL-1(3 and 
(3-adrenoceptor agonists. The precise relationship between adipocytes 
and macrophages, and the possible interconversion between the two, 
with respect to dysfunction and cytokine release in obesity must be 
established.
Therefore, experiments similar to those performed here (in Chapter 3) 
should be undertaken on the individual separated fractions of adipose 
tissue, the adipocytes, immune cells and stromal vascular cells, along 
with the determination of the relative contribution of each. Of particular 
interest would be the investigation of adipocyte release of IL-6, in the 
absence of other adipose tissue cells. This would provide a clearer 
indication of the true importance of adipocyte-derived IL-6 within the 
adipose tissue milieu. At the biochemical level, it would be worthwhile 
defining further the mechanism of IL-6 secretion; considering that the 
process was shown here to be Golgi-dependent, its precise route from 
the cytoplasm to the plasma membrane would enhance the knowledge of 
adipocyte secretion pathways to add to the different ones already known 
for leptin and LPL. One possible mechanism of IL-6 release that deserves 
attention is the stimulation of the prostaglandin (PG) pathway. The 
pathway is involved in the release of IL-6 from macrophages [454]. 
Furthermore, IL-1(3 and stimulated (3-adrenoceptors -  both of which 
increased IL-6 release from adipocytes -  can induce the production of 
PGE2 [455-458] which, through interactions with its four cognate 
receptors (EP1-4), stimulates the induction of IL-6 [454].
In terms of the effects of IL-6 on adipocytes, the mechanisms of 
glucose uptake and lipolysis as a result of IL-6 must be established, and 
the effects of IL-6 during adipogenesis better understood. For the 
adipogenesis study, a repeat of the methodologies described here but
163
using gene microarray instead of PCR would provide a wealth of 
information on the changes in cellular expression that are related to the 
inclusion of IL-6 in the differentiation media. Of course, there are 
considerable cost implications for this approach, and real-time rt-PCR is 
an effective alternative. The use of end-point rt-PCR was shown to be 
less effective in this study; the difficulties in interpreting data when 
changes are minimal between two samples indicate its limitations. It 
remains a useful and cost-effective method for determining gross 
changes in expression (i.e. for studies that show a change from no 
expression in a system to measurable expression).
The glucose uptake studies, which confirmed previous reports of 
an increase in glucose uptake by IL-6, were, unfortunately, not completed 
in time. The subcellular distribution study of the GLUTs was a promising 
investigation into the mechanism of IL-6-induced glucose uptake. 
Similarly, investigations into the mechanism of IL-6 inhibition of 
adrenoceptor-agonist-induced lipolysis (such as NO signalling) is an 
important step in determining the true effect of IL-6 on lipolysis, for which 
there have been many conflicting reports. For completeness of the 
studies described, it would have been advantageous to investigate a 
number of different IL-6 concentrations, to determine how the adipocyte 
reacts (and possibly to explain some of the data reported here in 
comparison with data from other groups). The next stage, using these 
methodologies, would be to use primary fibroblasts as the precursor to 
the experiments, instead of the committed cell lines used here. 
Furthermore, glucose uptake and lipolysis measurements on explanted 
adipose tissue (from various depots), under the same conditions used 
here, would further delineate the true effect of IL-6 on adipose tissue, as 
well as the importance of the depot and the non-adipocyte cells.
Had the time and funds been available, one method that might 
have resulted in some persuasive data would be the use of transgenic 
animals. Two mouse models would make good starting blocks for the 
investigation of adipose-tissue-derived IL-6 on the phenotype: the 
lipodystrophic mouse and the IL-6-knockout mouse. By developing an
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IL-6-overexpressing cell line (such as 3T3-L1s or 3T3-F442As) that can 
be grafted into the adipose tissue of the mouse, this will:
(i) For the lipodystrophic mouse, provide an in vivo in which the major 
adipose tissue sources (all implanted) are releasing excess IL-6. The 
effects on body composition can, therefore, be compared with mice 
transplanted with untransfected adipocytes.
(ii) Similarly, for IL-6-knockout mice, a similar comparison can be 
made in vivo, to measure the effects of adipose-tissue-derived IL-6 when 
it is the only source. This will be of particular interest to compare with the 
study of Wallenius et al. [275], to ascertain whether adipose-tissue- 
derived IL-6 can have central effects to reduce obesity, and if insulin 
resistance is improved or accentuated.
The results presented here have established that the mouse is a 
useful model for studying IL-6 in obesity. Using a knockout model, such 
as the leptin-deficient mouse used here, might be misleading in future 
studies, however, especially those investigating the whole-body effects of 
adipocyte-derived IL-6. Therefore, diet-induced obesity represents the 
best physiological model for studying obesity in the mouse to understand 
the mechanisms through which IL-6 has its effects. Translating these data 
to human obesity is, of course, desirable, but is unlikely to be realised in 
the immediate future. In the meantime, establishing the precise roles of 
IL-6 in vitro and in rodent models of obesity and adipose tissue will 
enable us to ascertain how harmful is the constitutive release of IL-6 from 
adipose tissue. The development of a specific inhibitor for adipocyte- and 
adipose-tissue-derived IL-6 would enable significant advances to be 
made in the study of IL-6 and obesity.
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Appendix
Derivation of the real-time rt-PCR Method
The following describes the derivation of the 2_AACt method for determining 
relative expression of genes, as developed by Livak and Schmittgen 
[295]. This is an abridged reproduction of the derivation described within 
that paper.
The exponential amplification of PCR is described as
Xn = X0 X (1 + Ex)n 
Where: Xn is the number of target molecules at cycle n of the
reaction
Xo is the initial number of target molecules 
Ex is the efficiency of target amplification 
n is the number of cycles
The threshold cycle (Ct) indicates the fractional cycle number at which the 
amount of amplified target reaches a fixed threshold. Thus,
XT = Xo x (1 + Ex)0*1* = Kx 
Where: X j is the threshold number of target molecules
Ct,x is the threshold cycle for target amplification 
Kx is a constant
A similar equation for the endogenous reference (internal control gene) 
reaction is
RT = R oX(1+ER)cw,='kR
Where: RT is the threshold number of reference molecules
Ro is the initial number of reference molecules 
Er is the efficiency of reference amplification 
Ct,R is the threshold cycle for reference amplification 
Kr is a constant
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Dividing XT by Rt give the expression
XT _ J . XQ + E J** K. I:
Rt ~ R .x d + E j)^  K* "
The exact values of Xt and Rt depends on factors relating to the reporter 
dye used, but assuming efficiencies of the target and the references are 
the same,
Ex = Er = E
—  x<l + E)Ct* Ct,R = K 
R.
or
XN x (1 + E)ACt = K 
Where: XN equals the amount of normalised target (Xo/R0)
ACt equals the difference in threshold cycles for target and 
reference (Ct,x -  Ct,R)
Which rearranges as
XN = K x (1 + E)-40*
Then, divide the Xn for any sample q by the Xn for the calibrator (cb), to 
give
J i s .  .  K* (1+E^  ,  <1+E)**a
Xucfc K x d  + Ey4^ **
Such that -AACt = -(ACt,q - ACt,cb).
For amplicons fewer than 150 base pairs, and in which primer and 
magnesium concentrations are optimised, the efficiency is close to one. 
Therefore, the amount of target, normalised to an endogenous reference 
and relative to a calibrator is given by
Amount of target = rMCt
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Example of the data obtained from real-time rt-PCR
Data for real-time rt-PCR are obtained automatically using the software 
for the PCR machine. The graph below is representative of the output 
from a real-time rt-PCR experiment (showing three samples, repeated in 
triplicate or quadruplicate), showing the change in relative number (y 
axis) during the amplification cycle (x axis). Each line represents the 
change in double-stranded DNA in one well, such that a complete 96-well 
plate would have data for 96 individual samples. One sample is a 
negative control (which does not rise far above the basal level) and the 
remaining two samples show a varying copy number.
When the PCR cycle has completed and a graph is obtained, an 
arbitrary value for a cut-off point must be chosen -  the point at which all 
readings are taken. This cut-off must be in the linear phase of expansion 
of the samples, as early as possible into the exponential-growth phase. In 
the example below, a value of 1 on the y-axis might be used. Therefore, 
all measurements of Ct value, the cycle number at which the sample 
crosses the threshold, are taken when the sample reaches am absorption 
value of 1.
The Ct values obtained in this way are used in the calculations 
above to provide a relative amount of product that was present in the 
sample.
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Figure I -  Sample real-time rt-PCR graph.
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